60 Degrees Pharmaceuticals (SXTP) S-1 14 Feb 25 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2024
Document Information Line Items
Entity Central Index Key	0001946563
Document Type	S-1
Entity Registrant Name	60 DEGREES PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Amendment Flag	false

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($)		Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and Cash Equivalents		$ 3,300,688	$ 2,142,485	$ 264,865
Accounts Receivable		323,822	231,332	45,965
Prepaid and Other Assets		1,102,948	4,402,602	200,967
Deferred Offering Costs				68,629
Short-Term Investments		1,711,497
Inventory		452,036	466,169	518,578
Total Current Assets		6,890,991	7,242,588	1,099,004
Property and Equipment, net		155,257	57,761	21,300
Other Assets:
Right of Use Asset			13,517	12,647
Long-Term Prepaid Expense		110,294	242,647
Intangible Assets, net		264,351	227,258	164,255
Total Other Assets		374,645	483,422	176,902
Total Assets		7,420,893	7,783,771	1,297,206
Current Liabilities:
Accounts Payable and Accrued Expenses		677,617	506,206	758,668
Lease Liability			13,650	13,000
Deferred Compensation				325,000
Debenture				4,276,609
SBA EIDL (including accrued interest)		8,772	8,772	2,750
Promissory Notes (including accrued interest)				16,855,887
Derivative Liabilities		623,762	2,306,796	1,129,840
Total Current Liabilities:		1,310,151	2,835,424	23,921,211
Long-Term Liabilities:
Deferred Compensation				255,000
SBA EIDL (including accrued interest)		147,895	150,251	160,272
Promissory Notes (including accrued interest)				1,109,783
Total Long-Term Liabilities		147,895	150,251	1,525,055
Total Liabilities		1,458,046	2,985,675	25,446,266
Commitments and Contingencies
SHAREHOLDERS’ EQUITY:
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 78,803 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		9,567,439	9,858,040
Common stock, value	[1]	186	48
Additional Paid-in Capital	[1]	34,815,642	27,457,335
Accumulated Other Comprehensive Income		139,207	135,561	73,708
Accumulated Deficit		(38,482,920)	(32,580,850)	(28,815,148)
60P Shareholders’ Equity:		6,039,554	4,870,134	(23,576,740)
Noncontrolling Interest		(76,707)	(72,038)	(572,320)
Total Shareholders’ Equity		5,962,847	4,798,096	(24,149,060)
Total Liabilities and Shareholders’ Equity		$ 7,420,893	7,783,771	1,297,206
Related Party
Current Liabilities:
Related Party Notes, net (including accrued interest)				195,097
Derivative Liabilities - Related Parties				364,360
Previously Reported
SHAREHOLDERS’ EQUITY:
Common stock, value			581	239
Additional Paid-in Capital			27,456,802	5,164,461
Total Shareholders’ Equity			$ 4,798,096	$ (24,149,060)
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - $ / shares		Sep. 30, 2024		Dec. 31, 2023		Dec. 31, 2022
Common stock, par value (in Dollars per share)		$ 0.0001	[1]	$ 0.0001	[1]	$ 0.0001
Common Stock, shares authorized		150,000,000	[1]	150,000,000	[1]	150,000,000
Common stock, shares issued	[1]	1,861,914		484,187
Common stock, shares outstanding	[1]	1,861,914		484,187
Series A Preferred Stock
Preferred stock, par value (in Dollars per share)		$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		1,000,000		1,000,000		1,000,000
Preferred stock, shares issued		76,480		78,803
Preferred stock, shares outstanding		76,480		78,803
Previously Reported
Common stock, shares issued				5,810,089		2,386,009
Common stock, shares outstanding				5,810,089		2,386,009
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited) - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2024		Sep. 30, 2023		Sep. 30, 2024		Sep. 30, 2023		Dec. 31, 2023	Dec. 31, 2022
Product and Service Revenues, net	$ 135,293		$ 51,188		$ 376,728		$ 127,892		$ 253,573	$ 223,208
Cost of Revenues	111,687		71,196		266,688		328,293		474,550	432,370
Gross Profit (Loss)	23,606		(20,008)		110,040		(200,401)		(220,977)	(209,162)
Research Revenues	12,818		75,566		43,177		82,974			288,002
Net Revenue (Loss)	36,424		55,558		153,217		(117,427)		(220,977)	78,840
Operating Expenses:
Research and Development	940,063		263,703		4,372,571		591,569		691,770	525,563
General and Administrative Expenses	1,215,053		1,313,617		3,419,747		2,551,426		4,241,836	1,303,722
Total Operating Expenses	2,155,116		1,577,320		7,792,318		3,142,995		4,933,606	1,829,285
Loss from Operations	(2,118,692)		(1,521,762)		(7,639,101)		(3,260,422)		(5,154,583)	(1,750,445)
Interest Expense	(1,467)		(40,106)		(6,490)		(2,281,191)		(2,286,637)	(3,989,359)
Derivative Expense							(399,725)		(399,725)	(504,613)
Change in Fair Value of Derivative Liabilities	(56,712)		92,490		1,683,034		95,324		(37,278)	(10,312)
Loss on Debt Extinguishment			(391,593)				(1,231,480)		(1,231,480)	120,683
Change in Fair Value of Promissory Note			6,105,066				5,379,269		5,379,269
Other Income (Expense), net	16,623		(70,490)		56,569		(69,169)		(83,116)	(43,238)
Total Interest and Other Income (Expense), net	(41,556)		5,695,367		1,733,113		1,493,028		1,341,033	(4,426,839)
(Loss) Income from Operations before Provision for Income Taxes	(2,160,248)		4,173,605		(5,905,988)		(1,767,394)		(3,813,550)	(6,177,284)
Provision for Income Taxes (Note 9)	250		63		751		189		250	500
Net (Loss) Income including Noncontrolling Interest	(2,160,498)		4,173,542		(5,906,739)		(1,767,583)		(3,813,800)	(6,177,784)
Net (Loss) Income - Noncontrolling Interest	(713)		(9,656)		(4,669)		(14,165)		(48,098)	3,936
Net (Loss) Income - attributed to 60 Degrees Pharmaceuticals, Inc.	(2,159,785)		4,183,198		(5,902,070)		(1,753,418)		(3,765,702)	(6,181,720)
Comprehensive (Loss) Income:
Net (Loss) Income	(2,160,498)		4,173,542		(5,906,739)		(1,767,583)		(3,813,800)	(6,177,784)
Unrealized Foreign Currency Translation Gain (Loss)	4,403		9,342		3,646		7,678		61,853	(2,127)
Total Comprehensive (Loss) Income	(2,156,095)		4,182,884		(5,903,093)		(1,759,905)		(3,751,947)	(6,179,911)
Net (Loss) Income - Noncontrolling Interest	(713)		(9,656)		(4,669)		(14,165)		(48,098)	3,936
Comprehensive (Loss) Income – attributed to 60 Degrees Pharmaceuticals, Inc.	(2,155,382)		4,192,540		(5,898,424)		(1,745,740)		(3,703,849)	(6,183,847)
Cumulative Dividends on Series A Preferred Stock	(116,571)		(101,538)		(352,333)		(101,538)		(220,714)
Net (Loss) Income - attributed to Common Shareholders	$ (2,271,953)		$ 4,091,002		$ (6,250,757)		$ (1,847,278)		$ (3,924,563)	$ (6,183,847)
Net (Loss) Income per Common Share:
Basic (in Dollars per share)	$ (0.93)	[1]	$ 9.13	[1]	$ (4.35)	[1]	$ (6.59)	[1]	$ (0.99)	$ (2.61)
Diluted (in Dollars per share)	$ (0.93)	[1]	$ 9.13	[1]	$ (4.35)	[1]	$ (6.59)	[1]	$ (0.99)	$ (2.61)
Weighted average number of common shares outstanding
Basic (in Shares)	2,443,198	[1]	448,174	[1]	1,437,584	[1]	280,391	[1]	3,960,280	2,367,729
Diluted (in Shares)	2,443,198	[1]	448,174	[1]	1,437,584	[1]	280,391	[1]	3,960,280	2,367,729
Product Revenues - net of Discounts and Rebates
Product and Service Revenues, net	$ 135,293		$ 51,188		$ 365,939		$ 127,892		$ 253,573	$ 192,913
Service Revenues
Product and Service Revenues, net					$ 10,789					$ 30,295
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Shareholders’ Equity (Deficit) (Unaudited) - USD ($)		Preferred Stock Series A	Preferred Stock Previously Reported	Common Stock Previously Reported	Common Stock		Additional Paid-In Capital Previously Reported	Additional Paid-In Capital		Accumulated Deficit Previously Reported	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss) Previously Reported	Accumulated Other Comprehensive Income (Loss)	Total Shareholders’ Equity (Deficit) Attributable to 60P Previously Reported	Total Shareholders’ Equity (Deficit) Attributable to 60P	Noncontrolling Interest on Shareholders Previously Reported	Noncontrolling Interest on Shareholders	Members’ Equity Previously Reported	Members’ Equity	Previously Reported	Total
Balance at Dec. 31, 2021											$ (22,633,428)		$ 75,835		$ (17,578,228)		$ (576,256)		$ 4,979,365		$ (18,154,484)
Balance (in Shares) at Dec. 31, 2021																			18,855,165
issuance of warrants in private placement, net of offering costs paid at closing and deferred offering costs of $582,600					$ 4			185,331							185,335						185,335
issuance of warrants in private placement, net of offering costs paid at closing and deferred offering costs of $582,600 (in Shares)					37,067
Net foreign translation gain after June 1, 2022													26,527		26,527		611				27,138
Net (loss) income after June 1, 2022											(4,232,474)				(4,232,474)		2,566				(4,229,908)
Net foreign translation loss													(28,654)		(28,654)		(611)				(29,265)
Net (loss) income through May 31, 2022											(1,949,246)				(1,949,246)		1,370				(1,947,876)
Business combination June 1, 2022: 60P LLC into 60P, Inc. (Note 6)					$ 235			4,979,130											$ (4,979,365)
Business combination June 1, 2022: 60P LLC into 60P, Inc. (Note 6) (in Shares)					2,348,942														(18,855,165)
Net income (loss)																					(6,177,784)
Balance at Dec. 31, 2022				$ 239	$ 20	[1]	$ 5,164,461	5,164,680	[1]	$ (28,815,148)	(28,815,148)	$ 73,708	73,708	$ (23,576,740)	(23,576,740)	$ (572,320)	(572,320)			$ (24,149,060)	(24,149,060)
Balance (in Shares) at Dec. 31, 2022				2,386,009	198,836	[1]
Cancellation of common stock					$ (12)	[1]		12	[1]
Cancellation of common stock (in Shares)	[1]				(120,919)
Share-based compensation to vendors for services					$ 12	[1]		5,378,896	[1]						5,378,908						5,378,908
Share-based compensation to vendors for services (in Shares)	[1]				120,253
Net foreign translation loss						[1]			[1]				(1,290)		(1,290)						(1,290)
Net income (loss)						[1]			[1]		(2,600,061)				(2,600,061)		2,527				(2,597,534)
Balance at Mar. 31, 2023					$ 20	[1]		10,543,588	[1]		(31,415,209)		72,418		(20,799,183)		(569,793)				(21,368,976)
Balance (in Shares) at Mar. 31, 2023					198,170	[1]
Balance at Dec. 31, 2022				$ 239	$ 20	[1]	5,164,461	5,164,680	[1]	(28,815,148)	(28,815,148)	73,708	73,708	(23,576,740)	(23,576,740)	(572,320)	(572,320)			(24,149,060)	(24,149,060)
Balance (in Shares) at Dec. 31, 2022				2,386,009	198,836	[1]
Net income (loss)																					(1,767,583)
Balance at Sep. 30, 2023		$ 9,858,040			$ 48	[1]		27,183,447	[1]		(30,568,566)		81,386		6,554,355		(38,105)				6,516,250
Balance (in Shares) at Sep. 30, 2023		78,803			483,307	[1]
Balance at Dec. 31, 2022				$ 239	$ 20	[1]	5,164,461	5,164,680	[1]	(28,815,148)	(28,815,148)	73,708	73,708	(23,576,740)	(23,576,740)	(572,320)	(572,320)			(24,149,060)	$ (24,149,060)
Balance (in Shares) at Dec. 31, 2022				2,386,009	198,836	[1]
Voluntary conversion of Series A Preferred Stock into common stock			$ (270,460)	$ 5			270,455
Voluntary conversion of Series A Preferred Stock into common stock (in Shares)			(2,162)	45,560
Cancellation of common stock				$ (145)			145
Cancellation of common stock (in Shares)				(1,451,000)																	256,000
Share-based compensation to vendors for services				$ 148			5,682,908							5,683,056						5,683,056
Share-based compensation to vendors for services (in Shares)				1,482,799
Warrants reclassed from derivative liabilities to equity							838,748							838,748						838,748
Share-based compensation under 2022 Equity Incentive Plan				$ 4			528,922							528,926						528,926
Share-based compensation under 2022 Equity Incentive Plan (in Shares)				40,000
Deemed capital contribution for related party compensation expense (Note 11)							163,228							163,228						163,228
Net foreign translation loss												61,853		61,853						61,853
Conversion of debt into common stock upon initial public offering				$ 171			7,989,427							7,989,598						7,989,598
Conversion of debt into common stock upon initial public offering (in Shares)				1,707,179
Conversion of debt into Series A Preferred Stock upon initial public offering			$ 10,128,500											10,128,500						10,128,500
Conversion of debt into Series A Preferred Stock upon initial public offering (in Shares)			80,965
Issuance of common stock pursuant to IPO, net of underwriting discounts, commissions, and deferred offering costs of $1,266,740				$ 141			6,235,135							6,235,276						6,235,276
Issuance of common stock pursuant to IPO, net of underwriting discounts, commissions, and deferred offering costs of $1,266,740 (in Shares)				1,415,095
Issuance of common stock upon exercise of warrants				$ 18			1,131,753							1,131,771						1,131,771
Issuance of common stock upon exercise of warrants (in Shares)				184,447
Contribution from noncontrolling interest							(548,380)							(548,380)		548,380
Net income (loss)										(3,765,702)				(3,765,702)		(48,098)				(3,813,800)	$ (3,813,800)
Balance at Dec. 31, 2023		$ 9,858,040	$ 9,858,040	$ 581	$ 48	[1]	27,456,802	27,457,335	[1]	(32,580,850)	(32,580,850)	135,561	135,561	4,870,134	4,870,134	(72,038)	(72,038)			4,798,096	4,798,096
Balance (in Shares) at Dec. 31, 2023		78,803	78,803	5,810,089	484,187	[1]
Balance at Mar. 31, 2023					$ 20	[1]		10,543,588	[1]		(31,415,209)		72,418		(20,799,183)		(569,793)				(21,368,976)
Balance (in Shares) at Mar. 31, 2023					198,170	[1]
Net foreign translation loss						[1]			[1]				(374)		(374)						(374)
Net income (loss)						[1]			[1]		(3,336,555)				(3,336,555)		(7,036)				(3,343,591)
Balance at Jun. 30, 2023					$ 20	[1]		10,543,588	[1]		(34,751,764)		72,044		(24,136,112)		(576,829)				(24,712,941)
Balance (in Shares) at Jun. 30, 2023					198,170	[1]
Voluntary conversion of Series A Preferred Stock into common stock		$ (270,460)				[1]		270,460	[1]
Voluntary conversion of Series A Preferred Stock into common stock (in Shares)		(2,162)			3,797	[1]
Share-based compensation expense						[1]		271,066	[1]						271,066						271,066
Net foreign translation loss						[1]			[1]				9,342		9,342						9,342
Issuance of common stock for payment of deferred compensation						[1]		155,000	[1]						155,000						155,000
Issuance of common stock for payment of deferred compensation (in Shares)	[1]				2,438
Conversion of debt into common stock upon initial public offering					$ 14	[1]		7,989,584	[1]						7,989,598						7,989,598
Conversion of debt into common stock upon initial public offering (in Shares)	[1]				142,270
Conversion of debt into Series A Preferred Stock upon initial public offering		$ 10,128,500				[1]			[1]						10,128,500						10,128,500
Conversion of debt into Series A Preferred Stock upon initial public offering (in Shares)		80,965
Reclassification of liability-classified warrants to equity-classified						[1]		838,748	[1]						838,748						838,748
Issuance of common stock pursuant to IPO, net of underwriting discounts, commissions, and deferred offering costs of $1,266,740					$ 12	[1]		6,235,264	[1]						6,235,276						6,235,276
Issuance of common stock pursuant to IPO, net of underwriting discounts, commissions, and deferred offering costs of $1,266,740 (in Shares)	[1]				117,925
Issuance of common stock upon exercise of warrants					$ 2	[1]		1,131,769	[1]						1,131,771						1,131,771
Issuance of common stock upon exercise of warrants (in Shares)	[1]				15,371
Issuance of common stock pursuant to share-based compensation awards						[1]		187,200	[1]						187,200						187,200
Issuance of common stock pursuant to share-based compensation awards (in Shares)	[1]				3,336
Prepaid share-based compensation						[1]		109,148	[1]						109,148						109,148
Contribution from noncontrolling interest						[1]		(548,380)	[1]						(548,380)		548,380
Net income (loss)						[1]			[1]		4,183,198				4,183,198		(9,656)				4,173,542
Balance at Sep. 30, 2023		$ 9,858,040			$ 48	[1]		27,183,447	[1]		(30,568,566)		81,386		6,554,355		(38,105)				6,516,250
Balance (in Shares) at Sep. 30, 2023		78,803			483,307	[1]
Balance at Dec. 31, 2023		$ 9,858,040	$ 9,858,040	$ 581	$ 48	[1]	27,456,802	27,457,335	[1]	(32,580,850)	(32,580,850)	135,561	135,561	4,870,134	4,870,134	(72,038)	(72,038)			4,798,096	4,798,096
Balance (in Shares) at Dec. 31, 2023		78,803	78,803	5,810,089	484,187	[1]
issuance of warrants in private placement, net of offering costs paid at closing and deferred offering costs of $582,600					$ 44	[1]		1,898,252	[1]						1,898,296						1,898,296
issuance of warrants in private placement, net of offering costs paid at closing and deferred offering costs of $582,600 (in Shares)	[1]				438,414
Issuance of common stock upon exercise of Pre-Funded Warrants					$ 4	[1]		4,991	[1]						4,995						4,995
Issuance of common stock upon exercise of Pre-Funded Warrants (in Shares)	[1]				41,630
Issuance of shares for RSUs					$ 2	[1]		(2)	[1]
Issuance of shares for RSUs (in Shares)	[1]				16,001
Net foreign translation loss						[1]			[1]				(3,894)		(3,894)						(3,894)
Net income (loss)											430,470				430,470		(2,485)				427,985
Balance at Mar. 31, 2024		$ 9,858,040			$ 98	[1]		29,360,576	[1]		(32,150,380)		131,667		7,200,001		(74,523)				7,125,478
Balance (in Shares) at Mar. 31, 2024		78,803			980,232	[1]
Balance at Dec. 31, 2023		$ 9,858,040	$ 9,858,040	$ 581	$ 48	[1]	$ 27,456,802	27,457,335	[1]	$ (32,580,850)	(32,580,850)	$ 135,561	135,561	$ 4,870,134	4,870,134	$ (72,038)	(72,038)			$ 4,798,096	4,798,096
Balance (in Shares) at Dec. 31, 2023		78,803	78,803	5,810,089	484,187	[1]
Net income (loss)																					(5,906,739)
Balance at Sep. 30, 2024		$ 9,567,439			$ 186	[1]		34,815,642	[1]		(38,482,920)		139,207		6,039,554		(76,707)				5,962,847
Balance (in Shares) at Sep. 30, 2024		76,480			1,861,914	[1]
Balance at Mar. 31, 2024		$ 9,858,040			$ 98	[1]		29,360,576	[1]		(32,150,380)		131,667		7,200,001		(74,523)				7,125,478
Balance (in Shares) at Mar. 31, 2024		78,803			980,232	[1]
Issuance of common stock upon exercise of Pre-Funded Warrants					$ 4	[1]		4,991	[1]						4,995						4,995
Issuance of common stock upon exercise of Pre-Funded Warrants (in Shares)	[1]				41,629
Voluntary return of shares issued to vendor for services					$ (1)	[1]		1	[1]
Voluntary return of shares issued to vendor for services (in Shares)	[1]				(10,000)
Issuance of shares for RSUs					$ 1	[1]		(1)	[1]
Issuance of shares for RSUs (in Shares)	[1]				5,337
Net foreign translation loss						[1]			[1]				3,137		3,137						3,137
Net income (loss)									[1]		(4,172,755)				(4,172,755)		(1,471)				(4,174,226)
Balance at Jun. 30, 2024		$ 9,858,040			$ 102	[1]		29,365,567	[1]		(36,323,135)		134,804		3,035,378		(75,994)				2,959,384
Balance (in Shares) at Jun. 30, 2024		78,803			1,017,198	[1]
issuance of warrants in private placement, net of offering costs paid at closing and deferred offering costs of $582,600						[1]		3,414,502	[1]						3,414,502						3,414,502
Voluntary conversion of Series A Preferred Stock into common stock		$ (290,601)			$ 7	[1]		290,594	[1]
Voluntary conversion of Series A Preferred Stock into common stock (in Shares)		(2,323)			73,334	[1]
Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs of $264,774					$ 68	[1]		1,729,742	[1]						1,729,810						1,729,810
Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs of $264,774 (in Shares)	[1]				677,819
Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment					$ 9	[1]		(9)	[1]
Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment (in Shares)	[1]				93,563
Share-based compensation expense						[1]		15,246	[1]						15,246						15,246
Net foreign translation loss						[1]			[1]				4,403		4,403						4,403
Net income (loss)						[1]			[1]		(2,159,785)				(2,159,785)		(713)				(2,160,498)
Balance at Sep. 30, 2024		$ 9,567,439			$ 186	[1]		$ 34,815,642	[1]		$ (38,482,920)		$ 139,207		$ 6,039,554		$ (76,707)				$ 5,962,847
Balance (in Shares) at Sep. 30, 2024		76,480			1,861,914	[1]
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders’ Equity (Deficit) (Unaudited) (Parentheticals) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Issuance of common stock net of offering costs paid	$ 264,774
Issuance of warrants in Private Placement, net of offering costs paid	$ 582,600
Issuance of common stock pursuant to IPO, net of underwriting discounts		$ 1,266,740
Previously Reported
Issuance of common stock pursuant to IPO, net of underwriting discounts			$ 1,266,740

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (5,906,739)	$ (1,767,583)	$ (3,813,800)	$ (6,177,784)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation	6,277	19,287	21,162	27,648
Amortization	28,004	20,606	29,157	5,118
Amortization of Debt Discount		669,148	669,148	1,090,387
Amortization of ROU Asset	13,517	37,035	50,053	46,020
Amortization of Note Issuance Costs		67,728	67,728	74,496
Amortization of Capitalized Share-Based Payments	3,531,763	690,173	994,643
Share-Based Compensation to Vendors for Services		212,605	212,605
Share-Based Compensation under Equity Incentive Plan	15,246	458,266	528,926
Deemed Capital Contribution for Related Party Compensation Expense (Note 11)			163,228
Loss on Debt Extinguishment		1,231,480	1,231,480	(120,683)
Change in Fair Value of Derivative Liabilities	(1,683,034)	(95,324)	37,278	10,312
Derivative Expense		399,725	399,725	504,613
Change in Fair Value of Promissory Note		(5,379,269)	(5,379,269)
Write-offs of Capitalized Patents	11,300
Inventory Reserve		(139,946)	(160,338)	160,338
Changes in Operating Assets and Liabilities:
Accounts Receivable	(92,490)	(92,044)	(185,367)	100,397
Prepaid and Other Assets	(99,756)	(1,512,578)	(522,370)	24,902
Inventory	14,133	60,205	212,747	10,126
Accounts Payable and Accrued Liabilities	171,411	(489,337)	(214,734)	169,990
Accrued Interest, net	(5,853)	1,267,703	1,265,361	2,685,678
Reduction of Lease Liability	(13,650)	(37,122)	(50,273)	(46,795)
Deferred Compensation		(100,000)	(100,000)	425,257
Net Cash Used in Operating Activities	(4,009,871)	(4,479,242)	(4,542,910)	(1,009,980)
CASH FLOWS FROM INVESTING ACTIVITIES
Capitalization of Patents	(49,869)	(29,220)	(39,982)	(33,063)
Purchases of Fixed Assets	(103,773)	(1,823)	(57,623)
Acquisition of Intangibles	(25,374)	(18,283)	(18,283)	(27,070)
Purchase of Short-Term Investments	(1,708,000)
Net Cash Used in Investing Activities	(1,887,016)	(49,326)	(115,888)	(60,133)
CASH FLOWS FROM FINANCING ACTIVITIES
Net Proceeds from January 2024 Offering	1,914,513
Payment of Deferred Offering Costs	(102,077)	(150,420)	(150,420)	(68,629)
Proceeds from IPO and Over-Allotment, net of underwriting discounts and commissions paid at closing of $1,047,692		6,454,325	6,454,325
Proceeds from ATM Offering, net of offering costs paid at closing of $203,914	1,790,670
Proceeds from Private Placement, net of offering costs paid at closing of $557,600	3,439,502
Proceeds from Exercise of Warrants		1,131,771	1,131,771
Proceeds from Exercise of Pre-Funded Warrants	9,990
Proceeds from Notes Payable		650,000	650,000	800,000
Proceeds from Notes Payable - Related Parties				305,000
Repayment of Notes Payable		(1,611,111)	(1,611,111)
Proceeds from Advances - Related Party		250,000	250,000	185,335
Repayment of Related Party Advances		(250,000)	(250,000)
Net Cash Provided by Financing Activities	7,052,598	6,474,565	6,474,565	1,221,706
Foreign Currency Translation Gain (Loss)			61,853	(2,127)
Effect of Exchange Rate Changes on Cash	2,492	7,678
Change in Cash and Cash Equivalents	1,158,203	1,953,675	1,877,620	149,466
Cash and Cash Equivalents-Beginning of Period	2,142,485	264,865	264,865	115,399
Cash and Cash Equivalents-End of Period	3,300,688	2,218,540	2,142,485	264,865
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid During the Year for Interest			179,117	2,193
Cash paid During the Year for Income Taxes			1,000	1,000
NONCASH INVESTING/FINANCING ACTIVITIES
Conversion of Debt into Common Stock		7,989,598	7,989,598
Conversion of Related Party Advance into Common Stock				185,335
Conversion of Debt into Series A Preferred Stock		10,128,500	10,128,500
Conversion of Series A Preferred Stock into Common Stock	290,601	270,460	270,460
Capitalized Share-Based Payments to Vendors		4,916,556	4,916,555
Fair Value of Warrants Issued to Underwriters	71,364	301,416	301,416
Reclassification of Liability-classified Warrants to Equity-classified		838,748	838,748
Additions to ROU Assets for Lease Renewal		50,922	50,922
Additions to Lease Liabilities for Lease Renewal		50,570	50,570
Conversion of 60P LLC Member Units to Common Stock				4,979,365
Debt Discount Recorded in Connection with Derivative Liabilities		650,000	650,000	1,105,000
Stock Issued for Payment of Deferred Compensation		480,000	520,000
Stock Issued for Acquisition of Intangibles		$ 33,895	$ 33,895

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Cash Flows [Abstract]
Net of underwriting discounts and commissions paid at closing	$ 1,047,692	$ 1,047,692	$ 1,047,692
ATM Offering, net of offering costs paid	203,914
Private Placement, net of offering costs	$ 557,600

Nature of Operations

Nature of Operations	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Nature of Operations [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS 60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010. 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA ® (a) Initial Public Offering On July 14, 2023, the Company closed its initial public offering consisting of 117,925 units at a price of $63.60 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $73.14 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $76.32 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants were immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028). The Company granted the underwriters a 45-day over-allotment option to purchase up to 17,689 shares of the Company’s common stock at a price of $63.36 per share and/or 17,689 Tradeable Warrants at a price of $0.12 per Tradeable Warrant and/or 17,689 Non-tradeable Warrants at $0.12 per Non-tradeable Warrant, or any combination thereof (the “IPO Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 8,387 Tradeable Warrants and 8,387 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 7,076 shares of the Company’s common stock, at an exercise price of $69.96 per share, equal to 110% of the offering price per unit (the “IPO Representative Warrants”). The IPO Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028). The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “IPO Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. (b) Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued. In view of these matters, continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from their single marketed product. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern. Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved. On September 30, 2024, the Company had cash and cash equivalents totaling $3,300,688, as compared to cash and cash equivalents totaling $2,142,485 at December 31, 2023. During the nine months ended September 30, 2024, the Company used $4,009,871 of cash in its operating activities. The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, proceeds from the issuance of convertible debt, and borrowings under loan and security agreements. The Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. The Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these consolidated condensed financial statements. As such, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt about the Company’s ability to continue as a going concern. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself. The Company also expects to use cash and cash equivalents to fund activities relating to commercial support for its existing product and any future clinical research trials and operating activities. The Company’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments. The Company’s capital commitments over the next twelve months include interest obligations on the Company’s debt arrangements of $8,772 and $677,617 to satisfy current accounts payable and accrued expenses.	1. NATURE OF OPERATIONS 60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia. Initial Public Offering On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants are immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028). The Company granted the underwriters a 45-day over-allotment option to purchase up to 212,265 shares of the Company’s common stock at a price of $5.28 per share and/or 212,265 Tradeable Warrants at a price of $0.01 per Tradeable Warrant and/or 212,265 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination thereof (the “Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 100,644 Tradeable Warrants and 100,644 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 84,906 shares of the Company’s common stock, at an exercise price of $5.83 per share, equal to 110% of the offering price per unit (the “Representative Warrants”). The Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028). The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. See Note 6 for further details. Risks and Uncertainties The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company’s ability to obtain regulatory approval of its such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition. In addition, higher rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company’s business and financial condition, including the Company’s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company’s ability to pursue its business strategy. Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these financial statements are issued. In view of these matters, continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from their single marketed product. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern. Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved. On December 31, 2023, the Company had cash and cash equivalents totaling $2,142,485, as compared to cash and cash equivalents totaling $264,865 at December 31, 2022. During the twelve months ended December 31, 2023, the Company used cash of $4,542,910 in its operating activities. The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements. The Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. The Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these consolidated financial statements. As such, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt about the Company’s ability to continue as a going concern. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself. The Company also expects to use cash and cash equivalents to fund activities relating to commercial support for its existing product and any future clinical research trials and operating activities. The Company’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments. The Company’s capital commitments over the next twelve months include interest obligations on the Company’s debt arrangements of $8,772, $13,650 for payments due under operating lease liabilities, and $506,206 to satisfy accounts payable and accrued expenses.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation The financial statements of 60P and its subsidiary are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended December 31, 2023 and 2022, included in the Company’s annual report on Form 10-K, as filed with the SEC on April 1, 2024 (the “Annual Report”). Certain information and footnote disclosures that would substantially duplicate the disclosures contained in the Annual Report have been omitted. (b) Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. The increase in the Company’s proportional interest is reflected as a contribution from noncontrolling interest in the accompanying consolidated condensed statement of shareholders’ equity (deficit). For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated condensed financial statements. (c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, and derivative liabilities. (d) Reverse Stock Split Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12 (the “Reverse Stock Split”), which was effective as of August 12, 2024. Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company’s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable in accordance with the terms of the instruments. Unless otherwise noted, all references to numbers of shares of the Company’s common stock and per share information presented in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. (e) Cash and Cash Equivalents The Company’s cash consists of cash deposited in demand accounts at financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company considers short-term highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at times, may exceed the FDIC insurable limits (currently $250,000). The Company has not experienced any losses related to amounts in excess of FDIC Limits. The Company periodically assesses the credit risk associated with these financial institutions and believes that the risk of loss is minimal. (f) Short-term Investments Short-term investments consist of certificates of deposit with original maturities of greater than three months and less than twelve months, which are classified as held-to-maturity as the Company has the intent and ability to hold these investments until they mature. The classification of short-term investments is determined at the time of purchase and is reevaluated at each balance sheet date. Short-term investments are reported at amortized cost. (g) Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, an Australian pharmaceutical distributor, and a large American pharmaceutical distributor. There was no allowance as of September 30, 2024 or December 31, 2023. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. As of September 30, 2024, the American pharmaceutical distributor accounted for 96% of the accounts receivable balance (79% as of December 31, 2023) and the US government accounted for none of the outstanding accounts receivable balance (13% as of December 31, 2023). (h) Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number. The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to Cost of Revenues in the Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income. During the three months ended September 30, 2024 and 2023, write-downs for expired inventory totaled $1,165 and $0, respectively ($18,490 and $94,977 for the nine months ended September 30, 2024 and 2023, respectively). (i) Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of September 30, 2024, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations, as a component of other income or expense as change in fair value of derivative liabilities. The Company uses a Monte Carlo simulation model or a probability-weighted discounted cash flow model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date. (j) Equity-Classified Warrants As of September 30, 2024, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding. (k) Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. At September 30, 2024, significant customers represented 97% of receivables (consisting of two customers and one significant customer at 97%). At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively). For the three months ended September 30, 2024, 92% of total net revenues (consisting of two customers and one significant customer) were generated from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers. For the nine months ended September 30, 2024, 94% of total net revenues (consisting of three customers and one significant customer) were generated from significant customers. For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28%. Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). (l) Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. A single management team that reports to the Chief Executive Officer comprehensively manages the business. Accordingly, since its inception, the Company has managed its business in one identifiable segment. (m) Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers. (n) Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepayments for research and development services are deferred and amortized over the service period as the services are provided. Advance payments for specific materials, equipment, or facilities determined to have no alternative future use are initially deferred and recognized as research and development expense when the related goods are delivered. The Company recorded $940,063 and $263,703 in research and development expense during the three months ended September 30, 2024 and 2023, respectively, ($4,372,571 and $591,569 for the nine months ended September 30, 2024 and 2023, respectively). (o) Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the Consolidated Condensed Balance Sheets and any change in fair value unrelated to credit risk is recorded in Other Expense, net in the Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income. Changes in fair value related to credit risk are recognized as other comprehensive income or loss. As a result of the completion of the IPO in July 2023, all financial instruments for which the FVO was elected were extinguished. See Note 7 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at September 30, 2024, and December 31, 2023 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 8 for more information on Derivative Liabilities. Liabilities measured at fair value at September 30, 2024 and December 31, 2023 are as follows: September 30, 2024 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 623,762 $ 623,762 Total $ - $ - $ 623,762 $ 623,762 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796 There were no transfers of financial instruments between Level 1, Level 2, and Level 3 during the periods presented. A rollforward of liabilities measured at fair value using Level 3 inputs outstanding during the three and nine months ended September 30, 2024 and 2023 are presented in Note 7 (Debt) and Note 8 (Derivative Liabilities), respectively. (p) Assets and Liabilities Not Measured at Fair Value on a Recurring Basis In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company’s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the assets’ projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized. As of September 30, 2024, and December 31, 2023, the fair value of Cash and Cash Equivalents, Short-Term Investments, Accounts Receivable, Prepaid Expenses and Other Current Assets, and Accounts Payable and Accrued Expenses approximated their carrying values due to the short-term nature of these assets and liabilities. (q) Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements. For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as Unrealized Foreign Currency Translation Gain or Loss. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate As of Three Months Ended Nine Months Ended September 30, December 31, Currency 2024 2023 2024 2023 2024 2023 1 AUD = 0.67 USD 0.65 USD 0.66 USD 0.67 USD 0.69 USD 0.68 USD (r) Reclassifications Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive (loss) income, shareholders’ equity (deficit), or cash flows. (s) Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 10. The Company accounts for share-based payments in accordance with ASC Subtopic 718, Compensation - Stock Compensation The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note 10 for further details. (t) Leases The Company applies ASC Topic 842, Leases The Company determines if an arrangement is a lease at contract inception. The Company’s contracts are determined to contain a lease when all of the following criteria, based on the specific circumstances of the arrangement, are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset. At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreement does not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate (“IBR”), to discount lease payments, which represents the rate of interest the Company would pay to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. (u) Net (Loss) Income per Common Share Net (Loss) Income per Common Share is computed by dividing net (loss) income attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company has included the Pre-Funded Warrants issued in January 2024 and September 2024 (See Note 6) in its computation of basic and diluted net (loss) income per share due to their nominal exercise prices. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an addition to net loss or a reduction of net income in determining basic and diluted net (loss) income attributable to common stockholders. As the Company reported a net loss for the nine months ended September 30, 2024 and 2023 and the three months ended September 30, 2024, the calculation of diluted net loss per common share is the same as basic net loss per common share. For the three months ended September 30, 2023, all securities that could potentially dilute basic earnings per share in the future have been excluded from the diluted calculation because the effect would be antidilutive. The potential dilutive securities for the three months ended September 30, 2023 included: common stock warrants, stock options and unvested restricted stock units granted under the 2022 Plan. As a result of the Reverse Stock Split, which was effective as of August 12, 2024, all shares of outstanding common stock and net (loss) income per common share calculations have been retroactively adjusted for all periods presented. (v) Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. (w) Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through November 14, 2024, which is the date the consolidated condensed financial statements were issued. See Note 12. (x) Recently Issued Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company’s financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated financial statements pursuant to the instructions to Form 10-K and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. Principles of Consolidation and Noncontrolling Interest The Company’s consolidated financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd, as well as the financial statements of 60P Singapore Pty Lte, a wholly owned subsidiary of 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. 60P Singapore Pty Lte was closed via dissolution as of March 31, 2022. 60P Singapore Pty Lte was originally set up to conduct research in Singapore. The entity had no assets and its liabilities were to both 60P Australia Pty Ltd, its direct owner, and 60P. Through consolidation accounting the closure of the business unit resulted in a currency exchange gain. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated financial statements. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. The increase in the Company’s proportional interest is reflected as a Contribution from Noncontrolling Interest in the accompanying Consolidated Statements of Shareholders’ and Members’ Equity (Deficit). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, and valuation allowance for the deferred tax asset. Cash and Cash Equivalents The Company’s cash consists of cash deposited in demand accounts at financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company considers short-term highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at times, may exceed the FDIC insurable limits (currently $250,000). The Company has not experienced any losses related to amounts in excess of FDIC Limits. The Company periodically assesses the credit risk associated with these financial institutions and believes that the risk of loss is minimal. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, an Australian pharmaceutical distributor and a large American pharmaceutical distributor. There was no allowance as of December 31, 2023 and December 31, 2022. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. At December 31, 2023, the US government accounted for 13% of the outstanding accounts receivable balance (66% at December 31, 2022) and the American pharmaceutical distributor accounted for 79% of the outstanding accounts receivable balance (30% for the year ended December 31, 2022). Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number. The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to Cost of Revenues in the Consolidated Statements of Operations and Comprehensive Loss. During the year ended December 31, 2023, write-downs for expired inventory totaled $191,111 ($162,222 for the year ended December 31, 2022). Property and Equipment Property and equipment are stated at cost. Normal repairs and maintenance costs are charged to earnings as incurred and additions and major improvements are capitalized. The cost of assets retired or otherwise disposed of and the related depreciation are eliminated from the accounts in the period of disposal and the resulting gain or loss is credited or charged to earnings. Depreciation is computed over the estimated useful lives of the related asset type or term of the operating lease using the straight-line method for financial statement purposes. The estimated service lives for Property and Equipment is either three (3), five (5) or seven (7) years. Impairment of Long-lived Assets Long-lived assets, such as property and equipment and identifiable intangibles with finite useful lives, are periodically evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We look for indicators of a trigger event for asset impairment and pay attention to any adverse change in the extent or manner in which the asset is being used or in its physical condition. Assets are grouped and evaluated for impairment at the lowest level of which there are identifiable cash flows, which is generally at a location level. Assets are reviewed using factors including, but not limited to, our future operating plans and projected cash flows. The determination of whether impairment has occurred is based on an estimate of undiscounted future cash flows directly related to the assets, compared to the carrying value of the assets. If the sum of the undiscounted future cash flows of the assets does not exceed the carrying value of the assets, full or partial impairment may exist. If the asset’s carrying amount exceeds its fair value, an impairment charge is recognized in the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined using an income approach, which requires discounting the estimated future cash flows associated with the asset. Intangible Assets The Company capitalizes its patent and filing fees and legal patent and prosecution fees in connection with internally developed pending patents. When pending patents are issued, patents will be amortized over the expected period to be benefitted, not to exceed the patent lives, which may be as long as ten to fifteen years. Website Development Costs The Company accounts for website development costs in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic No. 350-50, Website Development Costs. Accordingly, all costs incurred in the planning stage are expensed as incurred, costs incurred in the website application and infrastructure development stage that meet specific criteria are capitalized and costs incurred in the day-to-day operation of the website are expensed as incurred. All costs associated with the websites are subject to straight-line amortization over a three-year period. Gain/Loss on Debt Extinguishment Gain or loss on debt extinguishment is generally recorded upon an extinguishment of a debt instrument or the conversion of certain of the Company’s convertible debt determined to have variable share settlement features. Gain or loss on extinguishment of debt is calculated as the difference between the reacquisition price and net carrying amount of the debt, which includes unamortized debt issuance costs and the fair value of any related derivative instruments. In the case of debt instruments for which the fair value option has been elected, the net carrying value is equal to its fair value on the date of extinguishment and no gain or loss is recognized. Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of December 31, 2023, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date. Equity-Classified Warrants The Company accounts for the Tradeable Warrants, the Non-tradeable Warrants, the Representative Warrants, and the Bridge Warrants (following the IPO, see Note 6) as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding. IPO and Over-Allotment The Over-Allotment option granted to the underwriters was evaluated in accordance with the guidance in ASC 480 and ASC 815 and was determined to meet all of the criteria for equity classification. The Company allocated the proceeds from the sale of the IPO units (net of offering costs paid at closing and deferred offering costs incurred prior to the IPO) between the common stock, the Tradeable Warrants, the Non-tradeable Warrants, and the Over-Allotment, using the relative fair value method. Original Issue Discount (“OID”) For certain notes issued, the Company may provide the debt holder with an original issue discount. The original issue discount is recorded as a debt discount and is amortized to interest expense using the effective interest method over the life of the debt in the Consolidated Statements of Operations and Comprehensive Loss. Debt Issuance Costs Debt issuance costs paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense over the life of the underlying debt instrument, in the Consolidated Statements of Operations and Comprehensive Loss, with the exception of certain debt for which we elected the fair value option. Debt issuance costs associated with debt for which the fair value option is elected are expensed as incurred. Income Taxes 60 Degrees Pharmaceuticals, Inc. is a corporation and has accepted the default taxation status of C corporation. The Merger in 2022 (See Note 6) did not materially impact tax matters as 60P LLC had elected to be taxed as a C corporation for income tax purposes at the beginning of 2022. The District of Columbia (“DC”) taxes corporations on form D-20 (DC Corporation Franchise Tax Return) and returns have a minimum tax due of $250 if gross receipts are at $1 million or less and $1,000 if above. The tax years that remain subject to examination by major tax jurisdictions include the years ended December 31, 2020, 2021, 2022 and 2023. 60P Australia Pty Ltd. is subject to the taxes of the Australian Taxation Office and 60P Singapore Pte Ltd. was subject to the taxes of the Inland Revenue Authority of Singapore prior to its dissolution as of March 31, 2022. Management assesses, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carry-back net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. On the basis of this evaluation, the Company has determined that it is more likely than not that the Company will not recognize the benefits of the U.S. Federal, state and net deferred tax assets, and, as a result, a full valuation allowance has been set against its net deferred tax assets as of December 31, 2023 and December 31, 2022. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. The Company establishes reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when the Company believes that certain positions might be challenged despite its belief that its tax return positions are fully supportable. The Company adjusts these reserves in light of changing facts and circumstances, such as the outcome of tax examinations. As of December 31, 2023 and December 31, 2022, no reserves for uncertain tax positions have been established. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as income tax expense. During the years ended December 31, 2023 and 2022 the Company did not recognize interest and penalties related to unrecognized tax benefits. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively) and 93% of total net revenues (consisting of two significant customers at 72% and 21%, respectively). At December 31, 2022, 96% of the Company’s receivables (consisting of three customers and two significant customers at 66% and 30%), and 100% of total net revenues (consisting of four customers and three significant at 40%, 39% and 14%, respectively). Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended in 2022 and near-term receivables and revenues from the government are not currently anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). As of December 31, 2023, 0% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, previously the senior secured lender and also a publicly traded Canadian company. Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. To date, the Company has managed its business in one identifiable segment. Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers. Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $691,770 in research and development costs during the year ended December 31, 2023 ($525,563 for the year ended December 31, 2022). During the year ended December 31, 2023, the Company has also issued shares of common stock to nonemployees in exchange for research and development services. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. 718, Compensation-Stock Compensation. See Note 11 for further details. Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the Consolidated Balance Sheets and any change in fair value unrelated to credit risk is recorded in Other Expense, net in the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value related to credit risk are recognized in Other Comprehensive Loss. As a result of the completion of the IPO, all financial instruments for which the FVO was elected were extinguished. See Note 8 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at December 31, 2023, and December 31, 2022 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 9 for more information on Derivative Liabilities. Liabilities measured at fair value at December 31, 2023 and 2022 are as follows: December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200 There were no transfers of financial instruments between Level 1, Level 2, and Level 3 during the periods presented. However, certain liabilities measured at fair value and using Level 3 inputs were extinguished during the year. A rollforward of level 3 liabilities measured at fair value for the years ended December 31, 2023 and 2022 are presented in Notes 8 and 9 for Promissory Notes and Derivative Liabilities, respectively. Assets and Liabilities Not Measured at Fair Value on a Recurring Basis In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company’s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the assets’ projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized. As of December 31, 2023 and 2022, the fair value of Cash and Cash Equivalents, Accounts Receivable, Prepaid Expenses and Other Current Assets, and Accounts Payable and Accrued Expenses approximated their carrying values due to the short-term nature of these assets and liabilities. Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated financial statements of the Company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated financial statements. For the purpose of presenting consolidated financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as Unrealized Foreign Currency Translation Gain (Loss). Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Year Ended As of Currency 2023 2022 December 31, December 31, 1 AUD = 0.66 USD 0.69 USD 0.68 USD 0.68 USD 1 SGD = NA 1.02 AUD* NA 1.02 AUD* * Through 4/30/2022 (account closure date) Reclassifications Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive loss, shareholders’ and members’ equity (deficit), or cash flows. Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 11. The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur. The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note 11 for further details. Leases The Company applies ASC Topic 842, Leases The Company determines if an arrangement is a lease at contract inception. The Company’s contracts are determined to contain a lease when all of the following criteria, based on the specific circumstances of the arrangement, are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset. At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreement does not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate (“IBR”), to discount lease payments, which represents the rate of interest the Company would pay to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Net Loss per Common Share Net Loss per Common Share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during each period. For the purposes of calculating the weighted average number of common shares outstanding for periods prior to the Merger (See Note 6), each of 60P LLC’s outstanding membership units as of June 1, 2022 have been retrospectively adjusted for the equivalent number of common shares issued pursuant to the Merger. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an addition to net loss in determining basic and diluted net loss attributable to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share

Inventory

Inventory	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Inventory [Abstract]
INVENTORY	3. INVENTORY Inventory consists of the following major classes: September 30, December 31, Work in Process $ 367,587 $ 278,987 Finished Goods 84,449 187,182 Inventory $ 452,036 $ 466,169	3. INVENTORY Inventory consists of the following major classes: December 31, December 31, Raw Material (API) $ - $ 397,487 Work in Process 278,987 97,486 Finished Goods 187,182 183,943 Total Inventory 466,169 678,916 Reserve for Expiring Inventory - (160,338 ) Inventory, net $ 466,169 $ 518,578

Property and Equipment

Property and Equipment	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT As of September 30, 2024 and December 31, 2023, Property and Equipment, net consists of: September 30, December 31, Lab Equipment $ 233,411 $ 132,911 Machinery 55,800 55,800 Computer Equipment 7,000 14,084 Furniture 3,030 3,030 Property and Equipment, at cost 299,241 205,825 Accumulated Depreciation (143,984 ) (148,064 ) Property and Equipment, Net $ 155,257 $ 57,761 Machinery of $55,800 has not yet been placed into service and therefore depreciation has not commenced as of September 30, 2024. Depreciation expense for the three months ended September 30, 2024 and 2023 was in the amount of $4,334 and $5,485, respectively ($6,277 and $19,287 for the nine months ended September 30, 2024 and 2023, respectively).	4. PROPERTY AND EQUIPMENT As of December 31, 2023 and 2022, Property and Equipment, net consists of: December 31, December 31, 2023 2022 Lab Equipment $ 132,911 $ 132,911 Machinery 55,800 - Computer Equipment 14,084 12,261 Furniture 3,030 3,030 Property and Equipment, at cost 205,825 148,202 Accumulated Depreciation (148,064 ) (126,902 ) Property and Equipment, Net $ 57,761 $ 21,300 Depreciation expenses for the years ended December 31, 2023 and 2022 were in the amount of $21,162 and $27,648, respectively.

Intangible Assets

Intangible Assets	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets [Abstract]
INTANGIBLE ASSETS	5. INTANGIBLE ASSETS As of September 30, 2024 and December 31, 2023, Intangible Assets, net consists of: September 30, December 31, Patents $ 225,485 $ 185,595 Website Development Costs 104,622 79,248 Intangible Assets, at cost 330,107 264,843 Accumulated Amortization (65,756 ) (37,585 ) Intangible Assets, net $ 264,351 $ 227,258 During the three months ended September 30, 2024 and 2023, the Company capitalized website development-related costs of $3,299 and $12,283, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www.60degreespharma.com ($25,374 and $52,178 for the nine months ended September 30, 2024 and 2023, respectively). Amortization expenses for the three months ended September 30, 2024 and 2023 were in the amounts of $10,325 and $7,414, respectively ($28,004 and $20,606 for the nine months ended September 30, 2024 and 2023, respectively). During the three months ended September 30, 2024 and 2023, there were write-downs for expired or obsolete patents of $2,922 and $0, respectively ($11,300 and $0 for the nine months ended September 30, 2024 and 2023, respectively). The following table summarizes the estimated future amortization expense for our patents and website development costs as of September 30, 2024: Period Patents Website Development 2024 (remaining three months) $ 1,753 $ 8,718 2025 7,010 31,761 2026 7,010 12,432 2027 7,010 3,094 2028 7,010 - Thereafter 51,106 - Total $ 80,899 $ 56,005 The Company has recorded $128,722 in capitalized patent expenses that will become amortizable as the patents they are associated with are awarded.	5. INTANGIBLE ASSETS As of December 31, 2023 and 2022, Intangible Assets, net consist of: December 31, December 31, Patents $ 185,595 $ 145,613 Website Development Costs 79,248 27,070 Intangible Assets, at cost 264,843 172,683 Accumulated Amortization (37,585 ) (8,428 ) Intangible Assets, net $ 227,258 $ 164,255 During the years ended December 31, 2023 and 2022, the Company capitalized website development or related costs of $52,178 and $27,070, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www. 60degreespharma.com. Amortization expense for the years ended December 31, 2023, and 2022 was in the amount of $29,157 and $5,118, respectively. The following table summarizes the estimated future amortization expense for our patents and website development costs as of December 31, 2023: Period Patents Website 2024 $ 6,612 $ 26,416 2025 6,612 23,303 2026 6,612 3,974 2027 6,612 - 2028 6,612 - Thereafter 41,817 - Total $ 74,877 $ 53,693 The Company additionally has $93,545 in capitalized patent expenses that will become amortizable as the patents they are associated with are awarded.

Stockholders' Equity

Stockholders' Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	6. STOCKHOLDERS’ EQUITY Pursuant to the Certificate of Incorporation of 60 Degrees Pharmaceuticals, Inc., the Company’s authorized shares consist of (a) 150,000,000 shares of common stock, par value $0.0001 per share and (b) 1,000,000 shares of preferred stock, par value $0.0001 per share, of which 80,965 have been designated as Series A Non-Voting Convertible Preferred Stock (“Series A Preferred Stock”). As of September 30, 2024, 1,861,914 shares of common stock and 76,480 shares of Series A Preferred Stock are issued and outstanding. Following stockholder approval in July 2024, on July 30, 2024, the Company filed an Amendment to the Certificate of Incorporation with the Secretary of State of Delaware to effect the 1:12 Reverse Stock Split of the issued and outstanding shares of the Company’s common stock, which was effective as of August 12, 2024. As of the effective time of the Reverse Stock Split, every twelve (12) issued and outstanding shares of the Company’s common stock were automatically combined and converted into one (1) issued and outstanding share of the Company’s common stock, reducing the number of shares of common stock outstanding from 21,219,937 shares to 1,768,337 shares. No fractional shares of common stock were issued in connection with the Reverse Stock Split and all fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. The Company issued an additional 93,563 shares of common stock on August 19, 2024 for rounding due to fractional shares. The Reverse Stock Split did not change the authorized number of shares of common stock or preferred stock, or the number of issued and outstanding shares of Series A Preferred Stock. All references to numbers of shares of the Company’s common stock and per share information have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Split. (a) Common Stock In January and March 2023, the Board of Directors, with the consent of Tyrone Miller and Geoffrey S. Dow, respectively, approved resolutions to cancel an aggregate of 16,009 shares of common stock issued to Tyrone Miller and 104,910 shares of common stock issued to the Geoffrey S. Dow Revocable Trust to allow the Company to issue new shares to vendors in exchange for valuable services to be provided for use in the Company’s operations. The cancelled shares represented approximately 61% of the issued and outstanding shares as of December 31, 2022. In January and March 2023, the Company issued a total of 120,253 shares of common stock to certain vendors as payment for services rendered or to be provided to the Company. In connection with the closing of the Company’s IPO as discussed in Note 1, the Company issued common stock as follows: ● As a result of the effectiveness of the Registration Statement on July 11, 2023, the Company issued a total of 3,336 restricted shares of common stock to the following directors and in the amounts listed: (i) Stephen Toovey (834 restricted shares of common stock), (ii) Charles Allen (834 restricted shares of common stock), (iii) Paul Field (834 restricted shares of common stock) and (iv) Cheryl Xu (834 restricted shares of common stock), by virtue of the directors’ agreements discussed in Note 11. ● On July 14, 2023, the IPO closed, and the Company issued 117,925 shares of common stock from the sale of units at a price of $63.60 per unit, generating $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated IPO expenses. As a result of the completion of the IPO and as required under the terms of the respective agreements, on July 14, 2023: o The Company issued an aggregate of 142,270 shares of common stock upon conversion of the Company’s outstanding debt obligations as follows: (i) 31,996 shares issued to the holders of the 2022 and 2023 Bridge Notes and the Related Party Notes, (ii) 17,912 shares issued pursuant to the Xu Yu Note, including the Amendment, and (iii) 92,362 shares issued to Knight upon conversion of the principal amount of the Convertible Knight Loan, in each case at the conversion prices detailed in Note 8. o The Company issued 2,438 shares of common stock to BioIntelect as deferred equity compensation valued in the amount of $155,000. In July 2023, the Company issued an aggregate of 15,371 shares of common stock upon the exercise of (i) 2,621 Bridge Warrants (as defined below), (ii) 5,000 Non-tradeable Warrants, and (iii) 7,750 Tradeable Warrants. On July 25, 2023, the Company converted 2,162 shares of Series A Preferred Stock held by Knight into 3,797 shares of common stock. On January 29, 2024, the Company, entered into an Underwriting Agreement with WallachBeth Capital LLC (the “Underwriting Agreement”), relating to the Company’s public offering (the “January 2024 Offering”) of 438,409 units (the “Units”) at an offering price of $4.62 per Unit and 83,259 pre-funded units (the “Pre-Funded Units”) at an offering price of $4.50 per Pre-Funded Unit. Each Unit consisted of one share of common stock and one warrant exercisable for one share of common stock (the “January 2024 Warrants”). Each January 2024 Warrant has an exercise price of $5.082 per share (110% of the offering price per Unit), was exercisable immediately upon issuance and expires five years from the date of issuance. Each Pre-Funded Unit consists of one pre-funded warrant exercisable for one share of common stock (the “January 2024 Pre-Funded Warrants”) and one warrant identical to the January 2024 Warrants included in the Units. The purchase price of each Pre-Funded Unit was equal to the price per Unit sold to the public in the offering, minus $0.12, and the exercise price of each January 2024 Pre-Funded Warrant is $0.12 per share. The January 2024 Pre-Funded Warrants were immediately exercisable and may be exercised at any time until exercised in full. The Company granted WallachBeth Capital LLC an option, exercisable within 45 days after the closing of the offering, to purchase up to 65,762 shares of the Company’s common stock at a price of $4.62 per share and/or 78,250 January 2024 Warrants at a price of $0.12 per warrant and/or 12,489 January 2024 Pre-Funded Warrants at a price of $4.50 per pre-funded warrant, or any combination of additional shares of common stock, January 2024 Warrants and/or January 2024 Pre-Funded Warrants, representing, in the aggregate, up to 15% of the number of Units sold in the offering, 15% of the January 2024 Warrants underlying the Units and Pre-Funded Units sold in the offering and 15% of the January 2024 Pre-Funded Warrants underlying the Pre-Funded Units sold in the offering, in all cases less the underwriting discount to cover over-allotments, if any. WallachBeth Capital LLC partially exercised its over-allotment option with respect to 68,182 January 2024 Warrants on January 31, 2024, and purchased an additional 5 shares of common stock at a purchase price of $4.50 per share and 5 January 2024 Warrants at a purchase price of $0.12 per warrant on February 14, 2024. The Company also issued to WallachBeth Capital LLC warrants (the “January 2024 Representative Warrants”) to purchase 31,300 shares of the Company’s common stock, which is equal to 6% of the common stock sold that were part of the Units and the January 2024 Pre-Funded Warrants sold in the Offering, at an exercise price of $5.082 per share (110% of the offering price per Unit). The January 2024 Representative Warrants are exercisable beginning on January 31, 2024 until January 31, 2029. The Units and Pre-Funded Units were offered and sold pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-276641), originally filed with the SEC on January 22, 2024 (the “January 2024 Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The January 2024 Registration Statement was declared effective by the SEC on January 29, 2024. The closing of the January 2024 Offering occurred on January 31, 2024. The net proceeds to the Company from the January 2024 Offering were approximately $1.9 million, after deducting underwriting discounts and commissions and the payment of other offering expenses payable by the Company. On February 1, 2024 and April 9, 2024, the Company issued 41,630 shares and 41,629 shares of common stock, respectively upon the exercise of 41,630 and 41,629 January 2024 Pre-Funded Warrants, respectively, resulting in aggregate proceeds to the Company of $9,990. On April 1, 2024, the Company entered into an Amendment to the Debt Exchange Agreement with Trevally, LLC (“Trevally”), which amends the original agreement with Trevally (executed in January 2023). Pursuant to the Amendment, Trevally agreed to return 10,000 shares of the Company’s common stock, initially issued to Trevally in January 2023 as advance consideration for agreeing to complete the synthesis of research materials for the Company. Trevally returned the previously issued shares for no consideration on April 3, 2024. Trevally delivered the completed research materials to the Company on July 1, 2024. On July 12, 2024, the Company entered into an At-the-Market Issuance Sales Agreement (the “ATM Agreement”) with WallachBeth Capital LLC as sales agent, to sell shares of common stock having an aggregate offering price of up to $1,253,603 from time to time, through an “at the market offering” program (the “ATM Offering”). The offer and sale of shares of common stock from the ATM Offering was made pursuant to the Company’s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796) contained therein which became effective on July 18, 2024. The prospectus supplement was subsequently amended on July 22, 2024, July 24, 2024, July 26, 2024, and August 2, 2024, to increase the maximum aggregate offering price under the ATM Agreement to $1,774,640, $1,890,705, $2,190,416, and $2,295,192, respectively. From July 19, 2024 to August 1, 2024, the Company sold a total of 677,819 shares in the ATM Offering, for gross proceeds of $1,994,583. On July 22, 2024 and July 26, 2024, the Company converted 1,291 and 1,032 shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into 40,000 shares and 33,334 shares of common stock, respectively. (b) Common Stock Warrants As of September 30, 2024, the Company accounts for all issued and outstanding warrants to purchase common stock as equity-classified instruments based on the guidance in ASC 480 and ASC 815. In May 2022 and May 2023, in connection with the issuance of the Related Party Notes and the 2022 and 2023 Bridge Notes as described in Note 8, the Company issued five-year warrants to each of the noteholders with an exercise price dependent on the IPO price (collectively, the “Bridge Warrants”). The number of shares issuable upon exercise of the warrants was contingent on the number of shares issued upon conversion of the notes following the Company’s IPO. As of the closing of the Company’s IPO, the Bridge Warrants became exercisable into an aggregate of 19,330 shares of the Company’s common stock, 6,661 of which have an exercise price of $57.24 (90% of the IPO price), and 12,669 with an exercise price of $69.96 (110% of the IPO Price). Prior to the IPO, the Bridge Warrants were classified as derivative liabilities in accordance with the provisions of ASC 815 and were carried at their respective fair values. (See Note 8). In connection with the IPO, the terms of the Bridge Warrants became fixed. The Company determined the event resulted in equity classification for the Bridge Warrants and, accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified the warrants to additional paid-in capital. As of the respective issuance dates, the Company accounts for the Tradeable Warrants, the Non-tradeable Warrants, and the IPO Representative Warrants (each as defined in Note 1), the January 2024 Pre-Funded Warrants, the January 2024 Warrants, and the January 2024 Representative Warrants (each as defined above) as equity-classified financial instruments. On September 4, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor, agreeing to issue and sell in a private placement offering (the “Private Placement”) (i) pre-funded warrants to purchase 2,898,551 shares of common stock (the “September 2024 Pre-Funded Warrants”), (ii) series A warrants to purchase 2,898,551 shares of common stock (the “Series A Warrants”), and (iii) series B warrants to purchase 2,898,551 shares of common stock (the “Series B Warrants) at a price of $1.379 per Pre-Funded Warrant and accompanying Series A and Series B Warrants. The Private Placement closed on September 5, 2024, generating net proceeds to the Company of $3,414,502, after deducting placement agent fees and offering expenses. The September 2024 Pre-Funded Warrants have an exercise price of $0.001 per share and are immediately exercisable, subject to certain ownership restrictions, and will remain exercisable until exercised in full. The Series A and Series B Warrants have an exercise price of $1.38 per share and will be exercisable beginning on the effective date of stockholder approval to approve the exercise of the Series A and Series B Warrants and the September 2024 Agent Warrants, defined below, to comply with applicable listing rules and regulations of the Nasdaq Stock Market (“Stockholder Approval”, and such date that approval is obtained, the “Stockholder Approval Date”). The Series A Warrants expire five years after the Stockholder Approval Date and the Series B Warrants will expire 18 months after the Stockholder Approval Date. As compensation for acting as the placement agent for the Private Placement, the Company issued to H.C. Wainwright & Co., LLC warrants to purchase up to 217,391 shares of stock (the “September 2024 Agent Warrants”). The September 2024 Agent Warrants have substantially the same terms as the Series A Warrants, except that the September 2024 Agent Warrants have an exercise price equal to $1.725 per share. The following table presents a summary of the activity for the Company’s equity-classified warrants during the three and nine months ended September 30, 2023: Number of Weighted Weighted Total outstanding, December 31, 2022 - $ - - Total outstanding, March 31, 2023 - $ - - Total outstanding, June 30, 2023 - $ - - Reclassified from derivative liabilities 19,330 65.58 4.15 Granted 259,700 74.60 5.00 Exercised (15,371 ) 73.63 5.00 Forfeited - - - Expired - - - Total outstanding, September 30, 2023 263,659 $ 73.99 4.73 Total exercisable, September 30, 2023 263,659 $ 73.99 4.73 The following table presents a summary of the activity for the Company’s equity-classified warrants during the three and nine months ended September 30, 2024: Number of Weighted Weighted Total outstanding, December 31, 2023 263,659 $ 74.00 4.47 Granted 704,414 4.50 5.00 Exercised (41,630 ) 0.12 Indefinite Forfeited - - - Expired - - - Total outstanding, March 31, 2024 926,443 $ 24.47 4.67 Granted - - - Exercised (41,629 ) 0.12 Indefinite Forfeited - - - Expired - - - Total outstanding, June 30, 2024 884,814 $ 25.62 4.41 Granted (1) 8,913,044 0.94 - Exercised - - - Forfeited - - - Expired - - - Total outstanding, September 30, 2024 (1) 9,797,858 $ 3.17 4.16 Total exercisable, September 30, 2024 (2) 3,783,365 $ 5.99 4.16 (1) Weighted average remaining contractual life calculations exclude (i) 2,898,551 Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) 217,391 September 2024 Agent Warrants and 2,898,551 Series A Warrants issued September 2024 that will expire five years from the Stockholder Approval Date, defined above, and (iii) 2,898,551 Series B Warrants issued September 2024 that will expire eighteen months from the Stockholder Approval Date. (2) Weighted average remaining contractual life calculation excludes 2,898,551 exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date During the three and nine months ended September 30, 2023, the Company received aggregate cash proceeds of $1,131,771 upon the exercise of 2,621 Bridge Warrants with an exercise price of $69.96, 5,000 Non-tradeable Warrants with an exercise price of $76.32, and 7,750 Tradeable Warrants with an exercise price of $73.14. There were no warrants exercised during the three months ended September 30, 2024. During the nine months ended September 30, 2024, the Company received aggregate cash proceeds of $9,990 upon the exercise of 83,259 January 2024 Pre-Funded Warrants with an exercise price of $0.12. The following table summarizes the significant assumptions used in determining the fair value of equity-classified warrants granted during the nine months ended September 30, 2024: 2024 Stock price $ 3.36 Exercise price $ 5.08 Risk-free interest rate 3.91 % Expected volatility 95.00 % Expected term (years) 5.00 Expected dividend yield 0.00 % (c) Series A Preferred Stock The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below. Voting Rights Dividends Liquidation Rights - Conversion Rights	6. STOCKHOLDERS’ EQUITY On June 1, 2022, 60P LLC entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. (the “Merger”). The value of each outstanding member’s membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost basis equal to $5 per share. Pursuant to the Certificate of Incorporation of 60 Degrees Pharmaceuticals, Inc., the Company’s authorized shares consist of (a) 150,000,000 shares of common stock, par value $0.0001 per share and (b) 1,000,000 shares of preferred stock, par value $0.0001 per share, of which 80,965 have been designated as Series A Non-Voting Convertible Preferred Stock (“Series A Preferred Stock”). As of December 31, 2023, 5,810,089 shares of Common Stock and 78,803 shares of Series A Preferred Stock are issued and outstanding. Common Stock On June 30, 2022 the Company issued 37,067 shares of common stock to its Chief Executive Officer for $185,335 at a purchase price of $5 per share. In January and March 2023, the Board of Directors, with the consent of Tyrone Miller and Geoffrey S. Dow, respectively, approved resolutions to cancel an aggregate of 192,101 shares of common stock issued to Tyrone Miller and 1,258,899 shares of common stock issued to the Geoffrey S. Dow Revocable Trust to allow the Company to issue new shares to vendors in exchange for valuable services to be provided for use in the Company’s operations. The cancelled shares represented approximately 61% of the issued and outstanding shares as of December 31, 2022. In January and March 2023, the Company issued a total of 1,443,000 shares of common stock to certain vendors as payment for services rendered or to be provided to the Company. In connection with the closing of the Company’s IPO as discussed in Note 1, the Company issued common stock as follows: ● As a result of the effectiveness of the Registration Statement on July 11, 2023, the Company issued a total of 40,000 restricted shares of common stock to the following directors and in the amounts listed: (i) Stephen Toovey (10,000 restricted shares of common stock), (ii) Charles Allen (10,000 restricted shares of common stock), (iii) Paul Field (10,000 restricted shares of common stock) and (iv) Cheryl Xu (10,000 restricted shares of common stock), by virtue of the terms of the agreements discussed in Note 12. ● On July 13, 2023, the Company issued 31,447 shares of common stock upon the exercise of 31,447 Bridge Warrants (as defined below). ● On July 14, 2023, the IPO closed, and the Company issued 1,415,095 shares of common stock from the sale of units at a price of $5.30 per unit, generating $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated IPO expenses paid at closing. As a result of the completion of the IPO and as required under the terms of the respective agreements, on July 14, 2023: o The Company issued an aggregate of 383,908 shares of common stock upon conversion of the 2022 and 2023 Bridge Notes and the Related Party Notes described in Note 8. o The Company issued 29,245 shares of common stock to BioIntelect as deferred equity compensation valued in the amount of $155,000. o The Company issued 214,934 shares of common stock upon conversion of the Xu Yu Note, including the Amendment described in Note 8. o The Company issued 1,108,337 shares of common stock to Knight upon conversion of the cumulative outstanding principal as of March 31, 2022 at the conversion price detailed in Note 8 (representing 19.9% of our outstanding common stock after giving effect to the IPO). ● On July 17, 2023 the Company issued 60,000 shares of common stock upon the exercise of 60,000 Non-tradeable Warrants. ● On July 17, 2023, the Company issued 93,000 shares of common stock upon the exercise of 93,000 Tradeable Warrants. ● On July 28, 2023, the Company issued 45,560 shares of common stock to Knight upon conversion of 2,162 shares of Series A Preferred Stock. On December 28, 2023, the Company issued 10,554 shares of common stock to Red Chip as deferred equity compensation valued in the amount of $40,000, as required by the terms of the investment relations consulting agreement described in Note 7. Common Stock Warrants In May 2022 and May 2023, in connection with the issuance of the Related Party Notes and the 2022 and 2023 Bridge Notes as described in Note 8, the Company issued five-year warrants to each of the noteholders with an exercise price dependent on the IPO price (collectively, the “Bridge Warrants”). The number of shares issuable upon exercise of the warrants was contingent on the number of shares issued upon conversion of the notes following the Company’s IPO. As of the closing of the Company’s IPO, the Bridge Warrants became exercisable into an aggregate of 231,917 shares of the Company’s common stock, 79,926 of which are held by related parties and have an exercise price of $4.77 (90% of the IPO price), and 151,991 with an exercise price of $5.83 (110% of the IPO Price). Prior to the IPO, the Bridge Warrants were classified as derivative liabilities in accordance with the provisions of ASC 815 and were carried at their respective fair values. (See Note 9). In connection with the IPO, the terms of the Bridge Warrants became fixed. The Company determined the event resulted in equity classification for the Bridge Warrants and, accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified the warrants to Additional Paid-in Capital. On July 12, 2023, the Company executed a Warrant Agent Agreement with Equity Stock Transfer, LLC, acting as warrant agent for the IPO, which sets forth the procedures for registering, transferring and exercising the Tradeable Warrants and Non-tradeable Warrants issued in connection with the IPO. The Company accounts for the Tradeable Warrants, the Non-tradeable Warrants, and the Representative Warrants (defined in Note 1) as equity-classified financial instruments. There were no equity-classified warrants issued or outstanding prior to the Company’s IPO. The following table presents information related to stock warrants at December 31, 2023: Number of Weighted Weighted Total outstanding, December 31, 2022 - $ - - Reclassified from Derivative Liabilities 231,917 5.46 4.15 Granted 3,116,384 6.22 5.00 Exercised (184,447 ) 6.14 5.00 Forfeited - - - Expired - - - Total outstanding, December 31, 2023 3,163,854 $ 6.17 4.47 Total exercisable, December 31, 2023 3,163,854 $ 6.17 4.47 There were no warrant exercises, forfeitures, or expirations prior to the IPO. During the year ended December 31, 2023, the Company received aggregate cash proceeds of $1,131,771 upon the exercise of 31,447 Bridge Warrants, 60,000 Non-tradeable Warrants, and 93,000 Tradeable Warrants. The following table summarizes the significant assumptions used in determining the fair value of equity classified warrants on the respective grant or reclassification dates for the year ended December 31, 2023: 2023 Stock price $4.68 - 5.30 Exercise price $4.77 - 6.36 Risk-free interest rate 4.07 - 4.40 % Expected volatility 90 - 105 % Expected term (years) 3.86 - 5.00 Expected dividend yield 0.00% Series A Preferred Stock As described in Note 8, as a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the Company converted the entirety of the accumulated interest on the Convertible Knight Loan as of March 31, 2022 into 80,965 shares of Series A Preferred Stock at the Conversion Price detailed below. On July 25, 2023, the Company converted 2,162 shares of Series A Preferred Stock into 45,560 shares of Common Stock at the conversion rate detailed below. No The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below. Voting Rights Dividends Liquidation Rights - Conversion Rights

Debt

Debt	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Debt [Abstract]
DEBT	7. DEBT (a) Knight Therapeutics, Inc. On December 27, 2019 the Company restructured its cumulative borrowing with its senior secured lender, Knight Therapeutics, Inc. (“Knight”), into a note for the principal amount of $6,309,823 and accrued interest of $4,160,918 and a debenture of $3,483,851 (collectively, the “Knight Loan”). The Knight Loan had a maturity date of December 31, 2023. The principal and accrued interest portion of the Knight Loan bore an annual interest rate of 15%, compounded quarterly, whereas the debenture had a 9% interest rate until April 23, 2023 at which point interest ceased accruing. In January 2023, the Company and Knight executed the Knight Debt Conversion Agreement, pursuant to which the parties agreed to add a conversion feature to the cumulative outstanding Knight Loans, which was accounted for as a debt extinguishment, described further below. (b) Note, including Amendment The Company executed a promissory note (the “Note”) with an individual investor on October 11, 2017, later amended on December 11, 2022 (the “Amendment”). The Note, including the Amendment was set to mature 60 days after the Knight Loans were repaid, and contained a provision to automatically convert the outstanding principal and accumulated interest through March 31, 2022 into common shares in the event the Company consummated an IPO. Amortization of the discount on the Note, including the Amendment for the three months ended September 30, 2024 and 2023 was $0 and $3,869, respectively ($0 and $52,628 for the nine months ended September 30, 2024 and 2023, respectively). Interest expense related to the Note, including the Amendment, for the three months ended September 30, 2024 and 2023 was $0 and $4,944, respectively ($0 and $66,558 for the nine months ended September 30, 2024 and 2023, respectively). As a result of the completion of the IPO and as required under the terms of the Note, including the Amendment, the outstanding principal and accrued interest through March 31, 2022 converted to 17,912 shares of our common stock at a conversion rate equal to the IPO price, in full satisfaction of the outstanding debt obligation. The Company recognized a debt extinguishment gain of $223,077 upon conversion, representing the difference between (i) the reacquisition price, consisting of the fair value of the common shares issued, and (ii) the net carrying value of the debt, inclusive of unamortized discounts and issuance costs, on the date of conversion. As a result, as of September 30, 2024 and December 31, 2023 there were no amounts outstanding under the Note. (c) Convertible Promissory Notes and Warrants During May 2022 and May 2023 (the “2022 Bridge Notes” and “2023 Bridge Notes,” respectively), the Company executed promissory notes with various investors. The notes were due at the earlier of one year from the issuance date or the closing of an IPO. In connection with the issuance of the 2022 and 2023 Bridge Notes, the Company agreed to issue common stock to each noteholder equivalent to 100% of the face amount of the note divided by the IPO price per share. Additionally, each of these note holders received five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 110% of the IPO price. The Company performed an evaluation of the conversion features embedded in the 2022 and 2023 Bridge Notes and the warrants and concluded that such instruments qualified for treatment as derivative liabilities under ASC 815 and required bifurcation from the host contract. Derivative liabilities are carried at fair value at each balance sheet date, and any changes in fair value are recognized in the accompanying Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income. See Note 8 for further details. As a result of the completion of the IPO and as required under the terms of the 2022 and 2023 Bridge Notes, the Company issued the holders 25,335 shares of common stock, determined by the outstanding principal balance of each note divided by the IPO price. In addition, the Company made cash payments to the holders of the 2022 and 2023 Bridge Notes totaling $1,749,488, in full settlement of the outstanding debt obligations. The embedded derivative liability (conversion feature) was marked to market on the settlement date, and the Company recognized a debt extinguishment loss of $614,670 upon settlement, representing the difference between (i) the reacquisition price, consisting of cash and shares, and (ii) the net carrying value of the debt including associated derivative liabilities on the date of conversion. As such, as of September 30, 2024 and December 31, 2023 there were no amounts outstanding under the 2022 and 2023 Bridge Notes. (d) Related Party Notes During May 2022, the Company executed convertible promissory notes with the Company’s Chief Executive Officer and a family member related to the Chief Executive Officer. The notes were due at the earlier of one-year (1) from the issuance date or the closing of an IPO, later extended an additional two months to July 2023 (the “Related Party Notes”). Upon the closing of the IPO, these notes were mandatorily convertible at a conversion rate determined at a 20% discount to the IPO price, discussed further below. Additionally, each of these note holders received five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 90% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Related Party Notes and the warrants and concluded that such instruments qualified for treatment as derivative liabilities under ASC 815 and required bifurcation from the host contract. See Note 8 for further details. As a result of the completion of the IPO and as required under the terms of the Related Party Notes, the entirety of the outstanding principal balance converted to 6,661 shares of common stock at a conversion rate equal to 80% of the IPO price, fully satisfying the Company’s obligations with respect to the principal amount. In addition, the Company made cash payments to the related party holders totaling $31,968 in full settlement of the outstanding debt obligation. As such, as of September 30, 2024 and December 31, 2023 there were no amounts outstanding under the Related Party Notes. Significant terms of the Bridge Notes and Related Party Notes are summarized as follows: 2022 Related 2023 Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 2 Interest rate 10% 6% 10% Default interest rate 15% 15% 15% Collateral Unsecured Unsecured Unsecured Conversion rate 3 3 3 1 - earlier of 1 year from date of issuance or closing of IPO, later extended to July 2023 2 - earlier of 1 year from date of issuance or closing of IPO 3 - see discussion above in (c) and (d) for Bridge Notes and Related Party Notes, respectively For the nine months ended September 30, 2024 and 2023, the Company recorded amortization of debt discounts, including issuance costs, of $0 and $670,550, respectively. (e) Knight Debt Conversion On January 9, 2023, and in two subsequent amendments, the Company and Knight Therapeutics agreed to extinguish Knight’s debt in the event of an IPO. Key points of this agreement are as follows: ● The Parties agreed to fix Knight’s cumulative debt to the value as it stood on March 31, 2022, which consisted of $10,770,037 in principal and $8,096,486 in accumulated interest should the Company execute an IPO that results in gross proceeds of at least $7,000,000 prior to December 31, 2023. Should an IPO not occur by January 1, 2024 then all terms of the original debt would resume including any interest earned after March 31, 2022. ● The Parties agreed to convert the fixed principal amount into (i) that number of shares of common stock equal to dividing the principal amount by an amount equal to the offering price of the common stock in the IPO discounted by 15%, rounding up for fractional shares, in a number of common shares up to 19.9% of the Company’s outstanding common stock after giving effect of the IPO; (ii) the Company will make a milestone payment of $10 million to Knight if, after the date of a Qualifying IPO, the Company sells Arakoda™ or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda™ or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender; (iii) following the License and Supply agreement dated on December 10, 2015 and subsequently amended on January 21, 2019, an expansion of existing distribution rights to tafenoquine/Arakoda™ to include COVID-19 indications as well as malaria prevention across the Territory as defined in said documents, subject to US Army approval; and (iv) Company will retain Lender or an affiliate to provide financial consulting services, management, strategic and/or regulatory advice of value $30,000 per month for five years (the parties will negotiate the terms of that consulting agreement separately in good faith). ● The parties agreed to convert the accrued interest into that number of shares of a new class of preferred stock (the “Preferred Stock”) by dividing the fixed accumulated interest by $100.00, then rounding up. The Preferred Stock shall have the following rights, preferences, and designations: (i) have a 6% cumulative dividend accumulated annually on March 31; (ii) shall be non-voting stock; (iii) are not redeemable, (iv) be convertible to shares of common stock at a price equal to the lower of (1) the price paid for the shares of common stock in the initial public offering, as adjusted after the effective date of the Reverse Stock Split and (2) the 10 day volume weighted average share price immediately prior to conversion; and (v) conversion of the preferred stock to common shares will be at the Company’s sole discretion. Notwithstanding the foregoing, the Preferred Stock shall not be converted into shares of common stock if as a result of such conversion Knight will own 19.9% or more of our outstanding common stock. ● In addition to the conversion of the debt, for a period commencing on January 1, 2022 and ending upon the earlier of 10 years after the Closing or the conversion or redemption in full of the Preferred Stock, Company shall pay Lender a royalty equal to 3.5% of the Company’s net sales (the “Royalty”), where “Net Sales” has the same meaning as in the Company’s license agreement with the U.S. Army for tafenoquine. Upon success of the Qualified IPO, the Company shall calculate the royalty payable to Knight at the end of each calendar quarter. The Company shall pay to Knight the royalty amounts due with respect to a given calendar quarter within fifteen (15) business days after the end of such calendar quarter. Each payment of royalties due to Knight shall be accompanied by a statement specifying the total gross sales, the net sales and the deductions taken to arrive to net sales. For clarification purposes, the first royalty payment will be performed following the above instructions, on the first calendar quarter in which the Qualified IPO takes place and will cover the sales for the period from January 1, 2022 until the end of said calendar quarter. The Company evaluated the January 9, 2023 exchange agreement in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment because a substantial conversion feature was added to the debt terms. In January 2023, the Company recorded a loss upon extinguishment in the amount of $839,887 and elected to recognize the new debt under the ASC 825 fair value option until it was settled, which occurred in the third quarter of 2023 (see below). Therefore, there were no amounts outstanding as of September 30, 2024 or December 31, 2023. A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 21,815,841 Fair value - mark to market adjustment 1,064,849 Accrued interest recognized 659,306 Promissory Notes, at fair value at June 30, 2023 23,539,996 Fair value - mark to market adjustment (6,105,066 ) Extinguishment of Promissory Notes (17,434,930 ) Promissory Notes, at fair value at September 30, 2023 $ - As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 92,362 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,105,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment. The Company performed an evaluation of the contingent payment features and concluded that the contingent milestone payment is a freestanding financial instrument that meets the definition of a derivative under ASC 815, and accordingly, the fair value of the derivative liability is marked to market each reporting period until settled. The future Royalty payment due to Knight was determined to be an embedded component of the Series A Preferred Stock, however is exempt from derivative accounting under the ASC 815 scope exception for specified volumes of sales or service revenues. Therefore, the Company accrues a royalty expense within cost of sales as sales are made. (f) Debenture On April 24, 2019, 60P entered into the Knight debenture of $3,000,000 with an original issue discount of $2,100,000, which was being amortized using the effective interest method. The Company subsequently restructured the Knight Loans, including the debenture, pursuant to the Knight Debt Conversion Agreement (see above). $13,696 of the original issue discount was amortized to interest expense during the nine months ended September 30, 2023 prior to the amendment. The Knight Debt Conversion Agreement in January 2023 was accounted for as an extinguishment of the Debenture, as discussed above. Therefore, there were no amounts outstanding as of September 30, 2024 or December 31, 2023. (g) SBA COVID-19 EIDL On May 14, 2020, the Company received COVID-19 EIDL lending from the Small Business Administration (SBA) in the amount of $150,000. The loan bears interest at an annual rate of 3.75% calculated on a monthly basis. The balance as of September 30, 2024 and December 31, 2023 was $156,667 and $159,023, respectively. The current maturity at September 30, 2024 is $8,772 and the long-term liability is $147,895 ($8,772 and $150,251 at December 31, 2023, respectively). The loan is collateralized by all tangible and intangible personal property of the Company. The Company is prohibited from accepting future advances under any superior liens on the collateral without the prior consent of SBA. The current future payment obligations of the principal are as follows: Period Principal 2024 (remaining three months) $ - 2025 - 2026 683 2027 3,228 2028 3,342 Thereafter 142,747 Total $ 150,000 Due to the deferral, the Company is expected to make a balloon payment of approximately $28,154 to be due on October 12, 2050.	8. DEBT Knight Therapeutics, Inc. On December 27, 2019 the Company restructured its cumulative borrowing with its senior secured lender, Knight Therapeutics, Inc. (‘Knight’), into a note for the principal amount of $6,309,823 and accrued interest of $4,160,918 and a debenture of $3,483,851 (collectively, the ‘Knight Loan’). The Knight Loan had a maturity date of December 31, 2023. The principal and accrued interest portion of the Knight Loan bore an annual interest rate of 15%, compounded quarterly, whereas the debenture had a 9% interest rate until April 23, 2023 at which point interest ceased accruing. As of December 31, 2022, the aggregate outstanding balance of the Knight Loan was $20,596,595. In January 2023, the Company and Knight executed the Knight Debt Conversion Agreement, pursuant to which the parties agreed to add a conversion feature to the cumulative outstanding Knight Loans, which was accounted for as a debt extinguishment, described further below. Note, including Amendment On October 11, 2017 the Company issued a promissory note (“Note”) with an individual investor in the amount of $750,000. The Note was set to mature 60 days after the Knight Loans were repaid. The Note originally bore an interest rate of 5% from inception for the first six months and 10% per annum thereafter both compounded quarterly. On December 11, 2022, the Company and the individual investor amended the Note (“the Amendment”). The Amendment added a provision to automatically convert the outstanding principal and accumulated interest through March 31, 2022 into common shares in the event the Company consummated an IPO. The Amendment also provided the lender the option to convert the outstanding principal and accumulated interest through March 31, 2022 into equity shares of the Company at the maturity date, which option would expire 30 days after maturity. Cumulative interest after March 31, 2022 was to be forfeited should the lender elect to convert the Note into equity. At the Amendment date, the Company recorded a discount of $120,683 related to the excess fair value of the Note and incurred costs with third parties directly related to the Amendment of $1,767, which were amortized over the remaining life of the debt using the effective interest method. Amortization of the discount on the Note for the years ended December 31, 2023 and 2022 was $52,628 and $4,955, respectively. Interest expense related to the Note, for the years ended December 31, 2023 and 2022 was $66,558 and $115,546, respectively. As a result of the completion of the IPO and as required under the terms of the Note, including the Amendment, the outstanding principal and accrued interest through March 31, 2022 converted to 214,934 shares of our common stock at a conversion rate equal to the IPO price, in full satisfaction of the outstanding debt obligation. The Company recognized a debt extinguishment gain of $223,077 upon conversion, representing the difference (i) the reacquisition price, consisting of the fair value of the common shares issued, and (ii) the net carrying value of the debt, inclusive of unamortized discounts and issuance costs, on the date of conversion. Promissory notes are summarized as follows at December 31, 2023: Knight Note, Bridge Total Promissory Notes (including accrued interest) $  - $ - $ - $ - Promissory Notes (including accrued interest) - - - - Less Current Maturities - - - - Long Term Promissory Notes $ - $ - $ - $ - Promissory notes are summarized as follows at December 31, 2022: Knight Note, Bridge Total Promissory Notes (including accrued interest) $ 16,319,986 $ 1,109,783 $ 535,901 $ 17,965,670 Less Current Maturities 16,319,986 - 535,901 16,855,887 Long Term Promissory Notes $ - $ 1,109,783 $ - $ 1,109,783 Convertible Promissory Notes and Warrants During May 2022, the Company executed promissory notes having a face amount of $888,889. The notes contained an original issue discount of 10% ($88,889) and debt issuance costs of $91,436, resulting in net proceeds of $708,564. These notes bore interest at 10% with a default interest rate of 15% and were unsecured. The notes were due at the earlier of one year from the issuance date or the closing of an IPO (the “2022 Bridge Notes”). In connection with the issuance of the 2022 Bridge Notes, the Company agreed to issue common stock to each noteholder equivalent to 100% of the face amount of the note divided by the IPO price per share. Additionally, each of these note holders were entitled to receive five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 110% of the IPO price (See Note 6). In May 2023, the maturity date for the 2022 Bridge Notes was extended for an additional two months. In exchange for extension of the maturity date, the Company agreed to additional cash payments totaling $22,222 due to the holders of the 2022 Bridge Notes at maturity (the “Extension Payments”). During May 2023, the Company executed promissory notes having an aggregate face amount of $722,222. The notes contained an original issue discount of 10% ($72,222) and the Company incurred debt issuance costs of $95,000, resulting in net proceeds to the Company of $555,000. These notes bore interest at 10% with a default interest rate of 15% and were unsecured. The notes were due at the earlier of one-year from the issuance date or the closing of an IPO (the “2023 Bridge Notes”). In connection with the issuance of the 2023 Bridge Notes, the Company also agreed to issue common stock to each note holder equivalent to 100% of the face amount of the note divided by the IPO price per share. Additionally, each of these noteholders were entitled to receive five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 110% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Bridge Notes and the warrants and concluded that such instruments qualify for treatment as derivative liabilities under ASC 815 and require bifurcation from the host contract. Derivative liabilities are carried at fair value at each balance sheet date, and any changes in fair value are recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss. See Note 9 for further details. As a result of the completion of the IPO and as required under the terms of the 2022 and 2023 Bridge Notes, the Company issued the holders 303,982 shares of common stock, determined by the outstanding principal balance of each note divided by the IPO price. In addition, the Company made cash payments to the holders of the 2022 and 2023 Bridge Notes totaling $1,749,488 for the outstanding principal, accrued interest and Extension Payments (2022 Bridge Notes only), in full settlement of the outstanding debt obligations. The embedded derivative liability (conversion feature) was marked to market on the settlement date, and the Company recognized a debt extinguishment loss of $614,670 upon settlement, representing the difference between (i) the reacquisition price, consisting of cash and shares, and (ii) the net carrying value of the debt including associated derivative liabilities on the date of conversion. Related Party Notes During May 2022, the Company executed convertible promissory notes with the Company’s Chief Executive Officer and a family member related to the Chief Executive Officer, having an aggregate face amount of $338,889. The notes contained an original issue discount of 10% ($33,888) and debt issuance costs of $34,289, resulting in net proceeds of $270,711. These notes bore interest at 6% with a default interest rate of 15% and were unsecured. The notes were due at the earlier of one-year (1) from the issuance date or the closing of an IPO (the “Related Party Notes”). In May 2023, the maturity date for the Related Party Notes was extended for an additional two months. In exchange for extension of the maturity date, the Company agreed to additional cash payments totaling $8,472 due to the holders of the Related Party Notes at maturity (the “Extension Payments”). Upon the closing of the IPO, these notes were mandatorily convertible at a conversion rate determined at a 20% discount to the IPO price, discussed further below. Additionally, each of these note holders received five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 90% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Related Party Notes and the warrants and concluded that such instruments qualified for treatment as derivative liabilities under ASC 815 and required bifurcation from the host contract. See Note 9 for further details. Bridge Notes and Related Party Notes are summarized as follows at December 31, 2023 and 2022: 2022 Related 2023 Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 2 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 3 3 3 Face amount of notes $ 888,889 $ 338,889 $ - Less: unamortized debt discount (407,555 ) (155,443 ) - Add: accrued interest on promissory notes 54,567 11,651 - Balance - December 31, 2022 $ 535,901 $ 195,097 $ - Face amount of notes - - - Less: unamortized debt discount - - - Add: accrued interest on promissory notes - - - Balance - December 31, 2023 $ - $ - $ - 1 - earlier of 1 year from date of issuance or closing of IPO, later extended to July 2023 2 - earlier of 1 year from date of issuance or closing of IPO 3 - see discussion above for (a) and (b) For the years ended December 31, 2023 and 2022, the Company recorded amortization of debt discounts, including issuance costs, of $670,550 and $664,780, respectively. As a result of the completion of the IPO and as required under the terms of the Related Party Notes, the entirety of the outstanding principal balance converted to 79,926 shares of common stock at a conversion rate equal to 80% of the IPO price, fully satisfying the Company’s obligations with respect to the principal amount. In addition, the Company made cash payments to the related party holders totaling $31,968 in full settlement of the outstanding accrued interest and Extension Payments. The Company recognized a final mark to market adjustment of the embedded derivative liability (conversion feature), and as a result, no gain or loss was recognized on the debt extinguishment. Knight Debt Conversion On January 9, 2023, and in two subsequent amendments, the Company and Knight Therapeutics agreed to extinguish Knight’s debt in the event of an IPO. Key points of this agreement are as follows: ● The Parties agreed to fix Knight’s cumulative debt to the value as it stood on March 31, 2022, which consisted of $10,770,037 in principal and $8,096,486 in accumulated interest should the Company execute an IPO that results in gross proceeds of at least $7,000,000 prior to December 31, 2023. Should an IPO not occur by January 1, 2024 then all terms of the original debt would resume including any interest earned after March 31, 2022. ● The Parties agreed to convert the fixed principal amount into (i) that number of shares of common stock equal to dividing the principal amount by an amount equal to the offering price of the common stock in the IPO discounted by 15%, rounding up for fractional shares, in a number of common shares up to 19.9% of the Company’s outstanding common stock after giving effect of the IPO; (ii) the Company will make a milestone payment of $10 million to Knight if, after the date of a Qualifying IPO, the Company sells Arakoda™ or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda™ or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender; (iii) following the License and Supply agreement dated on December 10, 2015 and subsequently amended on January 21, 2019, an expansion of existing distribution rights to tafenoquine/Arakoda™ to include COVID-19 indications as well as malaria prevention across the Territory as defined in said documents, subject to US Army approval; and (iv) Company will retain Lender or an affiliate to provide financial consulting services, management, strategic and/or regulatory advice of value $30,000 per month for five years (the parties will negotiate the terms of that consulting agreement separately in good faith). ● The parties agreed to convert the accrued interest into that number of shares of a new class of preferred stock (the “Preferred Stock”) by dividing the fixed accumulated interest by $100.00, then rounding up. The Preferred Stock shall have the following rights, preferences, and designations: (i) have a 6% cumulative dividend accumulated annually on March 31; (ii) shall be non-voting stock; (iii) are not redeemable, (iv) be convertible to shares of common stock at a price equal to the lower of (1) the price paid for the shares of common stock in the initial public offering and (2) the 10 day volume weighted average share price immediately prior to conversion; and (v) conversion of the preferred stock to common shares will be at the Company’s sole discretion. Notwithstanding the foregoing, the Preferred Stock shall not be converted into shares of common stock if as a result of such conversion Knight will own 19.9% or more of our outstanding common stock. ● In addition to the conversion of the debt, for a period commencing on January 1, 2022 and ending upon the earlier of 10 years after the Closing or the conversion or redemption in full of the Preferred Stock, Company shall pay Lender a royalty equal to 3.5% of the Company’s net sales (the “Royalty”), where “Net Sales” has the same meaning as in the Company’s license agreement with the U.S. Army for tafenoquine. Upon success of the Qualified IPO, the Company shall calculate the royalty payable to Knight at the end of each calendar quarter. The Company shall pay to Knight the royalty amounts due with respect to a given calendar quarter within fifteen (15) business days after the end of such calendar quarter. Each payment of royalties due to Knight shall be accompanied by a statement specifying the total gross sales, the net sales and the deductions taken to arrive to net sales. For clarification purposes, the first royalty payment will be performed following the above instructions, on the first calendar quarter in which the Qualified IPO takes place and will cover the sales for the period from January 1, 2022 until the end of said calendar quarter. The Company evaluated the January 9, 2023 exchange agreement in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment because a substantial conversion feature was added to the debt terms. Upon extinguishment, the Company recorded a loss upon extinguishment in the amount of $839,887 and elected to recognize the new debt under the ASC 825 fair value option until it is settled. A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the year ended December 31, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (5,379,269 ) Accrued interest recognized 1,293,549 Extinguishment of Promissory Notes (17,434,930 ) Promissory Notes, at fair value at December 31, 2023 $ - As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,105,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment. The Company performed an evaluation of the contingent payment features and concluded that the contingent milestone payment is a freestanding financial instrument that meets the definition of a derivative under ASC 815, and accordingly, the fair value of the derivative liability is marked to market each reporting period until settled. The future Royalty payment due to Knight was determined to be an embedded component of the Series A Preferred Stock, however is exempt from derivative accounting under the ASC 815 scope exception for specified volumes of sales or service revenues. Therefore, the Company accrues a royalty expense within cost of sales as sales are made. Debenture On April 24, 2019, 60P entered into the Knight debenture of $3,000,000 with an original issue discount of $2,100,000, which was being amortized using the effective interest method. The Company subsequently restructured the Knight Loans, including the debenture, pursuant to the Knight Debt Conversion Agreement (see above). $13,696 of the original issue discount was amortized to interest expense in 2023 prior to the amendment ($500,103 during the year ended December 31, 2022) and the unamortized original issue discount at December 31, 2023 was $0 ($279,061 at December 31, 2022) as a result of the debt conversion (discussed above), which was accounted for as a debt extinguishment. The Knight debenture as of December 31, 2023 and 2022 consisted of the following: December 31, December 31, Original Debenture $ - $ 3,000,000 Unamortized Debt Discount - (279,061 ) Debenture Prior to Accumulated Interest - 2,720,939 Accumulated Interest - 1,555,670 Debenture $ - $ 4,276,609 SBA COVID-19 EIDL On May 14, 2020, the Company received COVID-19 EIDL lending from the Small Business Administration (SBA) in the amount of $150,000. The loan bears interest at an annual rate of 3.75% calculated on a monthly basis. The Company was committed to make $731 monthly payments first due June 4, 2021. On March 31, 2021, the SBA announced the deferment period was extended an additional eighteen months. Thus, the Company was first obligated to start making interest payments of $731 on November 4, 2022. The balance as of December 31, 2023 and 2022 is $159,023 and $163,022, respectively. The current maturity at December 31, 2023 is $8,772 and the long-term liability is $150,251 ($2,750 and $160,272 at December 31, 2022, respectively). The loan is collateralized by all tangible and intangible personal property of the Company. The Company is prohibited from accepting future advances under any superior liens on the collateral without the prior consent of SBA. The current future payment obligations of the principal are as follows: Period Principal Payments 2024 $ - 2025 - 2026 683 2027 3,228 2028 3,342 Thereafter 142,747 Total $ 150,000 Due to the deferral, the Company is expected to make a balloon payment of approximately $28,154 to be due on 10/12/2050. Related Party Advances In March 2023, the Company received a $200,000 short term advance from the Geoffrey S. Dow Revocable Trust. In April 2023, the Company received $50,000 as a short-term advance from management. The Geoffrey S. Dow Revocable Trust contributed $23,000 and Tyrone Miller contributed $27,000. On May 11, 2023, these short term advances were refunded in full for an aggregate amount of $250,000.

Derivative Liabilities

Derivative Liabilities	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Derivative Liabilities [Abstract]
DERIVATIVE LIABILITIES	8. DERIVATIVE LIABILITIES In accordance with the provisions of ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities. As discussed in Notes 6 and 7 above, certain of the Company’s bridge shares, warrants and convertible notes (containing an embedded conversion feature) were previously accounted for as derivative liabilities. The bridge shares and related conversion features were derecognized upon conversion of the related debt obligations on the date of the IPO. In addition, certain of the Company’s common stock warrants were previously accounted for as derivative liabilities as there was an unknown exercise price and number of shares associated with each instrument. In connection with the IPO, the terms of these warrants became fixed, at which point the Company determined the warrants met all of the criteria for equity classification and reclassified the warrants to additional paid-in capital at their fair value on the IPO date. As of September 30, 2024, derivative liabilities consist of the contingent milestone payment due to Knight upon a future sale of Arakoda™ or a Change of Control (See Note 7). The valuation of the contingent milestone payment includes significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. In connection with the valuation of the Company’s derivative liabilities related to the 2023 Bridge Notes and warrants, the Company determined a fair value on the commitment date (May 8, 2023) of $954,725. As the fair value of the derivative liabilities exceeded the net proceeds received of $555,000, the Company recorded a debt discount at the maximum amount allowed (the face amount of the debt less the original issue discount and issuance costs) and recorded the excess as derivative expense. Derivative expense recorded during the three and nine months ended September 30, 2023 is summarized as follows: Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2024: Contingent Milestone Payment Total Derivative liabilities - December 31, 2023 $ 2,306,796 $ 2,306,796 Fair value - mark to market adjustment (1,740,847 ) (1,740,847 ) Derivative liabilities - March 31, 2024 565,949 565,949 Fair value - mark to market adjustment 1,101 1,101 Derivative liabilities - June 30, 2024 567,050 567,050 Fair value - mark to market adjustment 56,712 56,712 Derivative liabilities - September 30, 2024 $ 623,762 $ 623,762 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2023: Bridge Warrants Convertible Contingent Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ - $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) - 5,134 Derivative liabilities - March 31, 2023 839,254 579,853 80,227 - 1,499,334 Fair value - commitment date 680,276 274,449 - - 954,725 Fair value - mark to market adjustment 8,896 (17,009 ) 145 - (7,968 ) Derivative liabilities - June 30, 2023 1,528,426 837,293 80,372 - 2,446,091 Fair value - mark to market adjustment prior to conversion or reclassification (105,790 ) 1,455 (45,207 ) - (149,542 ) Conversion of convertible promissory notes (1,422,636 ) - (35,165 ) - (1,457,801 ) Reclassification of warrants to equity - (838,748 ) - - (838,748 ) Recognition of contingent milestone liability - - - 2,117,142 2,117,142 Fair value - mark to market adjustment - - - 57,052 57,052 Derivative liabilities - September 30, 2023 $ - $ - $ - $ 2,174,194 $ 2,174,194 Changes in fair value of derivative liabilities (mark to market adjustment) are included in other income (expense) in the accompanying Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income. During the nine months ended September 30, 2024 and 2023, the Company recorded a net gain on the change in fair of derivative liabilities of $1,683,034 and $95,324, respectively. Prior to the Company’s IPO, the fair value of the Company’s potential future issuances of common stock related to common stock issued with promissory notes, warrants and embedded conversion features in convertible promissory notes was established with an estimate using the Monte Carlo Simulation Model to compute fair value as of each reporting date. The Monte Carlo simulation requires the input of assumptions, including our stock price, the volatility of our stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considered the probability of the occurrence or nonoccurrence of an IPO within the terms of liability-classified financial instruments, as an IPO could potentially impact the settlement.	9. DERIVATIVE LIABILITIES In accordance with the provisions of ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities. As discussed in Note 8 above, certain of the Company’s bridge shares, warrants and convertible notes (containing an embedded conversion feature) were previously accounted for as derivative liabilities. The bridge shares and related conversion features were derecognized upon conversion on the date of the IPO. The Bridge Warrants (defined in Note 6) were previously accounted for as derivative liabilities as there was an unknown exercise price and number of shares associated with each instrument. In connection with the IPO, the terms of the Bridge Warrants became fixed. The Company determined the event resulted in equity classification for the Bridge Warrants. Accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified the warrants to additional paid-in capital on the IPO date. As of December 31, 2023, derivative liabilities consist of the contingent milestone payment due to Knight upon a future sale of Arakoda™ or a Change of Control (See Note 8). The valuation of the contingent milestone payment includes significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. In connection with the valuation of the Company’s derivative liabilities Derivative expense recorded during the year ended December 31, 2022 is summarized as follows: Commitment Date May 24, Fair value of derivative liabilities $ 1,483,888 Less: face amount of debt (979,275 ) Derivative expense $ 504,613 In connection with the valuation of the Company’s derivative liabilities related to the 2023 Bridge Notes and warrants, the Company determined a fair value on the commitment date (May 8, 2023) of $954,725. As the fair value of the derivative liabilities exceeded the net proceeds received of $555,000, the Company recorded a debt discount at the maximum amount allowed (the face amount of the debt less the OID and debt issuance costs detailed in Note 8) and recorded the excess as derivative expense. Derivative expense recorded during the year ended December 31, 2023 is summarized as follows: Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at December 31, 2023 and 2022: Bridge Shares Warrants Convertible Contingent Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ - $ 1,494,200 Fair value - mark to market adjustment 13,798 (15,320 ) (1,312 ) - (2,834 ) Fair value - commitment date 680,276 274,449 - - 954,725 Fair value - mark to market adjustment prior to conversion or reclassification (105,790 ) 1,455 (45,207 ) - (149,542 ) Conversion of convertible promissory notes (1,422,636 ) - (35,165 ) - (1,457,801 ) Reclassification of warrants to equity - (838,748 ) - - (838,748 ) Recognition of contingent milestone liability - - - 2,117,142 2,117,142 Fair value - mark to market adjustment - - - 189,654 189,654 Derivative liabilities - December 31, 2023 $ - $ - $ - $ 2,306,796 $ 2,306,796 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at December 31, 2022 and 2021: Bridge Shares Warrants Convertible Total Derivative liabilities - December 31, 2021 $ - $ - $ - $ - Fair value - commitment date 823,687 565,007 95,194 1,483,888 Fair value - mark to market adjustment 10,665 13,157 (13,510 ) 10,312 Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ 1,494,200 Changes in fair value of derivative liabilities (mark to market adjustment) are included in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. During the year ended December 31, 2023, the Company recorded a net change in the fair of derivative liabilities of ($37,278). During the year ended December 31, 2022, the Company recorded a net change in the fair value of derivative liabilities of ($10,312). On the respective commitment dates (Day 1 valuation), the fair value of the Company’s potential future issuances of common stock related to common stock issued with promissory notes, warrants and embedded conversion features in convertible promissory notes was established with an estimate using the Monte Carlo Simulation Model to compute fair value. The Monte Carlo simulation requires the input of assumptions, including our stock price, the volatility of our stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considered the probability of the occurrence or nonoccurrence of an IPO within the terms of liability-classified financial instruments, as an IPO could potentially impact the settlement. At each subsequent reporting period, the Company remeasures the fair value of liability-classified bridge shares, warrants and embedded conversion features in convertible promissory notes using the Monte Carlo simulation. The assumptions used to perform the Monte-Carlo Simulation as of the respective commitment dates, as well as December 31, 2022 were as follows: Commitment Dates May 2023 May 2022 Stock price $ 5.30 $ 5.00 Volatility 115.1 % 99.7 % Expected term (in years) - Notes 0.99 1.00-1.03 Expected term (in years) - Warrants 4.99 5.00 Risk-free interest rate 4.80 % 2.76% - 2.84% Dividend yield 0 % 0 % IPO probability (prior to note maturity date) 95 % 95 % Mark to Market December 31, Stock price $ 5.00 Volatility 101.9 % Expected term (in years) - Notes 0.39 - 0.41 Expected term (in years) - Warrants 4.39 Risk-free interest rate 4.06 % Dividend yield 0 % IPO probability (prior to note maturity date) 95 %

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Income Taxes [Abstract]
INCOME TAXES	9. INCOME TAXES The Company did not record a federal income tax provision or benefit for each of the three and nine months ended September 30, 2024 and 2023 due to taxable losses. The Company recorded a provision for income taxes for the District of Columbia of $250 and $63 for the three months ended September 30, 2024 and 2023, respectively, thereby reflecting the minimum statutory tax due ($751 and $189 for the nine months ended September 30, 2024 and 2023, respectively).	10. INCOME TAXES Loss before provision (benefit) for income taxes for the years ended December 31, 2023 and 2022 consisted of the following: For the Year Ended 2023 2022 United States $ (3,006,861 ) $ (5,807,367 ) Foreign (806,689 ) (369,917 ) Total Loss before Income Taxes $ (3,813,550 ) $ (6,177,284 ) The components of the provision (benefit) for income taxes consisted of the following: For the Year Ended 2023 2022 Current: Federal $ - $ - State 250 500 Foreign - - Total current provision (benefit) 250 500 Deferred: Federal - - State - - Foreign - - Total deferred provision (benefit) - - Total Benefit $ 250 $ 500 The reconciliation between income taxes computed at the U.S. statutory income tax rate to the Company’s provision (benefit) for income taxes for the years ended December 31, 2023 and 2022 are as follows: For the Year Ended December 31, 2023 2022 Benefit for income taxes at 21% rate $ (800,846 ) 21.0 % $ (1,297,230 ) 21.0 % State income taxes, net of federal benefit (364,618 ) 9.6 (478,515 ) 7.7 Impact of non-U.S. earnings (33,994 ) 0.9 (33,897 ) 0.5 Permanent differences 280,654 (7.4 ) - 0.0 Change in fair value of promissory note (1,129,646 ) 29.6 - 0.0 Non-deductible interest expense 304,962 -8.0 - 0.0 Other reconciling items, net 2,042,657 (53.6 ) 683,359 (11.1 ) Change in valuation allowance (298,919 ) 7.8 1,126,783 (18.2 ) Benefit for Income Taxes $ 250 (0.1 )% $ 500 (0.1 )% Significant components of the Company’s deferred tax assets (liabilities) as of December 31, 2023 and 2022 are as follows: As of December 31, 2023 2022 Deferred tax assets: Net operating loss carry-forward $ 3,453,126 $ 3,338,726 Non-deductible reserves 1,058 - Capitalized R&D costs 189,893 - Lease liability 3,756 - Share-based compensation 94,034 - Gross deferred tax assets 3,741,867 3,338,726 Less valuation allowance (3,043,135 ) (3,338,726 ) Total deferred tax assets, net of valuation allowance 698,732 - Deferred tax liabilities: Right of use asset (3,719 ) - Prepaid expenses (695,013 ) - Total deferred tax liabilities (698,732 ) - Net deferred tax liabilities $ - $ - The valuation allowance increased by $295,591 during 2023. In determining the need for a valuation allowance, the Company has given consideration to its worldwide cumulative loss position when assessing the weight of the sources of taxable income that can be used to support the realization of deferred tax assets. The Company has assessed, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carry-back net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. The Company has determined that it is more likely than not that the Company will not recognize the benefits of the U.S. Federal, state and net deferred tax assets, and, as a result, a full valuation allowance has been set against its net deferred tax assets as of December 31, 2023 and December 31, 2022. At December 31, 2023, the Company had U.S. federal and state net operating loss carryforwards of approximately $6,339,101 and $6,338,851 respectively. At December 31, 2022, the Company had U.S. federal and state net operating loss carryforwards of approximately $5,807,867 and $5,807,367, respectively. The U.S. federal and state net operating losses carryforward indefinitely but may only be used to offset 80% of annual taxable income due to the Tax Cuts and Jobs Act. The Company had $6,835,123 and $6,560,235 of foreign net operating loss carryforwards which carryforward indefinitely at December 31, 2023 and December 31, 2022, respectively. The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10 and therefore has not included a tabular roll forward of unrecognized tax benefits. As there are no uncertain tax positions recognized, interest and penalties have not been accrued. The Company is subject to income tax in the United States, as well as various state and international jurisdictions. The Company has not been audited by any state tax authorities in connection with income taxes. The Company has not been audited by international tax authorities or any states in connection with income taxes. The Company’s tax years December 31, 2020 through December 31, 2023 generally remain open to adjustment for all federal, state and foreign tax matters until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization, and the applicable statutes of limitation have expired in the utilization year. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Utilization of the NOL carryforwards may be subject to limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and interest limitation carryforwards that can be utilized annually to offset future taxable income and tax, respectively. There could be additional ownership changes in the future, which may result in additional limitations on the utilization of the NOL and tax credit carryforwards. The Company conducts business globally and, as a result, it files income tax returns in U.S. federal and state jurisdictions and in Australia. In the normal course of business, the Company may be subject to examination by taxing authorities throughout the world. The tax years that remain subject to examination by major tax jurisdictions include the years ended December 31, 2020, 2021, 2022 and 2023. As of December 31, 2023, the Company is not under income tax examination in any jurisdiction. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. The Company establishes reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when the Company believes that certain positions might be challenged despite its belief that its tax return positions are fully supportable. The Company adjusts these reserves in light of changing facts and circumstances, such as the outcome of tax examinations. As of December 31, 2023 and December 31, 2022, no reserves for uncertain tax positions have been established. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as income tax expense. During the years ended December 31, 2023 and 2022 the Company did not recognize interest and penalties related to unrecognized tax benefits.

Share-Based Compensation

Share-Based Compensation	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	10. SHARE-BASED COMPENSATION The following is a summary of share-based compensation expenses reported in the Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income for the three and nine months ended September 30, 2024 and 2023: For the For the 2024 2023 2024 2023 Research and Development $ 600,000 $ - $ 3,227,300 $ 188,908 General and Administrative Expenses 68,974 549,031 319,709 1,172,136 Total Share-Based Compensation Expense Included in Operating Expenses $ 668,974 $ 549,031 $ 3,547,009 $ 1,361,044 (a) Share-Based Compensation under 2022 Equity Incentive Plan On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan (the “2022 Plan”), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. The 2022 Plan provides for an automatic increase in the number of shares available for issuance beginning on January 1, 2023 and each January 1 thereafter, by 4% of the number of outstanding shares of common stock on the immediately preceding December 31, or such number of shares as determined by the Board of Directors. On July 16, 2024, at the Company’s 2024 Annual Stockholders’ Meeting, the Company’s stockholders approved the proposal to amend the 2022 Plan to increase the number of shares available for issuance by 416,667 shares. As of September 30, 2024, the number of remaining shares available for issuance under the 2022 Plan is equal to 351,034. Stock Grants On July 11, 2023, the Company recognized $187,200 of share-based compensation expense upon the issuance of 3,336 shares of common stock to the Company’s Board of Directors, by virtue of the terms of the agreements described in Note 12, which is reflected in general and administrative expenses in the Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income. Stock Options The Company grants stock options to employees, non-employees, and Directors with exercise prices equal to the closing price of the underlying shares of the Company’s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted generally have a term of five or ten years from the grant date and are subject to vesting as determined in the individual award agreement. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model. The following table summarizes the significant assumptions used in determining the fair value of options granted for the three and nine months ended September 30, 2024: 2024 Weighted-average grant date fair value 1.76 Risk-free interest rate 3.62% - 4.17 % Expected volatility 86.0% - 87.0 % Expected term (years) 6.41 - 10.00 Expected dividend yield 0.00% The following table summarizes the significant assumptions used in determining the fair value of options granted for the three and nine months ended September 30, 2023: 2023 Weighted-average grant date fair value 41.04 Risk-free interest rate 4.25% - 4.33 % Expected volatility 105.0% - 110.0 % Expected term (years) 3.18 - 3.76 Expected dividend yield 0.00% Upon the Closing of the IPO on July 12, 2023, the Company granted an aggregate of 50,664 stock options to directors and executives, with a weighted average exercise price of $57.00. There were no stock options granted, issued, or outstanding prior to the IPO. Upon receiving shareholder approval to increase the number of shares available under the 2022 Plan on July 16, 2024, the Company determined that the grant date criteria (as defined in ASC 718) was met, and therefore granted 64,183 stock options to certain directors, executives, and non-employees, in accordance with the terms of the individuals’ employment agreements. On September 26, 2024, the Board of Directors approved the grant of an additional 20,834 stock options to an executive. For the three and nine months ended September 30, 2024, the weighted average grant date fair value of options granted was $10.92. For the three and nine months ended September 30, 2024, the Company recognized $15,246 of compensation expense related to stock option awards ($233,728 for the three and nine months ended September 30, 2023). Restricted Stock Units Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. Upon the Closing of the IPO on July 12, 2023, the Company granted an aggregate of 2,672 RSUs to directors of the Company. No RSUs were granted, vested, or outstanding prior to the IPO. For the three and nine months ended September 30, 2024 the Company recognized $0 of compensation expense related to the vesting of RSUs ($37,338 and 668 RSUs, for the three and nine months ended September 30, 2023). There were no RSUs granted during the three or nine months ended September 30, 2024. During the three and nine months ended September 30, 2024, the Company issued 0 and 21,338 shares of common stock, respectively, pursuant to RSUs granted to executives and directors in November 2023, which were fully vested as of December 31, 2023 (none during the three or nine months ended September 30, 2023). (b) Share-Based Payments to Vendors for Services During the nine months ended September 30, 2024 and 2023, the Company issued 0 and 77,500 fully vested, nonforfeitable common stock shares, respectively, as share-based payments to two nonemployees, Florida State University Research Fund, Inc. and Kentucky Technology Inc, in exchange for research and development services to be rendered to the Company in the future. The Company recognizes prepaid research and development costs on the grant date, as defined in ASC 718. Florida State University Research Fund, Inc. agreed to render research and development services related to development of celgosivir over a period of up to five years using the proceeds from the sale of the Company’s common shares to fund the services. Prepaid research and development costs recognized associated with the Florida State University Research Fund, Inc. are expected to be rendered within one year. Kentucky Technology Inc. agreed to furnish a written report on the potential development of SJ733 + tafenoquine in exchange for fully vested shares of the Company’s common stock. On May 3, 2024, the Company indicated to Kentucky Technology, Inc. that the report (delivered in April 2024) was acceptable to the Company. Upon acceptance, the Company recognized $2,625,000 of share-based compensation expense, which is reflected in Research and Development expense in the results of operations for the nine months ended September 30, 2024. As of September 30, 2024, the unamortized balance of prepaid assets related to these share-based payments for research and development costs for which the grant date criteria has been met and the services are expected to be rendered within one year is $103,385 ($2,730,685 at December 31, 2023), which is presented as a component of Prepaid and Other Assets on the accompanying Consolidated Condensed Balance Sheets. In addition to share-based payments for research and development services, during the nine months ended September 30, 2024 and 2023, 0 and 45,191 common stock shares, respectively, were issued as fully vested, nonforfeitable equity instruments to nonemployees (0 and 2,438 during the three months ended September 30, 2024 and 2023, respectively). As of September 30, 2024, the unamortized balance of current prepaid assets related to these share-based payments for which the services are expected to be rendered within one year is $176,471 ($948,581 at December 31, 2023), which is reported in Prepaid and Other Assets on the Consolidated Condensed Balance Sheets. The unamortized balance of noncurrent prepaid assets related to these share-based payments for which the services are expected to be rendered beyond one year is $110,294 ($242,647 at December 31, 2023), reported in Long-Term Prepaid Expense on the Consolidated Condensed Balance Sheets. The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments.	11. SHARE-BASED COMPENSATION The following is a summary of share-based compensation expenses reported in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022: For the Year Ended 2023 2022 Research and Development $ 192,371 $ - General and Administrative Expenses 1,543,803 - Total Share-Based Compensation Expense Included in Operating Expenses $ 1,736,174 $ - On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan (the “2022 Plan”), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. The 2022 Plan provides for an automatic increase in the number of shares available for issuance beginning on January 1, 2023 and each January 1 thereafter, by 4% of the number of outstanding shares of common stock on the immediately preceding December 31, or such number of shares as determined by the Board of Directors. As of December 31, 2023, the number of remaining shares available for issuance under the 2022 Plan is equal to 305. Stock Grants On July 11, 2023, the Company recognized $187,200 of share-based compensation expense upon the issuance of 40,000 shares of common stock to the Company’s Board of Directors, by virtue of the terms of the agreements described in Note 12, which is reflected in general and administrative expenses in the consolidated statement of operations. Stock Options The Company grants stock options to employees, non-employees, and Directors with exercise prices equal to the closing price of the underlying shares of the Company’s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted generally have a term of five years from the grant date and are subject to vesting as determined in the individual award agreement. As of December 31, 2023, stock options granted under the 2022 Plan consist of options granted to directors of the Company on the IPO date, which were fully vested on the date of grant. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model. The following table summarizes the significant assumptions used in determining the fair value of options on the respective grant dates or modification dates for the year ended December 31, 2023: 2023 Weighted-average grant date fair value $ 3.16 Risk-free interest rate 4.33 % Expected volatility 110.0 % Expected term (years) 3.18 Expected dividend yield 0.00 % The following table summarizes the Company’s stock option activities: Number of Weighted Aggregate Weighted Options outstanding, December 31, 2022 - $ - $ - - Granted 37,736 5.30 - 5.00 Exercised - - - - Forfeited - - - - Expired - - - - Options outstanding, December 31, 2023 37,736 $ 5.30 $ - 4.53 Options vested and exercisable, December 31, 2023 37,736 $ 5.30 $ - 4.53 The aggregate intrinsic value in the table above reflects the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options. The intrinsic value of stock options changes based on the price of the Company’s common stock. For the year ended December 31, 2023, the Company recognized $119,246 of compensation expense related to stock option awards ($0 for the year ended December 31, 2022). No stock options were exercised, forfeited, or expired during the period presented. At December 31, 2023, the Company had no unrecognized share-based compensation expense related to unvested options. The Company also has compensation agreements with two executives and a consultant, which provide the individuals the right to an aggregate of 740,000 stock options that are subject to shareholder approval to increase the number of shares available under the 2022 Plan. These options are subject to vesting annually over five years with the first vesting date being December 31, 2024, and have an exercise price that was initially equal to the closing share price on the date of the IPO and later amended to $1.00 per share. Pursuant to the directors’ agreements described in Note 12, the agreements provide for the issuance of an aggregate of 30,188 stock options to our directors with an exercise price of $5.30 per share, vesting 100% on July 11, 2024, also contingent on the receipt of shareholder approval. For accounting and disclosure purposes, no fair value has been ascribed to these stock option awards as no grant date (as defined in ASC 718) has been established. Restricted Stock Units The following table summarizes the Company’s RSU activity for the year ended December 31, 2023: Number of Units Weighted Average Grant Unvested balance, December 31, 2022 - $ - Granted 256,000 0.87 Vested (256,000 ) 0.87 Forfeited - - Unvested balance, December 31, 2023 - $ - During the year ended December 31, 2023, the Company granted 256,000 RSUs to employees, non-employees, and Directors. The Company recognized $222,480 of compensation expense related to vested RSUs for the year ended December 31, 2023 ($0 for the year ended December 31, 2022). During the year ended December 31, 2023, 256,000 shares of common stock underlying RSUs vested. These shares are excluded from the number of shares outstanding at December 31, 2023, as the shares have not yet been issued to the respective employees, non-employees and Directors. At December 31, 2023, the Company had no unrecognized compensation cost related to unvested RSUs. Share-Based Payments to Vendors for Services During the year ended December 31, 2023, the Company issued 525,000 common stock shares and 405,000 common stock shares as share-based payments to two nonemployees, Kentucky Technology Inc. and Florida State University Research Fund, Inc., respectively, in exchange for research and development services to be rendered to the Company in the future. Kentucky Technology Inc. is expected to render research and development services to identify a combination drug partner for tafenoquine over a period of fifteen months. Florida State University Research Fund, Inc. is expected to render research and development services related to development of celgosivir over a period of up to five years. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. 718, Compensation-Stock Compensation. As of December 31, 2023, the unamortized balance of prepaid assets related to these share-based payments for research and development costs for which the grant date criteria has been met and the services are expected to be rendered within one year is $2,730,685 ($0 at December 31, 2022), which is presented as a component of Prepaid and Other Assets on the accompanying Consolidated Balance Sheets. In addition to share-based payments for research and development services, during the years ended December 31, 2023 and 2022, 552,799 and 0 common stock shares, respectively, were issued as fully vested, nonforfeitable equity instruments to nonemployees. 120,000 and 100,000 of the common stock shares issued during the year ended December 31, 2023, were issued to Trevally, LLC and Carmel, Milazzo & Feil LLP, respectively. Before June 30, 2024, Trevally, LLC is expected to provide castanopsermine, a stable starting material to support the manufacture of good manufacturing grade (GMP)-grade celgosivir for clinical studies. Sichenzia Ross Ference Carmel (formerly known as Carmel, Milazzo & Feil LLP) is expected to provide legal services before April 30, 2026. As of December 31, 2023, the unamortized balance of current prepaid assets related to these share-based payments for which the services are expected to be rendered within one year is $776,471 ($0 at December 31, 2022), which is reported in Prepaid and Other Assets on the Consolidated Balance Sheets. The unamortized balance of noncurrent prepaid assets related to these share-based payments for which the services are expected to be rendered beyond one year is $242,647 ( $0 The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments. Deemed Capital Contribution for Related Party Compensation Expense During the year ended December 31, 2023, the Company’s Chief Executive Officer, Geoff Dow, and Chief Financial Officer, Tyrone Miller, agreed to forego payment of cash compensation for certain periods they were active employees of the Company. In accordance with SEC Staff Accounting Bulletin (“SAB”) 5T, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES (a) Operating Lease On February 3, 2016, and subsequently amended, the Company entered into the lease agreement with CXI Corp to rent business premises. In January 2023, the lease was extended for an additional twelve-month term, which expired on March 31, 2024. In December 2023, the Company executed an additional amendment with CXI Corp, pursuant to which the Company agreed to relocate to a new office space as of April 1, 2024. The term covered by the new amendment expires on March 31, 2025. The Company has accounted for the amendment for the new office space as a separate contract. As the initial term for the new office space is 12 months, the lease is not recorded on the balance sheet. The Company recognizes lease expense on this lease as short-term lease costs. Operating lease costs, including short-term leases, were in the amount of $4,938 and $13,859 for the three months ended September 30, 2024 and 2023, respectively ($24,067 and $41,225 for the nine months ended September 30, 2024 and 2023, respectively). (b) Board of Directors In 2022, the Company signed agreements with its four Directors (Cheryl Xu, Paul Field, Charles Allen and Stephen Toovey) which came into effect on July 11, 2023, the date the Company’s IPO Registration Statement was declared effective. Each director is entitled to receive cash compensation of $11,250 quarterly. In addition, the two non-audit committee chairs (Toovey, Field) will receive $1,250 per quarter and the audit committee chair (Allen) will receive an additional $2,000 per quarter. In addition, each director is entitled to receive annual equity-based compensation awards, with the amounts and terms to be determined by the Compensation Committee. (c) Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. (d) Contingent Compensation Following the Company’s IPO and the conversion of the outstanding debt pursuant to the Knight Debt Conversion Agreement as discussed in Note 7, the Company is obligated to pay Knight a contingent milestone payment of $10 million if the Company sells Arakoda™ or if a Change of Control occurs. The Company accounts for the contingent milestone payment as a derivative liability (See Note 8). On July 15, 2015, the Company entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the “U.S. Army”), which was subsequently amended (the “U.S. Army Agreement”), in which the Company obtained a license to develop and commercialize the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. The term of the U.S. Army Agreement will continue until the expiration of the last to expire of the patent application or valid claim of the licensed technology, or 20 years from the start date of the U.S. Army Agreement, unless terminated earlier by the parties. The Company must make a minimum annual royalty payment of 3% of Net Sales (as defined in the U.S. Army Agreement) for Net Sales less than $35 million, and 5% of Net Sales greater than $35 million, with US government sales excluded from the definition of Net Sales. In addition, the Company must pay fees upon the achievement of certain milestones, including a sales-based milestone fee of $75,000 once cumulative Net Sales from all sources exceeds $6 million. The Company accrues the minimum annual royalty when the related sales occur. The Company achieved the sales-based milestone target during the year ended December 31, 2023, which was paid in full on June 13, 2024. The achievement of other milestones under the U.S. Army Agreement are not considered probable and thus no accruals for the related milestone payments have been made. (e) Litigation, Claims and Assessments From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 30, 2024, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.	12. COMMITMENTS AND CONTINGENCIES Operating Lease On February 3, 2016, and subsequently amended, the Company entered into the lease agreement with CXI Corp to rent business premises. In January 2023, the lease was extended for an additional twelve-month term expiring on March 31, 2024. In December 2023, the Company executed an additional amendment with CXI Corp, pursuant to which the Company agreed to relocate to a new office space which is estimated to be available for use by the Company on or around April 1, 2024. The term covered by the new amendment expires on March 31, 2025. Future minimum lease payments on a discounted and undiscounted basis under the Company’s operating lease Undiscounted Discount rate 15.00 % 2024 $ 13,992 Thereafter - Total undiscounted minimum future payments 13,992 Imputed interest (342 ) Total operating lease payments 13,650 Current lease liabilities 13,650 Non-current lease liabilities $ - Other information related to our operating lease is as follows: December 31, Weighted average remaining lease term (in years) 0.25 Weighted average discount rate 15.00 % Operating lease costs were in the amount of $55,084 and $51,894 for the year ended December 31, 2023, and 2022, respectively. Board of Directors In November and December 2022, the Company signed agreements with four director nominees (Cheryl Xu, Paul Field, Charles Allen and Stephen Toovey) which come into effect on the date the Company’s Registration Statement is declared effective. As described in Note 1, the Company’s Registration Statement was declared effective on July 11, 2023. Each director is entitled to receive cash compensation of $11,250 quarterly. In addition, the two non-audit committee chairs (Toovey, Field) will receive $1,250 per quarter and the audit committee chair (Allen) will receive an additional $2,000 per quarter. On July 11, 2023, each director received (i) a one-off issuance of 10,000 shares of common stock, and (ii) a fully vested, non-qualified option to purchase 9,434 shares of common stock at an exercise price of $5.30 per share. In addition, each director is entitled to receive annual equity compensation after July 11, 2023, and annually thereafter unless determined otherwise by the Board, in the form of restricted stock units valued at $40,000 (vesting quarterly over twelve months, with a cost basis of $5.00 per share) and a non-qualified option to purchase $40,000 of common stock (twelve month vesting with an exercise price equal to $5.30), in each case equity compensation is contingent on the receipt of shareholder approval to increase the number of shares authorized under the 2022 Plan. Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. Contingent Compensation Following the Company’s IPO and the conversion of the outstanding debt pursuant to the Knight Debt Conversion Agreement as discussed in Note 8, the Company is obligated to pay Knight a contingent milestone payment of $10 million if the Company sells Arakoda™ or if a Change of Control occurs. The Company accounts for the contingent milestone payment as a derivative liability (See Note 9). On July 15, 2015, the Company entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the “U.S. Army”), which was subsequently amended (the “U.S. Army Agreement”), in which the Company obtained a license to develop and commercialize the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. The term of the U.S. Army Agreement will continue until the expiration of the last to expire of the patent application or valid claim of the licensed technology, or 20 years from the start date of the U.S. Army Agreement, unless terminated earlier by the parties. The Company must make a minimum annual royalty payment of 3% of Net Sales (as defined in the U.S. Army Agreement) for Net Sales less than $35 million, and 5% of Net Sales greater than $35 million, with US government sales excluded from the definition of Net Sales. In addition, the Company must pay fees upon the achievement of certain milestones, including a sales-based milestone fee of $75,000 once cumulative Net Sales from all sources exceeds $6 million. The Company accrues the minimum annual royalty when the related sales occur. During the year ended December 31, 2023, the sales-based milestone target was achieved and therefore the Company has accrued a liability of $75,000 for the related payment, which is reflected in Accounts Payable and Accrued Expenses at December 31, 2023. The achievement of other milestones under the U.S. Army Agreement are not considered probable and thus no accruals for the related milestone payments have been made. Litigation, Claims and Assessments From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2023, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company has evaluated subsequent events through November 14, 2024, which is the date the consolidated condensed financial statements were issued. On October 1, 2024, the Company issued 206,551 shares of common stock upon the exercise of 206,551 September 2024 Pre-Funded Warrants, for aggregate cash proceeds to the Company of $207. On October 31, 2024, the Company issued an additional 229,000 shares of common stock upon the exercise of 229,000 September 2024 Pre-Funded Warrants, for aggregate cash proceeds to the Company of $229. On November 6, 2024, the Company conducted a Special Meeting of Stockholders (the “Meeting”). The Company’s stockholders of record at the close of business on September 20, 2024, the record date for the determination of stockholders entitled to vote at the Meeting, approved the proposals to (1) approve the exercise of the Series A Warrants, the Series B Warrants, and the September 2024 Agent Warrants (each as defined in Note 6) to purchase up to an aggregate of 6,014,493 shares of the Company’s common stock under applicable rules and regulations of the Nasdaq Stock Market LLC, (2) approve an amendment to the 2022 Plan to increase the number of shares of common stock available for issuance by 500,000 shares, and (3) approve an amendment to the Company’s Certificate of Incorporation, to effect a reverse stock split of our common stock at a reverse stock split ratio ranging from 1:3 to 1:5 inclusive, as may be determined at the appropriate time by the Board of Directors in its sole discretion. On November 12, 2024, the Board of Directors approved a one-off cash payment of $20,000 to each of the non-executive Directors in lieu of forfeiting the grant of restricted stock units that would have otherwise been granted for the second half of 2024. There have been no other events or transactions during this time which would have a material effect on these consolidated condensed financial statements.	13. SUBSEQUENT EVENTS The Company has evaluated subsequent events through April 1, 2024, which is the date the financial statements were issued. On January 10, 2024, the Company received a letter from the Listing Qualifications Staff of Nasdaq informing the Company that for the 10 consecutive business day period between December 26, 2023 through January 9, 2024, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the common stock and warrants of the Company were no longer subject to delisting. On January 22, 2024, the Company announced that following a Type C meeting with the U.S. Food and Drug Administration on January 17, 2024, the Company is planning to conduct a pivotal clinical study in support of a future indication for tafenoquine for treatment of hospitalized babesiosis patients, the patient enrollment of which is scheduled to begin in the summer of 2024. On January 29, 2024, the Company, entered into an Underwriting Agreement with WallachBeth Capital LLC (the “Underwriting Agreement”), relating to the Company’s public offering (the “January 2024 Offering”) of 5,260,901 units (the “Units”) at an offering price of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at an offering price of $0.375 per Pre-Funded Unit. Each Unit consisted of one share of common stock and one warrant exercisable for one share of common stock (the “Warrant”). Each Warrant has an exercise price of $0.4235 per share (110% of the offering price per Unit), is exercisable immediately upon issuance and expires five years from the date of issuance. Each Pre-Funded Unit consists of one pre-funded warrant exercisable for one share of common stock (the “Pre-Funded Warrant”) and one warrant identical to the Warrants included in the Units. The purchase price of each Pre-Funded Unit was equal to the price per Unit sold to the public in the offering, minus $0.01, and the exercise price of each Pre-Funded Warrant is $0.01 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Company granted WallachBeth Capital LLC an option, exercisable within 45 days after the closing of the offering, to purchase up to 789,136 shares of the Company’s common stock at a price of $0.385 per share and/or 938,997 Warrants at a price of $0.01 per Warrant and/or 149,862 Pre-Funded Warrants at a price of $0.375 per Pre-Funded Warrant, or any combination of additional shares of common stock, Warrants and/or Pre-Funded Warrants, representing, in the aggregate, up to 15% of the number of Units sold in the offering, 15% of the Warrants underlying the Units and Pre-Funded Units sold in the offering and 15% of the Pre-Funded Warrants underlying the Pre-Funded Units sold in the offering, in all cases less the underwriting discount to cover over-allotments, if any. On January 31, 2024, WallachBeth Capital LLC partially exercised its over-allotment option with respect to 818,177 Warrants. The Company also issued to WallachBeth Capital LLC warrants (the “January 2024 Representative Warrants”) to purchase 375,599 shares of the Company’s common stock, which is equal to 6% of the common stock sold that were part of the Units and the pre-funded warrants sold that were part of the Pre-Funded Units in the Offering, at an exercise price of $0.4235 per share (110% of the offering price per Unit). The January 2024 Representative Warrants may be exercised beginning on January 31, 2024 until January 31, 2029. The Units and Pre-Funded Units were offered and sold pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-276641), originally filed with the SEC on January 22, 2024 (the “January 2024 Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The January 2024 Registration Statement was declared effective by the SEC on January 29, 2024. The closing of the January 2024 Offering occurred on January 31, 2024. The net proceeds to the Company from the Offering were approximately $1.9 million, after deducting underwriting discounts and commissions and the payment of other offering expenses payable by the Company. The Company intends to use the net proceeds from the January 2024 Offering for increasing capitalization and financial flexibility and relaunching its malaria prevention project in the U.S. later in 2024. On February 1, 2024, the Company received proceeds of $4,995 upon the exercise of 499,538 Pre-Funded Warrants and issued 499,538 shares of common stock to the investors. On February 13, 2024, the Company, through its majority-owned subsidiary, 60P Australia Pty Ltd, signed a research and development agreement with Monash University to evaluate the efficacy of parenteral tafenoquine on Candida Candida auris On February 14, 2024, WallachBeth Capital LLC partially exercised its over-allotment option described above with respect to 50 shares of common stock at a purchase price of $0.3750 and 50 Warrants at a purchase price of $0.01. On February 27, 2024, the Company received a letter from The Nasdaq Capital Market stating that for the 31 consecutive business days ending on February 27, 2024, the Company’s common stock had not maintained the minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market. The Company was provided an initial period of 180 calendar days, or until August 26, 2024, to regain compliance. If the Company cannot regain compliance during the compliance period or any subsequently granted compliance period, the common stock and warrants of the Company may be subject to delisting. There have been no other events or transactions during this time which would have a material effect on these consolidated financial statements.

Deferred Compensation

Deferred Compensation	12 Months Ended
	Dec. 31, 2023
Deferred Compensation [Abstract]
DEFERRED COMPENSATION	7. DEFERRED COMPENSATION In 2020, the Company received consulting services from Biointelect Pty Ltd. of Australia (“Biointelect”) with a value of $100,000, which was payable contingent upon a future capital raise and was non-interest bearing. On May 5, 2022, the Company agreed to modify their contract with Biointelect. Previously, Biointelect potentially could earn $60,000 in deferred cash compensation and $400,000 in warrants in connection with a fundraise and other services provided. As the Company considered this compensation unlikely, it agreed to restructure by increasing the cash component to $100,000, tying $155,000 in equity compensation to an IPO or future qualifying transaction while leaving $245,000 in equity compensation with the original triggering events. As a result of the completion of the IPO and as required under the terms of the agreement with BioIntelect, the Company issued 29,245 shares of common stock to BioIntelect as deferred equity compensation and remitted payment in cash of $100,000 in full satisfaction of its obligations with respect to the services provided. Also in 2020, the Company entered into an agreement with Latham Biopharma for contingent compensation. On June 17, 2022 the Company and Latham Biopharma agreed to convert the $57,198 of deferred compensation that was earned and due and $12,500 of accrued expenses into a 100% contingent deferred compensation amount of $38,900 in cash and $60,000 in common shares of the Company if, within five years after 2022 the Company nets at least $10,000,000 in an IPO or any private financing that secures the retirement and/or conversion to equity of all secured debt excluding the loans advanced by the Small Business Administration. Then before the year ended December 31, 2022, the Company and Latham Biopharma initiated an agreement that converted the entire deferred compensation into 65,000 shares valued at $5 per share. As of December 31, 2022, the Company recognized a contingent liability related to the subsequent agreement of $325,000. On January 26, 2023, the Company issued 65,000 shares to Latham Biopharma in full satisfaction of its obligations with respect to the services provided. In March 2023, the Company signed an investment relations consulting agreement with Red Chip. This agreement obligated the Company to issue Red Chip $40,000 of Rule 144 stock, based on the 30-day average of the publicly traded common shares after the IPO. All shares were deemed earned immediately upon signing, acceptance, and execution of the agreement. On December 28, 2023, the Company issued 10,554 shares to Red Chip in full satisfaction of its obligations with respect to the services provided.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The financial statements of 60P and its subsidiary are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended December 31, 2023 and 2022, included in the Company’s annual report on Form 10-K, as filed with the SEC on April 1, 2024 (the “Annual Report”). Certain information and footnote disclosures that would substantially duplicate the disclosures contained in the Annual Report have been omitted.	Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated financial statements pursuant to the instructions to Form 10-K and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature.
Principles of Consolidation and Noncontrolling Interest	(b) Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. The increase in the Company’s proportional interest is reflected as a contribution from noncontrolling interest in the accompanying consolidated condensed statement of shareholders’ equity (deficit). For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated condensed financial statements.	Principles of Consolidation and Noncontrolling Interest The Company’s consolidated financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd, as well as the financial statements of 60P Singapore Pty Lte, a wholly owned subsidiary of 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. 60P Singapore Pty Lte was closed via dissolution as of March 31, 2022. 60P Singapore Pty Lte was originally set up to conduct research in Singapore. The entity had no assets and its liabilities were to both 60P Australia Pty Ltd, its direct owner, and 60P. Through consolidation accounting the closure of the business unit resulted in a currency exchange gain. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated financial statements. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. The increase in the Company’s proportional interest is reflected as a Contribution from Noncontrolling Interest in the accompanying Consolidated Statements of Shareholders’ and Members’ Equity (Deficit).
Use of Estimates	(c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, and derivative liabilities.	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, and valuation allowance for the deferred tax asset.
Reverse Stock Split	(d) Reverse Stock Split Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12 (the “Reverse Stock Split”), which was effective as of August 12, 2024. Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company’s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable in accordance with the terms of the instruments. Unless otherwise noted, all references to numbers of shares of the Company’s common stock and per share information presented in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.
Cash and Cash Equivalents	(e) Cash and Cash Equivalents The Company’s cash consists of cash deposited in demand accounts at financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company considers short-term highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at times, may exceed the FDIC insurable limits (currently $250,000). The Company has not experienced any losses related to amounts in excess of FDIC Limits. The Company periodically assesses the credit risk associated with these financial institutions and believes that the risk of loss is minimal.	Cash and Cash Equivalents The Company’s cash consists of cash deposited in demand accounts at financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company considers short-term highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at times, may exceed the FDIC insurable limits (currently $250,000). The Company has not experienced any losses related to amounts in excess of FDIC Limits. The Company periodically assesses the credit risk associated with these financial institutions and believes that the risk of loss is minimal. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase.
Short-term Investments	(f) Short-term Investments Short-term investments consist of certificates of deposit with original maturities of greater than three months and less than twelve months, which are classified as held-to-maturity as the Company has the intent and ability to hold these investments until they mature. The classification of short-term investments is determined at the time of purchase and is reevaluated at each balance sheet date. Short-term investments are reported at amortized cost.
Accounts Receivable and Allowance for Doubtful Accounts	(g) Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, an Australian pharmaceutical distributor, and a large American pharmaceutical distributor. There was no allowance as of September 30, 2024 or December 31, 2023. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. As of September 30, 2024, the American pharmaceutical distributor accounted for 96% of the accounts receivable balance (79% as of December 31, 2023) and the US government accounted for none of the outstanding accounts receivable balance (13% as of December 31, 2023).	Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, an Australian pharmaceutical distributor and a large American pharmaceutical distributor. There was no allowance as of December 31, 2023 and December 31, 2022. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. At December 31, 2023, the US government accounted for 13% of the outstanding accounts receivable balance (66% at December 31, 2022) and the American pharmaceutical distributor accounted for 79% of the outstanding accounts receivable balance (30% for the year ended December 31, 2022).
Inventory	(h) Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number. The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to Cost of Revenues in the Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income. During the three months ended September 30, 2024 and 2023, write-downs for expired inventory totaled $1,165 and $0, respectively ($18,490 and $94,977 for the nine months ended September 30, 2024 and 2023, respectively).	Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number. The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to Cost of Revenues in the Consolidated Statements of Operations and Comprehensive Loss. During the year ended December 31, 2023, write-downs for expired inventory totaled $191,111 ($162,222 for the year ended December 31, 2022).
Derivative Liabilities	(i) Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of September 30, 2024, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations, as a component of other income or expense as change in fair value of derivative liabilities. The Company uses a Monte Carlo simulation model or a probability-weighted discounted cash flow model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date.	Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of December 31, 2023, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date.
Equity-Classified Warrants	(j) Equity-Classified Warrants As of September 30, 2024, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.	Equity-Classified Warrants The Company accounts for the Tradeable Warrants, the Non-tradeable Warrants, the Representative Warrants, and the Bridge Warrants (following the IPO, see Note 6) as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.
Concentrations	(k) Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. At September 30, 2024, significant customers represented 97% of receivables (consisting of two customers and one significant customer at 97%). At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively). For the three months ended September 30, 2024, 92% of total net revenues (consisting of two customers and one significant customer) were generated from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers. For the nine months ended September 30, 2024, 94% of total net revenues (consisting of three customers and one significant customer) were generated from significant customers. For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28%. Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”).	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively) and 93% of total net revenues (consisting of two significant customers at 72% and 21%, respectively). At December 31, 2022, 96% of the Company’s receivables (consisting of three customers and two significant customers at 66% and 30%), and 100% of total net revenues (consisting of four customers and three significant at 40%, 39% and 14%, respectively). Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended in 2022 and near-term receivables and revenues from the government are not currently anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). As of December 31, 2023, 0% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, previously the senior secured lender and also a publicly traded Canadian company.
Business Segments	(l) Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. A single management team that reports to the Chief Executive Officer comprehensively manages the business. Accordingly, since its inception, the Company has managed its business in one identifiable segment.	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. To date, the Company has managed its business in one identifiable segment.
Revenue Recognition	(m) Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.	Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.
Research and Development Costs	(n) Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepayments for research and development services are deferred and amortized over the service period as the services are provided. Advance payments for specific materials, equipment, or facilities determined to have no alternative future use are initially deferred and recognized as research and development expense when the related goods are delivered. The Company recorded $940,063 and $263,703 in research and development expense during the three months ended September 30, 2024 and 2023, respectively, ($4,372,571 and $591,569 for the nine months ended September 30, 2024 and 2023, respectively).	Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $691,770 in research and development costs during the year ended December 31, 2023 ($525,563 for the year ended December 31, 2022). During the year ended December 31, 2023, the Company has also issued shares of common stock to nonemployees in exchange for research and development services. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. 718, Compensation-Stock Compensation. See Note 11 for further details.
Fair Value of Financial Instruments and the Fair Value Option (“FVO”)	(o) Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the Consolidated Condensed Balance Sheets and any change in fair value unrelated to credit risk is recorded in Other Expense, net in the Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income. Changes in fair value related to credit risk are recognized as other comprehensive income or loss. As a result of the completion of the IPO in July 2023, all financial instruments for which the FVO was elected were extinguished. See Note 7 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at September 30, 2024, and December 31, 2023 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 8 for more information on Derivative Liabilities. Liabilities measured at fair value at September 30, 2024 and December 31, 2023 are as follows: September 30, 2024 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 623,762 $ 623,762 Total $ - $ - $ 623,762 $ 623,762 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796 There were no transfers of financial instruments between Level 1, Level 2, and Level 3 during the periods presented. A rollforward of liabilities measured at fair value using Level 3 inputs outstanding during the three and nine months ended September 30, 2024 and 2023 are presented in Note 7 (Debt) and Note 8 (Derivative Liabilities), respectively.	Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the Consolidated Balance Sheets and any change in fair value unrelated to credit risk is recorded in Other Expense, net in the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value related to credit risk are recognized in Other Comprehensive Loss. As a result of the completion of the IPO, all financial instruments for which the FVO was elected were extinguished. See Note 8 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at December 31, 2023, and December 31, 2022 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 9 for more information on Derivative Liabilities. Liabilities measured at fair value at December 31, 2023 and 2022 are as follows: December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200 There were no transfers of financial instruments between Level 1, Level 2, and Level 3 during the periods presented. However, certain liabilities measured at fair value and using Level 3 inputs were extinguished during the year. A rollforward of level 3 liabilities measured at fair value for the years ended December 31, 2023 and 2022 are presented in Notes 8 and 9 for Promissory Notes and Derivative Liabilities, respectively.
Assets and Liabilities Not Measured at Fair Value on a Recurring Basis	(p) Assets and Liabilities Not Measured at Fair Value on a Recurring Basis In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company’s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the assets’ projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized. As of September 30, 2024, and December 31, 2023, the fair value of Cash and Cash Equivalents, Short-Term Investments, Accounts Receivable, Prepaid Expenses and Other Current Assets, and Accounts Payable and Accrued Expenses approximated their carrying values due to the short-term nature of these assets and liabilities.	Assets and Liabilities Not Measured at Fair Value on a Recurring Basis In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company’s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the assets’ projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized. As of December 31, 2023 and 2022, the fair value of Cash and Cash Equivalents, Accounts Receivable, Prepaid Expenses and Other Current Assets, and Accounts Payable and Accrued Expenses approximated their carrying values due to the short-term nature of these assets and liabilities.
Foreign Currency Transactions and Translation	(q) Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements. For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as Unrealized Foreign Currency Translation Gain or Loss. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate As of Three Months Ended Nine Months Ended September 30, December 31, Currency 2024 2023 2024 2023 2024 2023 1 AUD = 0.67 USD 0.65 USD 0.66 USD 0.67 USD 0.69 USD 0.68 USD	Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated financial statements of the Company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated financial statements. For the purpose of presenting consolidated financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as Unrealized Foreign Currency Translation Gain (Loss). Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Year Ended As of Currency 2023 2022 December 31, December 31, 1 AUD = 0.66 USD 0.69 USD 0.68 USD 0.68 USD 1 SGD = NA 1.02 AUD* NA 1.02 AUD* * Through 4/30/2022 (account closure date)
Reclassifications	(r) Reclassifications Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive (loss) income, shareholders’ equity (deficit), or cash flows.	Reclassifications Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive loss, shareholders’ and members’ equity (deficit), or cash flows.
Share-Based Payments	(s) Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 10. The Company accounts for share-based payments in accordance with ASC Subtopic 718, Compensation - Stock Compensation The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note 10 for further details.	Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 11. The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur. The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note 11 for further details.
Leases	(t) Leases The Company applies ASC Topic 842, Leases The Company determines if an arrangement is a lease at contract inception. The Company’s contracts are determined to contain a lease when all of the following criteria, based on the specific circumstances of the arrangement, are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset. At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreement does not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate (“IBR”), to discount lease payments, which represents the rate of interest the Company would pay to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.	Leases The Company applies ASC Topic 842, Leases The Company determines if an arrangement is a lease at contract inception. The Company’s contracts are determined to contain a lease when all of the following criteria, based on the specific circumstances of the arrangement, are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset. At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreement does not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate (“IBR”), to discount lease payments, which represents the rate of interest the Company would pay to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.
Net Loss per Common Share	(u) Net (Loss) Income per Common Share Net (Loss) Income per Common Share is computed by dividing net (loss) income attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company has included the Pre-Funded Warrants issued in January 2024 and September 2024 (See Note 6) in its computation of basic and diluted net (loss) income per share due to their nominal exercise prices. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an addition to net loss or a reduction of net income in determining basic and diluted net (loss) income attributable to common stockholders. As the Company reported a net loss for the nine months ended September 30, 2024 and 2023 and the three months ended September 30, 2024, the calculation of diluted net loss per common share is the same as basic net loss per common share. For the three months ended September 30, 2023, all securities that could potentially dilute basic earnings per share in the future have been excluded from the diluted calculation because the effect would be antidilutive. The potential dilutive securities for the three months ended September 30, 2023 included: common stock warrants, stock options and unvested restricted stock units granted under the 2022 Plan. As a result of the Reverse Stock Split, which was effective as of August 12, 2024, all shares of outstanding common stock and net (loss) income per common share calculations have been retroactively adjusted for all periods presented.	Net Loss per Common Share Net Loss per Common Share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during each period. For the purposes of calculating the weighted average number of common shares outstanding for periods prior to the Merger (See Note 6), each of 60P LLC’s outstanding membership units as of June 1, 2022 have been retrospectively adjusted for the equivalent number of common shares issued pursuant to the Merger. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an addition to net loss in determining basic and diluted net loss attributable to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
Related Parties	(v) Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.	Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Subsequent Events	(w) Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through November 14, 2024, which is the date the consolidated condensed financial statements were issued. See Note 12.	Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through April 1, 2024, which is the date the financial statements were issued. See Note 13.
Recently Adopted and Issued Accounting Pronouncements	(x) Recently Issued Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company’s financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures	Recently Adopted and Issued Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on these consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from U.S. GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted this pronouncement on January 1, 2022; however, the adoption of this standard did not have a material effect on the Company’s consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This latter standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company’s adoption of this standard in 2022 did not have a material effect on the Company’s consolidated financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company’s adoption of ASU 2021-08 did not have an effect on its consolidated financial statements. In November 2023, the FASB issued 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. The ASU also requires entities with a single reportable segment to provide all segment disclosures under ASC 280, including the new required disclosures under the ASU. The ASU is effective for all public entities with fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The ASU must be applied retrospectively. The Company is currently evaluating the impact that ASU 2023-07 will have on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its financial statement disclosures.
Property and Equipment		Property and Equipment Property and equipment are stated at cost. Normal repairs and maintenance costs are charged to earnings as incurred and additions and major improvements are capitalized. The cost of assets retired or otherwise disposed of and the related depreciation are eliminated from the accounts in the period of disposal and the resulting gain or loss is credited or charged to earnings. Depreciation is computed over the estimated useful lives of the related asset type or term of the operating lease using the straight-line method for financial statement purposes. The estimated service lives for Property and Equipment is either three (3), five (5) or seven (7) years.
Impairment of Long-lived Assets		Impairment of Long-lived Assets Long-lived assets, such as property and equipment and identifiable intangibles with finite useful lives, are periodically evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We look for indicators of a trigger event for asset impairment and pay attention to any adverse change in the extent or manner in which the asset is being used or in its physical condition. Assets are grouped and evaluated for impairment at the lowest level of which there are identifiable cash flows, which is generally at a location level. Assets are reviewed using factors including, but not limited to, our future operating plans and projected cash flows. The determination of whether impairment has occurred is based on an estimate of undiscounted future cash flows directly related to the assets, compared to the carrying value of the assets. If the sum of the undiscounted future cash flows of the assets does not exceed the carrying value of the assets, full or partial impairment may exist. If the asset’s carrying amount exceeds its fair value, an impairment charge is recognized in the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined using an income approach, which requires discounting the estimated future cash flows associated with the asset.
Intangible Assets		Intangible Assets The Company capitalizes its patent and filing fees and legal patent and prosecution fees in connection with internally developed pending patents. When pending patents are issued, patents will be amortized over the expected period to be benefitted, not to exceed the patent lives, which may be as long as ten to fifteen years.
Website Development Costs		Website Development Costs The Company accounts for website development costs in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic No. 350-50, Website Development Costs. Accordingly, all costs incurred in the planning stage are expensed as incurred, costs incurred in the website application and infrastructure development stage that meet specific criteria are capitalized and costs incurred in the day-to-day operation of the website are expensed as incurred. All costs associated with the websites are subject to straight-line amortization over a three-year period.
Gain/Loss on Debt Extinguishment		Gain/Loss on Debt Extinguishment Gain or loss on debt extinguishment is generally recorded upon an extinguishment of a debt instrument or the conversion of certain of the Company’s convertible debt determined to have variable share settlement features. Gain or loss on extinguishment of debt is calculated as the difference between the reacquisition price and net carrying amount of the debt, which includes unamortized debt issuance costs and the fair value of any related derivative instruments. In the case of debt instruments for which the fair value option has been elected, the net carrying value is equal to its fair value on the date of extinguishment and no gain or loss is recognized.
IPO and Over-Allotment		IPO and Over-Allotment The Over-Allotment option granted to the underwriters was evaluated in accordance with the guidance in ASC 480 and ASC 815 and was determined to meet all of the criteria for equity classification. The Company allocated the proceeds from the sale of the IPO units (net of offering costs paid at closing and deferred offering costs incurred prior to the IPO) between the common stock, the Tradeable Warrants, the Non-tradeable Warrants, and the Over-Allotment, using the relative fair value method.
Original Issue Discount (“OID”)		Original Issue Discount (“OID”) For certain notes issued, the Company may provide the debt holder with an original issue discount. The original issue discount is recorded as a debt discount and is amortized to interest expense using the effective interest method over the life of the debt in the Consolidated Statements of Operations and Comprehensive Loss.
Debt Issuance Costs		Debt Issuance Costs Debt issuance costs paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense over the life of the underlying debt instrument, in the Consolidated Statements of Operations and Comprehensive Loss, with the exception of certain debt for which we elected the fair value option. Debt issuance costs associated with debt for which the fair value option is elected are expensed as incurred.
Income Taxes		Income Taxes 60 Degrees Pharmaceuticals, Inc. is a corporation and has accepted the default taxation status of C corporation. The Merger in 2022 (See Note 6) did not materially impact tax matters as 60P LLC had elected to be taxed as a C corporation for income tax purposes at the beginning of 2022. The District of Columbia (“DC”) taxes corporations on form D-20 (DC Corporation Franchise Tax Return) and returns have a minimum tax due of $250 if gross receipts are at $1 million or less and $1,000 if above. The tax years that remain subject to examination by major tax jurisdictions include the years ended December 31, 2020, 2021, 2022 and 2023. 60P Australia Pty Ltd. is subject to the taxes of the Australian Taxation Office and 60P Singapore Pte Ltd. was subject to the taxes of the Inland Revenue Authority of Singapore prior to its dissolution as of March 31, 2022. Management assesses, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carry-back net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. On the basis of this evaluation, the Company has determined that it is more likely than not that the Company will not recognize the benefits of the U.S. Federal, state and net deferred tax assets, and, as a result, a full valuation allowance has been set against its net deferred tax assets as of December 31, 2023 and December 31, 2022. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. The Company establishes reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when the Company believes that certain positions might be challenged despite its belief that its tax return positions are fully supportable. The Company adjusts these reserves in light of changing facts and circumstances, such as the outcome of tax examinations. As of December 31, 2023 and December 31, 2022, no reserves for uncertain tax positions have been established. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as income tax expense. During the years ended December 31, 2023 and 2022 the Company did not recognize interest and penalties related to unrecognized tax benefits.
Segment Information		Segment Information A single management team that reports to the Chief Executive Officer comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of Liabilities Measured at Fair Value	Liabilities measured at fair value at September 30, 2024 and December 31, 2023 are as follows: September 30, 2024 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 623,762 $ 623,762 Total $ - $ - $ 623,762 $ 623,762 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796	Liabilities measured at fair value at December 31, 2023 and 2022 are as follows: December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements	Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate As of Three Months Ended Nine Months Ended September 30, December 31, Currency 2024 2023 2024 2023 2024 2023 1 AUD = 0.67 USD 0.65 USD 0.66 USD 0.67 USD 0.69 USD 0.68 USD	Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Year Ended As of Currency 2023 2022 December 31, December 31, 1 AUD = 0.66 USD 0.69 USD 0.68 USD 0.68 USD 1 SGD = NA 1.02 AUD* NA 1.02 AUD* * Through 4/30/2022 (account closure date)

Inventory (Tables)

Inventory (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Inventory [Abstract]
Schedule of Inventory	Inventory consists of the following major classes: September 30, December 31, Work in Process $ 367,587 $ 278,987 Finished Goods 84,449 187,182 Inventory $ 452,036 $ 466,169	Inventory consists of the following major classes: December 31, December 31, Raw Material (API) $ - $ 397,487 Work in Process 278,987 97,486 Finished Goods 187,182 183,943 Total Inventory 466,169 678,916 Reserve for Expiring Inventory - (160,338 ) Inventory, net $ 466,169 $ 518,578

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	As of September 30, 2024 and December 31, 2023, Property and Equipment, net consists of: September 30, December 31, Lab Equipment $ 233,411 $ 132,911 Machinery 55,800 55,800 Computer Equipment 7,000 14,084 Furniture 3,030 3,030 Property and Equipment, at cost 299,241 205,825 Accumulated Depreciation (143,984 ) (148,064 ) Property and Equipment, Net $ 155,257 $ 57,761	As of December 31, 2023 and 2022, Property and Equipment, net consists of: December 31, December 31, 2023 2022 Lab Equipment $ 132,911 $ 132,911 Machinery 55,800 - Computer Equipment 14,084 12,261 Furniture 3,030 3,030 Property and Equipment, at cost 205,825 148,202 Accumulated Depreciation (148,064 ) (126,902 ) Property and Equipment, Net $ 57,761 $ 21,300

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	As of September 30, 2024 and December 31, 2023, Intangible Assets, net consists of: September 30, December 31, Patents $ 225,485 $ 185,595 Website Development Costs 104,622 79,248 Intangible Assets, at cost 330,107 264,843 Accumulated Amortization (65,756 ) (37,585 ) Intangible Assets, net $ 264,351 $ 227,258	As of December 31, 2023 and 2022, Intangible Assets, net consist of: December 31, December 31, Patents $ 185,595 $ 145,613 Website Development Costs 79,248 27,070 Intangible Assets, at cost 264,843 172,683 Accumulated Amortization (37,585 ) (8,428 ) Intangible Assets, net $ 227,258 $ 164,255
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs	The following table summarizes the estimated future amortization expense for our patents and website development costs as of September 30, 2024: Period Patents Website Development 2024 (remaining three months) $ 1,753 $ 8,718 2025 7,010 31,761 2026 7,010 12,432 2027 7,010 3,094 2028 7,010 - Thereafter 51,106 - Total $ 80,899 $ 56,005	The following table summarizes the estimated future amortization expense for our patents and website development costs as of December 31, 2023: Period Patents Website 2024 $ 6,612 $ 26,416 2025 6,612 23,303 2026 6,612 3,974 2027 6,612 - 2028 6,612 - Thereafter 41,817 - Total $ 74,877 $ 53,693

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of Equity-Classified Warrants	The following table presents a summary of the activity for the Company’s equity-classified warrants during the three and nine months ended September 30, 2023: Number of Weighted Weighted Total outstanding, December 31, 2022 - $ - - Total outstanding, March 31, 2023 - $ - - Total outstanding, June 30, 2023 - $ - - Reclassified from derivative liabilities 19,330 65.58 4.15 Granted 259,700 74.60 5.00 Exercised (15,371 ) 73.63 5.00 Forfeited - - - Expired - - - Total outstanding, September 30, 2023 263,659 $ 73.99 4.73 Total exercisable, September 30, 2023 263,659 $ 73.99 4.73 The following table presents a summary of the activity for the Company’s equity-classified warrants during the three and nine months ended September 30, 2024: Number of Weighted Weighted Total outstanding, December 31, 2023 263,659 $ 74.00 4.47 Granted 704,414 4.50 5.00 Exercised (41,630 ) 0.12 Indefinite Forfeited - - - Expired - - - Total outstanding, March 31, 2024 926,443 $ 24.47 4.67 Granted - - - Exercised (41,629 ) 0.12 Indefinite Forfeited - - - Expired - - - Total outstanding, June 30, 2024 884,814 $ 25.62 4.41 Granted (1) 8,913,044 0.94 - Exercised - - - Forfeited - - - Expired - - - Total outstanding, September 30, 2024 (1) 9,797,858 $ 3.17 4.16 Total exercisable, September 30, 2024 (2) 3,783,365 $ 5.99 4.16 (1) Weighted average remaining contractual life calculations exclude (i) 2,898,551 Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) 217,391 September 2024 Agent Warrants and 2,898,551 Series A Warrants issued September 2024 that will expire five years from the Stockholder Approval Date, defined above, and (iii) 2,898,551 Series B Warrants issued September 2024 that will expire eighteen months from the Stockholder Approval Date. (2) Weighted average remaining contractual life calculation excludes 2,898,551 exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date	The following table presents information related to stock warrants at December 31, 2023: Number of Weighted Weighted Total outstanding, December 31, 2022 - $ - - Reclassified from Derivative Liabilities 231,917 5.46 4.15 Granted 3,116,384 6.22 5.00 Exercised (184,447 ) 6.14 5.00 Forfeited - - - Expired - - - Total outstanding, December 31, 2023 3,163,854 $ 6.17 4.47 Total exercisable, December 31, 2023 3,163,854 $ 6.17 4.47
Schedule of Assumptions Used In Determining the Fair Value of Equity-Classified Warrants Granted	The following table summarizes the significant assumptions used in determining the fair value of equity-classified warrants granted during the nine months ended September 30, 2024: 2024 Stock price $ 3.36 Exercise price $ 5.08 Risk-free interest rate 3.91 % Expected volatility 95.00 % Expected term (years) 5.00 Expected dividend yield 0.00 %	The following table summarizes the significant assumptions used in determining the fair value of equity classified warrants on the respective grant or reclassification dates for the year ended December 31, 2023: 2023 Stock price $4.68 - 5.30 Exercise price $4.77 - 6.36 Risk-free interest rate 4.07 - 4.40 % Expected volatility 90 - 105 % Expected term (years) 3.86 - 5.00 Expected dividend yield 0.00%

Debt (Tables)

Debt (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Debt [Abstract]
Schedule of Bridge Notes and Related Party Notes	Significant terms of the Bridge Notes and Related Party Notes are summarized as follows: 2022 Related 2023 Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 2 Interest rate 10% 6% 10% Default interest rate 15% 15% 15% Collateral Unsecured Unsecured Unsecured Conversion rate 3 3 3	Bridge Notes and Related Party Notes are summarized as follows at December 31, 2023 and 2022: 2022 Related 2023 Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 2 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 3 3 3 Face amount of notes $ 888,889 $ 338,889 $ - Less: unamortized debt discount (407,555 ) (155,443 ) - Add: accrued interest on promissory notes 54,567 11,651 - Balance - December 31, 2022 $ 535,901 $ 195,097 $ - Face amount of notes - - - Less: unamortized debt discount - - - Add: accrued interest on promissory notes - - - Balance - December 31, 2023 $ - $ - $ -
Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note	A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 21,815,841 Fair value - mark to market adjustment 1,064,849 Accrued interest recognized 659,306 Promissory Notes, at fair value at June 30, 2023 23,539,996 Fair value - mark to market adjustment (6,105,066 ) Extinguishment of Promissory Notes (17,434,930 ) Promissory Notes, at fair value at September 30, 2023 $ -	A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the year ended December 31, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (5,379,269 ) Accrued interest recognized 1,293,549 Extinguishment of Promissory Notes (17,434,930 ) Promissory Notes, at fair value at December 31, 2023 $ -
Schedule of the Current Future Payment Obligations	The current future payment obligations of the principal are as follows: Period Principal 2024 (remaining three months) $ - 2025 - 2026 683 2027 3,228 2028 3,342 Thereafter 142,747 Total $ 150,000	The current future payment obligations of the principal are as follows: Period Principal Payments 2024 $ - 2025 - 2026 683 2027 3,228 2028 3,342 Thereafter 142,747 Total $ 150,000
Schedule of Promissory Notes		Promissory notes are summarized as follows at December 31, 2023: Knight Note, Bridge Total Promissory Notes (including accrued interest) $  - $ - $ - $ - Promissory Notes (including accrued interest) - - - - Less Current Maturities - - - - Long Term Promissory Notes $ - $ - $ - $ - Promissory notes are summarized as follows at December 31, 2022: Knight Note, Bridge Total Promissory Notes (including accrued interest) $ 16,319,986 $ 1,109,783 $ 535,901 $ 17,965,670 Less Current Maturities 16,319,986 - 535,901 16,855,887 Long Term Promissory Notes $ - $ 1,109,783 $ - $ 1,109,783
Schedule of the Knight Debenture		The Knight debenture as of December 31, 2023 and 2022 consisted of the following: December 31, December 31, Original Debenture $ - $ 3,000,000 Unamortized Debt Discount - (279,061 ) Debenture Prior to Accumulated Interest - 2,720,939 Accumulated Interest - 1,555,670 Debenture $ - $ 4,276,609

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Derivative Liabilities [Abstract]
Schedule of Derivative Expense	Derivative expense recorded during the three and nine months ended September 30, 2023 is summarized as follows: Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725	Derivative expense recorded during the year ended December 31, 2022 is summarized as follows: Commitment Date May 24, Fair value of derivative liabilities $ 1,483,888 Less: face amount of debt (979,275 ) Derivative expense $ 504,613 Derivative expense recorded during the year ended December 31, 2023 is summarized as follows: Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis	A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2024: Contingent Milestone Payment Total Derivative liabilities - December 31, 2023 $ 2,306,796 $ 2,306,796 Fair value - mark to market adjustment (1,740,847 ) (1,740,847 ) Derivative liabilities - March 31, 2024 565,949 565,949 Fair value - mark to market adjustment 1,101 1,101 Derivative liabilities - June 30, 2024 567,050 567,050 Fair value - mark to market adjustment 56,712 56,712 Derivative liabilities - September 30, 2024 $ 623,762 $ 623,762 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2023: Bridge Warrants Convertible Contingent Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ - $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) - 5,134 Derivative liabilities - March 31, 2023 839,254 579,853 80,227 - 1,499,334 Fair value - commitment date 680,276 274,449 - - 954,725 Fair value - mark to market adjustment 8,896 (17,009 ) 145 - (7,968 ) Derivative liabilities - June 30, 2023 1,528,426 837,293 80,372 - 2,446,091 Fair value - mark to market adjustment prior to conversion or reclassification (105,790 ) 1,455 (45,207 ) - (149,542 ) Conversion of convertible promissory notes (1,422,636 ) - (35,165 ) - (1,457,801 ) Reclassification of warrants to equity - (838,748 ) - - (838,748 ) Recognition of contingent milestone liability - - - 2,117,142 2,117,142 Fair value - mark to market adjustment - - - 57,052 57,052 Derivative liabilities - September 30, 2023 $ - $ - $ - $ 2,174,194 $ 2,174,194	A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at December 31, 2023 and 2022: Bridge Shares Warrants Convertible Contingent Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ - $ 1,494,200 Fair value - mark to market adjustment 13,798 (15,320 ) (1,312 ) - (2,834 ) Fair value - commitment date 680,276 274,449 - - 954,725 Fair value - mark to market adjustment prior to conversion or reclassification (105,790 ) 1,455 (45,207 ) - (149,542 ) Conversion of convertible promissory notes (1,422,636 ) - (35,165 ) - (1,457,801 ) Reclassification of warrants to equity - (838,748 ) - - (838,748 ) Recognition of contingent milestone liability - - - 2,117,142 2,117,142 Fair value - mark to market adjustment - - - 189,654 189,654 Derivative liabilities - December 31, 2023 $ - $ - $ - $ 2,306,796 $ 2,306,796 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at December 31, 2022 and 2021: Bridge Shares Warrants Convertible Total Derivative liabilities - December 31, 2021 $ - $ - $ - $ - Fair value - commitment date 823,687 565,007 95,194 1,483,888 Fair value - mark to market adjustment 10,665 13,157 (13,510 ) 10,312 Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ 1,494,200
Schedule of Fair Value of Liability-Classified Bridge Shares		At each subsequent reporting period, the Company remeasures the fair value of liability-classified bridge shares, warrants and embedded conversion features in convertible promissory notes using the Monte Carlo simulation. The assumptions used to perform the Monte-Carlo Simulation as of the respective commitment dates, as well as December 31, 2022 were as follows: Commitment Dates May 2023 May 2022 Stock price $ 5.30 $ 5.00 Volatility 115.1 % 99.7 % Expected term (in years) - Notes 0.99 1.00-1.03 Expected term (in years) - Warrants 4.99 5.00 Risk-free interest rate 4.80 % 2.76% - 2.84% Dividend yield 0 % 0 % IPO probability (prior to note maturity date) 95 % 95 % Mark to Market December 31, Stock price $ 5.00 Volatility 101.9 % Expected term (in years) - Notes 0.39 - 0.41 Expected term (in years) - Warrants 4.39 Risk-free interest rate 4.06 % Dividend yield 0 % IPO probability (prior to note maturity date) 95 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes Paid Net Abstract
Schedule of Loss Before Provision (Benefit) for Income Taxes	Loss before provision (benefit) for income taxes for the years ended December 31, 2023 and 2022 consisted of the following: For the Year Ended 2023 2022 United States $ (3,006,861 ) $ (5,807,367 ) Foreign (806,689 ) (369,917 ) Total Loss before Income Taxes $ (3,813,550 ) $ (6,177,284 )
Schedule of Provision (Benefit) for Income Taxes	The components of the provision (benefit) for income taxes consisted of the following: For the Year Ended 2023 2022 Current: Federal $ - $ - State 250 500 Foreign - - Total current provision (benefit) 250 500 Deferred: Federal - - State - - Foreign - - Total deferred provision (benefit) - - Total Benefit $ 250 $ 500
Schedule of Reconcilation Between Income Taxes Computed at the U.S. Statutory Income Tax Rate	The reconciliation between income taxes computed at the U.S. statutory income tax rate to the Company’s provision (benefit) for income taxes for the years ended December 31, 2023 and 2022 are as follows: For the Year Ended December 31, 2023 2022 Benefit for income taxes at 21% rate $ (800,846 ) 21.0 % $ (1,297,230 ) 21.0 % State income taxes, net of federal benefit (364,618 ) 9.6 (478,515 ) 7.7 Impact of non-U.S. earnings (33,994 ) 0.9 (33,897 ) 0.5 Permanent differences 280,654 (7.4 ) - 0.0 Change in fair value of promissory note (1,129,646 ) 29.6 - 0.0 Non-deductible interest expense 304,962 -8.0 - 0.0 Other reconciling items, net 2,042,657 (53.6 ) 683,359 (11.1 ) Change in valuation allowance (298,919 ) 7.8 1,126,783 (18.2 ) Benefit for Income Taxes $ 250 (0.1 )% $ 500 (0.1 )%
Schedule of Deferred Tax Assets (Liabilities)	Significant components of the Company’s deferred tax assets (liabilities) as of December 31, 2023 and 2022 are as follows: As of December 31, 2023 2022 Deferred tax assets: Net operating loss carry-forward $ 3,453,126 $ 3,338,726 Non-deductible reserves 1,058 - Capitalized R&D costs 189,893 - Lease liability 3,756 - Share-based compensation 94,034 - Gross deferred tax assets 3,741,867 3,338,726 Less valuation allowance (3,043,135 ) (3,338,726 ) Total deferred tax assets, net of valuation allowance 698,732 - Deferred tax liabilities: Right of use asset (3,719 ) - Prepaid expenses (695,013 ) - Total deferred tax liabilities (698,732 ) - Net deferred tax liabilities $ - $ -

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Compensation [Abstract]
Schedule of Share-Based Compensation Expenses	The following is a summary of share-based compensation expenses reported in the Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income for the three and nine months ended September 30, 2024 and 2023: For the For the 2024 2023 2024 2023 Research and Development $ 600,000 $ - $ 3,227,300 $ 188,908 General and Administrative Expenses 68,974 549,031 319,709 1,172,136 Total Share-Based Compensation Expense Included in Operating Expenses $ 668,974 $ 549,031 $ 3,547,009 $ 1,361,044	The following is a summary of share-based compensation expenses reported in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022: For the Year Ended 2023 2022 Research and Development $ 192,371 $ - General and Administrative Expenses 1,543,803 - Total Share-Based Compensation Expense Included in Operating Expenses $ 1,736,174 $ -
Schedule of Fair Value of Options Granted	The following table summarizes the significant assumptions used in determining the fair value of options granted for the three and nine months ended September 30, 2024: 2024 Weighted-average grant date fair value 1.76 Risk-free interest rate 3.62% - 4.17 % Expected volatility 86.0% - 87.0 % Expected term (years) 6.41 - 10.00 Expected dividend yield 0.00% The following table summarizes the significant assumptions used in determining the fair value of options granted for the three and nine months ended September 30, 2023: 2023 Weighted-average grant date fair value 41.04 Risk-free interest rate 4.25% - 4.33 % Expected volatility 105.0% - 110.0 % Expected term (years) 3.18 - 3.76 Expected dividend yield 0.00%	The following table summarizes the significant assumptions used in determining the fair value of options on the respective grant dates or modification dates for the year ended December 31, 2023: 2023 Weighted-average grant date fair value $ 3.16 Risk-free interest rate 4.33 % Expected volatility 110.0 % Expected term (years) 3.18 Expected dividend yield 0.00 %
Schedule of Stock Option Activities		The following table summarizes the Company’s stock option activities: Number of Weighted Aggregate Weighted Options outstanding, December 31, 2022 - $ - $ - - Granted 37,736 5.30 - 5.00 Exercised - - - - Forfeited - - - - Expired - - - - Options outstanding, December 31, 2023 37,736 $ 5.30 $ - 4.53 Options vested and exercisable, December 31, 2023 37,736 $ 5.30 $ - 4.53
Schedule of RSU Activity		The following table summarizes the Company’s RSU activity for the year ended December 31, 2023: Number of Units Weighted Average Grant Unvested balance, December 31, 2022 - $ - Granted 256,000 0.87 Vested (256,000 ) 0.87 Forfeited - - Unvested balance, December 31, 2023 - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Lease Payments on a Discounted and Undiscounted Basis	Future minimum lease payments on a discounted and undiscounted basis under the Company’s operating lease Undiscounted Discount rate 15.00 % 2024 $ 13,992 Thereafter - Total undiscounted minimum future payments 13,992 Imputed interest (342 ) Total operating lease payments 13,650 Current lease liabilities 13,650 Non-current lease liabilities $ -
Schedule of Other Information Related to our Operating Lease	Other information related to our operating lease is as follows: December 31, Weighted average remaining lease term (in years) 0.25 Weighted average discount rate 15.00 %

Nature of Operations (Details)

Nature of Operations (Details) - USD ($)					9 Months Ended			12 Months Ended
	Aug. 19, 2024	Jan. 29, 2024	Jul. 14, 2023	Jul. 13, 2023	Sep. 30, 2024		Sep. 30, 2023	Dec. 31, 2023		Dec. 31, 2022	Sep. 04, 2024	Feb. 14, 2024	May 31, 2023	Jun. 01, 2022	May 31, 2022
Nature of Operations [Line Items]
Price per unit		$ 0.12												$ 5
Net proceeds (in Dollars)							$ 6,454,325	$ 6,454,325
Exercise price per share		$ 5.082			$ 0.12						$ 1.379	$ 0.12	$ 5.83		$ 5.83
Percentage of offering price per unit		110%		110%	110%			110%
Representative warrants exercisable term		5 years			5 years
Cash and cash equivalents (in Dollars)					$ 3,300,688			$ 2,142,485
Net cash used in operating activities (in Dollars)					(4,009,871)		$ (4,479,242)	(4,542,910)		(1,009,980)
Company’s debt (in Dollars)					8,772			8,772		2,750
Accounts payable and accrued expenses (in Dollars)					$ 677,617			$ 506,206		$ 758,668
Common stock, par value					$ 0.0001	[1]		$ 0.0001	[1]	$ 0.0001
Purchase of shares (in Shares)	93,563
Cash and cash equivalents (in Dollars)								$ 2,142,485		$ 264,865
Operating lease liabilities (in Dollars)								13,650		$ 13,000
Non-Tradeable Warrants [Member]
Nature of Operations [Line Items]
Number of shares issued (in Shares)			117,925		12,669
Price per unit			$ 5.3	$ 69.96
Net proceeds (in Dollars)			$ 6,454,325					$ 7,000,000
Exercise price per share			$ 6.36
Initial public offering shares (in Shares)			1,415,095
Common stock, par value			$ 0.0001
Tradeable Warrants [Member]
Nature of Operations [Line Items]
Number of shares issued (in Shares)					17,689
Price per unit			63.6		$ 0.12			$ 0.01
Exercise price per share			6.095
Additional purchase of shares (in Shares)				8,387
Purchase of shares (in Shares)				100,644				212,265
Tradeable Warrants [Member] | Common Stock [Member]
Nature of Operations [Line Items]
Exercise price per share			73.14
Non-Tradeable Warrants [Member]
Nature of Operations [Line Items]
Number of shares issued (in Shares)					17,689
Price per unit					$ 0.12			$ 0.01
Exercise price per share			$ 76.32
Warrants expire term			5 years
Additional purchase of shares (in Shares)				8,387
Purchase of shares (in Shares)				100,644				212,265
Over-Allotment Option [Member]
Nature of Operations [Line Items]
Number of shares issued (in Shares)					17,689
Price per unit					$ 63.36			$ 5.28
Purchase of shares (in Shares)								212,265
Representative Warrants [Member]
Nature of Operations [Line Items]
Price per unit				$ 5.83
Additional purchase of shares (in Shares)				7,076
Representative warrants exercisable term				5 years
Purchase of shares (in Shares)				84,906
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 30, 2024	Aug. 02, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Line Items]
Reverse stock split	1:12				1:12
FDIC insurable limits (in Dollars)			$ 250,000		$ 250,000		$ 250,000
Inventory write-downs (in Dollars)			1,165	$ 0	18,490	$ 94,977	191,111	$ 162,222
Research and development costs (in Dollars)			$ 940,063	$ 263,703	$ 4,372,571	$ 591,569	$ 691,770	$ 525,563
Consolidated owner percentage							100%
Tax gross receipt (in Dollars)							$ 250
Non-related party debt rate							0%	85%
US Government Accounted [Member]
Summary of Significant Accounting Policies [Line Items]
Outstanding accounts receivable balance rate							13%	66%
American Pharmaceutical Distributor [Member]
Summary of Significant Accounting Policies [Line Items]
Outstanding accounts receivable balance rate							79%	30%
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Property and equipment estimated lives year							3 years
Tax gross receipt (in Dollars)							$ 1
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Property and equipment estimated lives year							7 years
Tax gross receipt (in Dollars)							$ 1,000
Median [Member]
Summary of Significant Accounting Policies [Line Items]
Property and equipment estimated lives year							5 years
Receivable [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							10%	96%
Significant Customers [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							92%
Significant Customers [Member] | Revenue from Rights Concentration Risk [Member] | Minimum [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							13%
Significant Customers [Member] | Revenue from Rights Concentration Risk [Member] | Maximum [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							79%
Total revenue [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							93%
Single Customers One [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							72%
Single Customers One [Member] | Revenue from Rights Concentration Risk [Member] | Minimum [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage								40%
Single Customers One [Member] | Revenue from Rights Concentration Risk [Member] | Maximum [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage								66%
Single Customers Two [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							21%
Single Customers Two [Member] | Revenue from Rights Concentration Risk [Member] | Minimum [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage								39%
Single Customers Two [Member] | Revenue from Rights Concentration Risk [Member] | Maximum [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage								30%
Net Revenue [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage								100%
Single Customers Three [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage								14%
60P Australia Pty Ltd [Member] | Geoffrey Dow [Member]
Summary of Significant Accounting Policies [Line Items]
Number of common shares issued (in Shares)		904,436
American Pharmaceutical Distributor [Member]
Summary of Significant Accounting Policies [Line Items]
Percentage of accounts receivable			96%		96%		79%
US Government Accounted [Member]
Summary of Significant Accounting Policies [Line Items]
Outstanding accounts receivable percentage							13%
60P Australia Pty Ltd [Member] | Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Proportional ownership percentage		87.53%
60P Australia Pty Ltd [Member] | Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Proportional ownership percentage		96.61%
Australia Pty Ltd [Member] | Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Proportional ownership percentage		87.53%
Australia Pty Ltd [Member] | Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Proportional ownership percentage		96.61%
Significant Customers [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage					10%
Significant Customers [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage				100%	100%		92%
Customer One [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage					97%
Significant Customer Two [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage					97%
Customer Three [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage							79%
Customer Two [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage					28%		13%
Two Customers and One Significant Customer [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage			92%
Three Customers and One Significant Customer [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage					94%
Customer One [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage					72%
Australia Pty Ltd [Member]
Summary of Significant Accounting Policies [Line Items]
Common stock shares (in Shares)		904,436

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities	$ 623,762	$ 2,306,796	$ 1,129,840
Level 1 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities
Level 2 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities
Level 3 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities	623,762	2,306,796
Derivative Liabilities [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities	623,762	2,306,796
Derivative Liabilities [Member] | Level 1 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities
Derivative Liabilities [Member] | Level 2 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities
Derivative Liabilities [Member] | Level 3 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Total derivative liabilities	$ 623,762	$ 2,306,796

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Average Exchange Rates (Details) - USD [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Schedule of Average Exchange Rates [Line Items]
Average Exchange Rate	0.67	0.65	0.66	0.67
Exchange rates	0.69		0.69		0.68

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventory [Abstract]
Work in Process	$ 367,587	$ 278,987	$ 97,486
Finished Goods	84,449	187,182	183,943
Inventory	$ 452,036	$ 466,169	$ 518,578

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment [Abstract]
Machinery	$ 55,800		$ 55,800
Depreciation expenses	$ 4,334	$ 5,485	$ 6,277	$ 19,287	$ 21,162	$ 27,648

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	$ 299,241	$ 205,825	$ 148,202
Accumulated Depreciation	(143,984)	(148,064)	(126,902)
Property and Equipment, Net	155,257	57,761	21,300
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	233,411	132,911	132,911
Machinery [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	55,800	55,800
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	7,000	14,084	12,261
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	$ 3,030	$ 3,030	$ 3,030

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Capitalized website development-related costs	$ 3,299	$ 12,283	$ 25,374	$ 52,178	$ 52,178	$ 27,070
Amortization expense	10,325	7,414	28,004	20,606	29,157	$ 5,118
Write-downs	$ 2,922	$ 0	11,300	$ 0
Capitalized patent expenses			$ 128,722		$ 93,545

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Abstract]
Patents	$ 225,485	$ 185,595	$ 145,613
Website Development Costs	104,622	79,248	27,070
Intangible Assets, at cost	330,107	264,843	172,683
Accumulated Amortization	(65,756)	(37,585)	(8,428)
Intangible Assets, net	$ 264,351	$ 227,258	$ 164,255

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2024 (remaining six months)	$ 1,753
2025	7,010	$ 6,612
2026	7,010	6,612
2027	7,010	6,612
2028	7,010	6,612
Thereafter	51,106	6,612
Total	80,899	74,877
Website Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
2024 (remaining six months)	8,718
2025	31,761	26,416
2026	12,432	23,303
2027	3,094	3,974
2028
Thereafter
Total	$ 56,005	$ 53,693

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)																		1 Months Ended			3 Months Ended					9 Months Ended			12 Months Ended
		Sep. 05, 2024	Aug. 19, 2024	Aug. 01, 2024	Jul. 30, 2024	Jul. 26, 2024	Jul. 22, 2024	Jul. 12, 2024	Apr. 01, 2024	Feb. 14, 2024	Jan. 31, 2024	Jan. 29, 2024	Jul. 14, 2023	Jul. 13, 2023	Jul. 11, 2023	Jun. 30, 2022	Mar. 31, 2022	May 31, 2023	May 31, 2022	Mar. 31, 2022	Sep. 30, 2024		Mar. 31, 2024	[2]	Sep. 30, 2023	Sep. 30, 2024		Sep. 30, 2023	Dec. 31, 2023		Dec. 31, 2022	Sep. 04, 2024	Aug. 02, 2024	Jul. 24, 2024	Apr. 09, 2024	Feb. 01, 2024	Dec. 28, 2023	Jul. 31, 2023	Jul. 28, 2023	Jul. 25, 2023	Jul. 17, 2023	Mar. 31, 2023	Jan. 31, 2023	Jun. 01, 2022	May 05, 2022
Stockholders’ Equity [Line Items]
Common stock shares authorized																					150,000,000	[1]				150,000,000	[1]		150,000,000	[1]	150,000,000
Common stock par value (in Dollars per share)																					$ 0.0001	[1]				$ 0.0001	[1]		$ 0.0001	[1]	$ 0.0001
Common stock, shares issued	[1]																				1,861,914					1,861,914			484,187
Common stock, shares outstanding	[1]																				1,861,914					1,861,914			484,187
Reverse stock split					1:12																					1:12
Issued an additional shares			93,563
Restricted shares of common stock															3,336
Sale of stock price per share (in Dollars per share)										$ 4.5
Common stock upon conversion													142,270
Deferred compensation equity (in Dollars)																																													$ 245,000
Exercise price of warrants (in Dollars per share)										$ 0.12		$ 5.082						$ 5.83	$ 5.83		$ 0.12					$ 0.12						$ 1.379
Offering price per unit												110%		110%												110%			110%
Issuance and expires												5 years									5 years					5 years
Price per share (in Dollars per share)												$ 0.12																																$ 5
Pre funded warrant (in Dollars per share)												$ 0.12																	$ 0.375
Exercise of warrants										5				31,447				151,991	151,991		83,259					83,259
Pre-funded warrants																										12,489
Percentage of warrant units sold																										15%
Percentage of warrant underlying the pre funded units sold																										15%
Percentage of Pre funded warrant underlying the pre funded unit sold																										15%
Additional common share										5
Net proceeds (in Dollars)																										$ 1,900,000
Pre funded warrants											9,990															2,898,551			149,862
Agreed to return shares									10,000
Common stock aggregate offering price (in Dollars)								$ 1,253,603
Deferred Offering Costs (in Dollars)						$ 2,190,416	$ 1,774,640																								$ 68,629		$ 2,295,192	$ 1,890,705
ATM Offering				677,819
Gross proceeds (in Dollars)				$ 1,994,583
Common stock upon conversion																																							45,560
Shares converted																	92,362			214,934						6,661			79,926
IPO price percentage																					110%					110%
Exercise price (in Dollars per share)																										$ 69.96
Deducting placement agent fees (in Dollars)		$ 3,414,502																								$ 3,439,502
Exercise price (in Dollars per share)																										$ 0.001		$ 73.14
Warrants to purchase																					217,391					217,391
Cash proceeds (in Dollars)																												$ 1,131,771	$ 1,131,771
Non-tradeable warrants																												7,750
Aggregate cash proceeds (in Dollars)																										$ 9,990
Dividends percentage																										6%			6%
Dividends preferred stock (in Dollars)																										$ 573,046
Percentage of shares issued and outstanding																															61%
Net proceeds (in Dollars)																												$ 6,454,325	$ 6,454,325
Common stock upon conversion													214,934
Bridge warrants exercisable into common stock																		231,917	231,917
IPO price percentage																		110%	110%
Common Stock Warrants [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																						15,371
Number of shares												1
Number of warrant exercisable												1
Exercise price of warrants (in Dollars per share)																					$ 0.12					$ 0.12
Pre funded warrant (in Dollars per share)																										$ 4.5
Exercise of warrants																					78,250					78,250			938,997
Pre funded warrants																										2,898,551
Pre-Funded Warrant [Member]
Stockholders’ Equity [Line Items]
Pre funded warrant units												83,259
Warrant offering price (in Dollars per share)												$ 4.5
Number of shares												1
Number of warrant exercisable												1
Cash proceeds (in Dollars)																									$ 1,131,771
January 2024 Representative Warrants [Member]
Stockholders’ Equity [Line Items]
Prefunded warrants sold percentage																										6%
Bridge Warrants [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued														31,447
Pre funded warrant units																									2,621			2,621
Exercise of warrants																													31,447
Non Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)																												$ 76.32
Non-Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise of warrants																													60,000
Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																									93,000
Exercise of warrants																													93,000												60,000
60P LLC [Member]
Stockholders’ Equity [Line Items]
Common stock par value (in Dollars per share)																																												$ 0.0001
60 Degrees Pharmaceuticals, Inc. [Member]
Stockholders’ Equity [Line Items]
Common stock shares authorized																													150,000,000
Common stock par value (in Dollars per share)																													$ 0.0001
January 2024 Offering [Member]
Stockholders’ Equity [Line Items]
Sale of stock price per share (in Dollars per share)												$ 4.62
Units issued												438,409
Maximum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares outstanding					21,219,937
Minimum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares outstanding					1,768,337
Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																													5,810,089						41,629	41,630				3,797
Common stock, shares outstanding																													5,810,089
Percentage of shares outstanding																															61%
Percentage of shares issued																															61%
Common stock upon conversion	[2]																								142,270
Shares of common stock															10,000
Converted preferred stock																																								45,560
Number of shares												1
Exercise of warrants																																			41,629	41,630
Purchase of common stock	[2]																				73,334				3,797
Shares converted						33,334	40,000
Shares of common stock	[2]																								15,371
IPO new shares																							438,414								37,067
Pre funded warrants																																2,898,551
Common Stock [Member] | Pre-Funded Warrant [Member]
Stockholders’ Equity [Line Items]
Number of shares												1
Common Stock [Member] | Non-Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Shares of common stock																																									60,000
Common Stock [Member] | Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Shares of common stock																																									93,000
Bridge Warrants [Member]
Stockholders’ Equity [Line Items]
Pre funded warrant units																																						2,621
Shares of common stock																										19,330
Non-tradeable warrants																												5,000
Non-Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Pre funded warrant units																																						5,000
Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Pre funded warrant units																																						7,750
Agent Warrants [Member]
Stockholders’ Equity [Line Items]
Pre funded warrants																										217,391
Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock shares authorized																													1,000,000
Preferred stock shares, par value (in Dollars per share)																													$ 0.0001
Restricted Shares [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued															40,000
Tyrone Miller [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																										192,101	192,101
Geoffrey S. Dow [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																										1,258,899	1,258,899
Vendors [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																										1,443,000	1,443,000
BioIntelect [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued													29,245
Deferred compensation equity (in Dollars)													$ 155,000
Knight [Member]
Stockholders’ Equity [Line Items]
Common stock upon conversion																	1,108,337
Red Chip [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																					10,554
Deferred compensation equity (in Dollars)																																					$ 40,000
Vendors [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																										120,253	120,253
Bridge Notes [Member]
Stockholders’ Equity [Line Items]
Shares of common stock													31,996
Xu Yu [Member]
Stockholders’ Equity [Line Items]
Shares of common stock													17,912
Knight Loan [Member]
Stockholders’ Equity [Line Items]
Shares of common stock													92,362
BioIntelect [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued													2,438
Deferred compensation equity (in Dollars)													$ 155,000
WallachBeth Capital LLC [Member]
Stockholders’ Equity [Line Items]
Price per share (in Dollars per share)																					$ 5.082					$ 5.082
Purchase of granted shares																										65,762
Purchased share price (in Dollars per share)																										$ 4.62
WallachBeth Capital LLC [Member] | Common Stock [Member] | January 2024 Representative Warrants [Member]
Stockholders’ Equity [Line Items]
Purchase of common stock																										31,300
HC Wainwright Co LLC [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)																										$ 1.725
Board of Directors [Member] | Tyrone Miller [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																										16,009	16,009
Board of Directors [Member] | Geoffrey S. Dow [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																																										104,910	104,910
Stephen Toovey [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued															10,000
Restricted shares of common stock															834
Charles Allen [Member]
Stockholders’ Equity [Line Items]
Restricted shares of common stock															834
Charles Allen [Member] | Restricted Shares [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued															10,000
Paul Field [Member]
Stockholders’ Equity [Line Items]
Restricted shares of common stock															834
Paul Field [Member] | Restricted Shares [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued															10,000
Cheryl Xu [Member]
Stockholders’ Equity [Line Items]
Restricted shares of common stock															834
Cheryl Xu [Member] | Restricted Shares [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued															10,000
Chief Executive Officer [Member]
Stockholders’ Equity [Line Items]
Price per share (in Dollars per share)																$ 5
Purchase price (in Dollars)																$ 185,335
Chief Executive Officer [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued																37,067
Series A Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock shares authorized																					1,000,000					1,000,000			1,000,000		1,000,000
Preferred stock shares, par value (in Dollars per share)																					$ 0.0001					$ 0.0001			$ 0.0001		$ 0.0001
Designated shares																													80,965
Preferred stock shares outstanding																					76,480					76,480			78,803
Preferred stock shares issued																					76,480					76,480			78,803
Converted preferred stock																																								2,162
Common stock upon conversion						1,032	1,291
Shares converted																	80,965
Dividends percentage																										19.90%			19.90%
Dividends preferred stock (in Dollars)																										$ 352,332		$ 101,538
Common stock conversion price per share (in Dollars per share)																										$ 100
Description of conversion term																										The “Conversion Price” is equal to the lesser of (a) the Liquidation Value, (b) the offering price per share of Common Stock in the Company’s IPO, as adjusted for the 1:12 Reverse Stock Split after August 12, 2024, or $60 per share or (c) the 10-day volume weighted average price per share of Common Stock, as reasonably determined by the Company.			The “Conversion Price” is equal to the lesser of (a) the Liquidation Value, (b) the offering price per share of Common Stock in the Company’s IPO, or (c) the 10-day volume weighted average price per share of Common Stock, as reasonably determined by the Company.
Preferred stock converted shares (in Dollars per share)																	$ 80,965			$ 80,965									$ 100
Preferred stock dividend outstanding																													220,714
Series A Preferred Stock [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Converted preferred stock																																							2,162
Series A Preferred Stock [Member] | Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Purchase of common stock																					(2,323)				(2,162)
Series A Non-Voting Convertible Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Designated shares																					80,965					80,965
Bridge Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)																												$ 69.96
Series A warrants [Member]
Stockholders’ Equity [Line Items]
Pre funded warrants																										2,898,551
Pre funded warrants																																2,898,551
Series B Warrants [Member]
Stockholders’ Equity [Line Items]
Issuance and expires																					18 months					18 months
Pre funded warrants																										2,898,551
Pre funded warrants																																2,898,551
Series A and Series B Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)																										$ 1.38
Preferred Class A [Member]
Stockholders’ Equity [Line Items]
Dividends preferred stock (in Dollars)																					$ 116,571				$ 101,538
Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued															3,336
IPO [Member]
Stockholders’ Equity [Line Items]
Common stock par value (in Dollars per share)													$ 0.0001
Common stock, shares issued													117,925								25,335					25,335
Sale of stock price per share (in Dollars per share)													$ 63.6
Net proceeds (in Dollars)													$ 6,454,325
Shares of common stock													1,415,095
Deferred compensation equity (in Dollars)																																													$ 155,000
Exercise price of warrants (in Dollars per share)													$ 6.36
Price per share (in Dollars per share)													$ 5.3	$ 69.96
IPO new shares													117,925													12,669
Net proceeds (in Dollars)													$ 6,454,325																$ 7,000,000
Common stock upon conversion													383,908
Common stock outstanding percentage																	19.90%			19.90%
IPO price percentage																		90%	90%
IPO [Member] | Common Stock Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price of warrants (in Dollars per share)																		$ 4.77	$ 4.77
IPO [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Sale of stock price per share (in Dollars per share)													$ 5.3
IPO [Member] | Related Parties [Member]
Stockholders’ Equity [Line Items]
Bridge warrants exercisable into common stock																		79,926	79,926
IPO [Member] | Bridge Warrants [Member]
Stockholders’ Equity [Line Items]
Share issued																					6,661					6,661
Exercise price (in Dollars per share)																										$ 57.24
IPO [Member] | Bridge Warrants [Member] | Common Stock Warrant [Member]
Stockholders’ Equity [Line Items]
IPO price percentage																					90%					90%
IPO [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued													1,415,095
Over-Allotment Option [Member]
Stockholders’ Equity [Line Items]
Issued an additional shares																													212,265
Price per share (in Dollars per share)																					$ 63.36					$ 63.36			$ 5.28
Shares warrants											68,182
IPO new shares																										17,689
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024. Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Equity-Classified Warrants (Details) - Warrants [Member] - $ / shares					3 Months Ended
	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2024		Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023
Class of Warrant or Right [Line Items]
Number of Warrants, Total outstanding, Ending	263,659				884,814		926,443
Weighted Average Exercise Price, Total outstanding, Ending	$ 74				$ 25.62		$ 24.47
Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending	4 years 5 months 19 days
Number of Warrants, Total outstanding, Ending					9,797,858	[1]	884,814	926,443	263,659
Weighted Average Exercise Price, Total outstanding, Ending					$ 3.17	[1]	$ 25.62	$ 24.47	$ 73.99
Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending					4 years 1 month 28 days	[1]	4 years 4 months 28 days	4 years 8 months 1 day	4 years 8 months 23 days
Number of Warrants,Total exercisable					3,783,365	[2]			263,659
Weighted Average Exercise Price,Total exercisable					$ 5.99	[2]			$ 73.99
Weighted Average Remaining Contractual Life (Years),Total exercisable					4 years 1 month 28 days	[2]			4 years 8 months 23 days
Number of Warrants, Reclassified from derivative liabilities									19,330
Weighted Average Exercise Price, Reclassified from derivative liabilities									$ 65.58
Weighted Average Remaining Contractual Life (Years), Reclassified from derivative liabilities									4 years 1 month 24 days
Number of Warrants, Granted					8,913,044	[1]		704,414	259,700
Weighted Average Exercise Price, Granted					$ 0.94	[1]		$ 4.5	$ 74.6
Weighted Average Remaining Contractual Life (Years), Granted						[1]		5 years	5 years
Number of Warrants, Exercised							(41,629)	(41,630)	(15,371)
Weighted Average Exercise Price, Exercised							$ 0.12	$ 0.12	$ 73.63
Weighted Average Remaining Contractual Life (Years), Exercised									5 years
Number of Warrants, Forfeited
Weighted Average Exercise Price, Forfeited
Weighted Average Remaining Contractual Life (Years), Forfeited
Number of Warrants, Expired
Weighted Average Exercise Price, Expired
Weighted Average Remaining Contractual Life (Years), Expired
[1] Weighted average remaining contractual life calculations exclude (i) 2,898,551 Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) 217,391 September 2024 Agent Warrants and 2,898,551 Series A Warrants issued September 2024 that will expire five years from the Stockholder Approval Date, defined above, and (iii) 2,898,551 Series B Warrants issued September 2024 that will expire eighteen months from the Stockholder Approval Date. Weighted average remaining contractual life calculation excludes 2,898,551 exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Assumptions Used In Determining the Fair Value of Equity-Classified Warrants Granted (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stockholders' Equity - Schedule of Assumptions Used In Determining the Fair Value of Equity-Classified Warrants Granted (Details) [Line Items]
Stock price (in Dollars per share)	$ 3.36
Exercise price (in Dollars per share)	$ 5.08
Risk-free interest rate	3.91%
Expected volatility	95%
Expected term (years)	5 years
Expected dividend yield	0%	0%

Debt (Details)

Debt (Details) - USD ($)											1 Months Ended				3 Months Ended				9 Months Ended		12 Months Ended
		Sep. 30, 2024	Jul. 14, 2023	Jan. 09, 2023	Nov. 04, 2022	Mar. 31, 2022	Jan. 01, 2022	May 14, 2020	Dec. 27, 2019	Oct. 11, 2017	May 31, 2023	Jan. 31, 2023	May 31, 2022	Mar. 31, 2022	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	May 11, 2023	May 08, 2023	Apr. 30, 2023	Apr. 23, 2023	May 24, 2022	Apr. 24, 2019
Debt [Line Items]
Debenture																												$ 3,000,000
Amortization discount															$ 0	$ 3,869			$ 0	$ 52,628	$ 52,628	$ 4,955
Interest expense						$ 17,912									$ 0	4,944			0	66,558	66,558	115,546
Extinguishment gain loss						$ 223,077						$ 839,887							$ 614,670		$ 17,434,930
Vested warrants																			5 years
Company issued holders common stock (in Shares)	[1]	1,861,914													1,861,914				1,861,914		484,187
Conversion rate, percentage											90%								80%
Converted shares (in Shares)						92,362								214,934					6,661		79,926
Accumulated interest																						1,555,670
Gross proceeds																				6,454,325	$ 6,454,325
Initial public offering discount, percentages																			15%		15%
Common stock outstanding, percentages																			19.90%		19.90%
Milestone payment																			$ 10,000,000		$ 10,000,000
Regulatory advice value																			$ 30,000		$ 30,000
Cumulative dividend		6%													6%				6%		6%
Common stock ownership percentage		19.90%													19.90%				19.90%		19.90%
Equal royalty pay to lender, percentage							$ 3.5												$ 3.5
Final mark-to-market adjustment																(6,105,066)	$ 1,064,849	$ (339,052)	6,105,066
Debt issuance costs																												2,100,000
Current maturity		$ 8,772													$ 8,772				8,772		$ 8,772			$ 555,000			$ 979,275
Long-term liability		147,895													147,895				147,895		$ 150,251	1,525,055
Knight Loan amount																						20,596,595
Maturity days																					30 days
Excess fair value discount																					$ 120,683
Note and incurred costs																					1,767
Debt extinguishment gain														$ 223,077
Original issue discount																				10,128,500	10,128,500
Debt extinguishment loss																					614,670
Additional cash payments due to the holders											$ 8,472
Extinguishment amount				$ 839,887												(391,593)				$ (1,231,480)	$ (1,231,480)	120,683
Description of knight debt conversion agreement																					As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,105,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment.
Unamortized original issue discount																					$ 0	279,061
Interest payments					$ 731																179,117	2,193
Long-term debt, current maturities		8,772													8,772				8,772		8,772	2,750
Current maturity																						2,750
Long-term liability amount		$ 147,895													$ 147,895				$ 147,895		150,251	160,272
Short term advance																		200,000					$ 250,000		$ 50,000
Knight Therapeutics, Inc. [Member]
Debt [Line Items]
Principal amount									$ 6,309,823
Accrued interest									4,160,918
Debenture									$ 3,483,851
Annual interest rate																										15%
Debenture interest rate																										9%
Maturity days										60 days
2022 Bridge Notes [Member]
Debt [Line Items]
Principal amount																						888,889
Accrued interest																					$ 1,749,488
Annual interest rate		15%													15%				15%
Debenture interest rate		10%													10%				10%
Maturity days																					1 year
Face amount, percentage													100%						100%
Debt issuance costs													$ 91,436
Balloon payment																					$ 28,154
Interest rate																					10%
Promissory notes face amount													$ 888,889
Discount rate													10%
Original issue discount													$ 88,889
Net proceeds													$ 708,564
Notes bear interest													10%
Default interest rate													15%
Additional cash payments											22,222
2022 and 2023 Bridge Notes [Member]
Debt [Line Items]
Settlement of outstanding debt obligations															$ 1,749,488
2023 Bridge Notes [Member]
Debt [Line Items]
Principal amount											$ 722,222
Annual interest rate		15%													15%				15%
Debenture interest rate		10%													10%				10%
Maturity days																					2 years
Amortization discount															$ 0	$ 670,550
Face amount, percentage											100%
Debt issuance costs											$ 95,000
Interest rate																					10%
Discount rate											10%
Original issue discount											$ 72,222
Net proceeds											$ 555,000
Notes bear interest											10%
Default interest rate											15%
Knight’s Cumulative Debt [Member]
Debt [Line Items]
Principal amount						$ 10,770,037								10,770,037
Accumulated interest						$ 8,096,486								$ 8,096,486
Debenture [Member]
Debt [Line Items]
Amortized interest expense																						500,103						$ 13,696
Small Business Administration [Member]
Debt [Line Items]
Principal amount								$ 150,000
Annual interest rate								3.75%
Principal payments		$ 156,667													156,667				$ 156,667		$ 159,023	163,022
Committed to monthly payments								$ 731
Balloon Payment [Member]
Debt [Line Items]
Balloon payment		$ 28,154													28,154				28,154
SBA [Member]
Debt [Line Items]
Maturity date		Oct. 12, 2050
Promissory Note [Member]
Debt [Line Items]
Promissory note										$ 750,000
Interest rate										5%
Note [Member]
Debt [Line Items]
Annual interest rate										10%
Related Party Notes [Member]
Debt [Line Items]
Amortization of debt discounts																					670,550	$ 664,780
Preferred Stock [Member]
Debt [Line Items]
Accumulated interest		$ 100													$ 100				100		100
Geoffrey S. Dow Revocable Trust [Member]
Debt [Line Items]
Short term advance																		$ 23,000
Tyrone Miller [Member]
Debt [Line Items]
Company issued holders common stock (in Shares)												192,101						192,101
Short term advance																		$ 27,000
Knight Debt [Member]
Debt [Line Items]
Ownership percentage						19.90%								19.90%
Chief Executive Officer [Member]
Debt [Line Items]
Debt issuance costs													$ 34,289
Promissory notes face amount													$ 338,889
Discount rate													10%
Original issue discount													$ 33,888
Net proceeds													$ 270,711
Notes bear interest													6%
Default interest rate													15%
Series A Preferred Stock [Member]
Debt [Line Items]
Converted shares (in Shares)						80,965
IPO [Member]
Debt [Line Items]
Accrued interest																			$ 31,968		31,968
Vested warrants																			1 year
Fully vested warrants exercise price percentage											110%								110%
Company issued holders common stock (in Shares)		25,335	117,925												25,335				25,335
Conversion rate, percentage											20%								20%
Gross proceeds			$ 6,454,325																		$ 7,000,000
Conversion rate, percentage																					80%
IPO [Member] | 2022 Bridge Notes [Member]
Debt [Line Items]
Fully vested warrants exercise price percentage											110%
IPO [Member] | Bridge Notes [Member]
Debt [Line Items]
Company issued holders common stock (in Shares)																					303,982
IPO [Member] | Chief Executive Officer [Member]
Debt [Line Items]
Conversion rate, percentage																			90%
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Debt - Schedule of Bridge Notes

Debt - Schedule of Bridge Notes and Related Party Notes (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
2022 Bridge Notes [Member]
Schedule of Bridge Notes and Related Party Notes [Line Items]
Maturity date of promissory notes	1
Interest rate	10%
Default interest rate	15%
Collateral	Unsecured	Unsecured
Conversion rate	3
Related Party Notes [Member]
Schedule of Bridge Notes and Related Party Notes [Line Items]
Maturity date of promissory notes	1
Interest rate	6%
Default interest rate	15%
Collateral	Unsecured	Unsecured
Conversion rate	3
2023 Bridge Notes [Member]
Schedule of Bridge Notes and Related Party Notes [Line Items]
Maturity date of promissory notes	2
Interest rate	10%
Default interest rate	15%
Collateral	Unsecured	Unsecured
Conversion rate	3

Debt - Schedule of Reconciliati

Debt - Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024
Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note [Abstract]
Beginning balance		$ 21,520,650
Fair value at modification date - January 9, 2023			21,520,650
Fair value - mark to market adjustment	$ (6,105,066)	1,064,849	(339,052)	$ 6,105,066
Extinguishment of Promissory Notes	(17,434,930)
Accrued interest recognized		659,306	634,243
Ending balance		$ 23,539,996	$ 21,815,841

Debt - Schedule of the Current

Debt - Schedule of the Current Future Payment Obligations (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of the Current Future Payment Obligations [Abstract]
2024 (remaining three months)
2025
2026	683
2027	3,228	683
2028	3,342	3,228
Thereafter	142,747	3,342
Total	$ 150,000	$ 150,000

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	May 08, 2023	May 24, 2022
Derivative Liabilities [Line Items]
Gain on change in fair of derivative liabilities	$ 1,683,034	$ 95,324	$ (37,278)	$ (10,312)
Derivative Liability, Statement of Financial Position [Extensible Enumeration]			Derivative Liabilities
Net proceeds received					$ 954,725	$ 1,483,888
Derivative liabilities			$ 37,278	$ 10,312
2023 Bridge Notes and Warrants [Member]
Derivative Liabilities [Line Items]
Fair value					954,725
2023 Bridge Notes [Member]
Derivative Liabilities [Line Items]
Net proceeds received	$ 555,000
2022 Bridge Notes and Warrants [Member]
Derivative Liabilities [Line Items]
Fair value on the commitment date amount						$ 1,483,888
Net proceeds received			979,275
2023 Bridge Notes and Warrants [Member]
Derivative Liabilities [Line Items]
Fair value on the commitment date amount					$ 954,725
Net proceeds received			$ 555,000

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Derivative Expense (Details) - Derivative Expense [Member] - USD ($)	3 Months Ended
	Sep. 30, 2024	May 08, 2023
Schedule Of Derivative Expense [Abstract]
Fair value of derivative liabilities		$ 954,725
Less: face amount of debt		$ (555,000)
Derivative expense	$ 399,725

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 567,050	$ 565,949	$ 2,306,796	$ 2,446,091	$ 1,499,334	$ 1,494,200	$ 2,306,796	$ 1,494,200	$ 1,494,200
Fair value - mark to market adjustment	56,712	1,101	(1,740,847)	57,052	(7,968)	5,134
Ending balance	623,762	567,050	565,949	2,174,194	2,446,091	1,499,334	623,762	2,174,194	2,306,796
Fair value - mark to market adjustment prior to conversion or reclassification				(149,542)
Conversion of convertible promissory notes				(1,457,801)
Reclassification of warrants to equity				(838,748)
Recognition of contingent milestone liability				2,117,142
Fair value - commitment date					954,725
Contingent Milestone Payment [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	567,050	565,949	2,306,796				2,306,796
Fair value - mark to market adjustment	56,712	1,101	(1,740,847)	57,052
Ending balance	$ 623,762	$ 567,050	$ 565,949	2,174,194			$ 623,762	2,174,194	2,306,796
Fair value - mark to market adjustment prior to conversion or reclassification
Conversion of convertible promissory notes
Reclassification of warrants to equity
Recognition of contingent milestone liability				2,117,142
Fair value - commitment date
Bridge Shares [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance				1,528,426	839,254	834,352		834,352	834,352
Fair value - mark to market adjustment					8,896	4,902
Ending balance					1,528,426	839,254
Fair value - mark to market adjustment prior to conversion or reclassification				(105,790)
Conversion of convertible promissory notes				(1,422,636)
Reclassification of warrants to equity
Recognition of contingent milestone liability
Fair value - commitment date					680,276
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance				837,293	579,853	578,164		578,164	578,164
Fair value - mark to market adjustment					(17,009)	1,689
Ending balance					837,293	579,853
Fair value - mark to market adjustment prior to conversion or reclassification				1,455
Conversion of convertible promissory notes
Reclassification of warrants to equity				(838,748)
Recognition of contingent milestone liability
Fair value - commitment date					274,449
Convertible Notes Payable [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance				80,372	80,227	81,684		81,684	$ 81,684
Fair value - mark to market adjustment					145	(1,457)
Ending balance					80,372	$ 80,227
Fair value - mark to market adjustment prior to conversion or reclassification				(45,207)
Conversion of convertible promissory notes				(35,165)
Reclassification of warrants to equity
Recognition of contingent milestone liability
Fair value - commitment date

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Provision for income taxes	$ 250	$ 63	$ 751	$ 189	$ 250	$ 500
Valuation allowance					295,591
U.S. federal net operating loss carryforwards					6,339,101	5,807,867
State net operating loss carryforwards					$ 6,338,851	5,807,367
Annual taxable income					80%
Foreign net operating loss carryforwards					$ 6,835,123	$ 6,560,235

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($)								3 Months Ended			9 Months Ended		12 Months Ended
		Sep. 26, 2024	Jul. 16, 2024	Jul. 11, 2024	Jul. 12, 2023	Jul. 11, 2023	Jan. 01, 2023	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Apr. 09, 2024	Feb. 01, 2024	Jul. 25, 2023	Jul. 14, 2023
Share-Based Compensation [Line Items]
Percentage of outstanding shares of common stock							4%
Remaining shares available for issuance			416,667
Compensation expense (in Dollars)								$ 668,974	$ 549,031		$ 3,547,009	$ 1,361,044	$ 119,246	$ 0
Common stock, shares issued	[1]							1,861,914			1,861,914		484,187
Aggregate of stock options		20,834	64,183
Weighted average exercise price (in Dollars per share)					$ 57
Weighted average fair value options granted (in Dollars per share)											$ 1.76	$ 41.04	$ 3.16
Granted of aggregate shares													256,000
Share issued as fully vested								2,438	0
Prepaid and other assets (in Dollars)								$ 176,471			$ 176,471		$ 948,581
Long-Term Prepaid Expense (in Dollars)								$ 110,294			$ 110,294		$ 242,647
Share based compensation recognized expense (in Dollars)						$ 187,200
Issuance of shares						40,000
Aggregate of stock options													740,000
Share price (in Dollars per share)													$ 5.3
Recognized stock options (in Dollars)													$ 222,480
Shares granted													256,000
Deemed capital contribution (in Dollars)													$ 163,228
Common Stock [Member]
Share-Based Compensation [Line Items]
Common stock, shares issued													5,810,089		41,629	41,630	3,797
Shares granted	[2]									(120,919)
Common stock shares issued	[2]								117,925
Two Thousand Twenty Two Equity Incentive Plan [Member]
Share-Based Compensation [Line Items]
Remaining shares available for issuance								351,034			351,034
Compensation expense (in Dollars)						$ 187,200
Florida State University Research Fund, Inc. [Member]
Share-Based Compensation [Line Items]
Compensation expense (in Dollars)											$ 2,625,000		$ 2,730,685
Trevally, LLC and Carmel, Milazzo & Feil LLP [Member]
Share-Based Compensation [Line Items]
Common stock shares issued													120,000	100,000
Carmel, Milazzo & Feil LLP [Member]
Share-Based Compensation [Line Items]
Common stock shares issued													776,471	0
Share Based Compensation [Member]
Share-Based Compensation [Line Items]
Weighted average fair value options granted (in Dollars per share)											$ 10.92
Equity Option [Member]
Share-Based Compensation [Line Items]
Compensation expense (in Dollars)								$ 15,246	$ 233,728			$ 233,728
RSU [Member]
Share-Based Compensation [Line Items]
Compensation expense (in Dollars)								$ 0	37,338			668
Granted of aggregate shares					2,672
Shares of common stock								0			21,338
Restricted Stock Units [Member]
Share-Based Compensation [Line Items]
Common stock, shares issued						40,000
Recognized stock options (in Dollars)														$ 0
Research and Development [Member]
Share-Based Compensation [Line Items]
Aggregate of stock options													2,730,685	0
Research and Development Expense [Member]
Share-Based Compensation [Line Items]
Compensation expense (in Dollars)								$ 600,000			$ 3,227,300	$ 188,908
Research and Development Expense [Member] | Florida State University Research Fund, Inc. [Member]
Share-Based Compensation [Line Items]
Compensation expense (in Dollars)											$ 103,385
Vendors [Member]
Share-Based Compensation [Line Items]
Compensation expense (in Dollars)									$ 0
Share issued as fully vested											0	77,500
Director [Member]
Share-Based Compensation [Line Items]
Aggregate of stock options													30,188
Common Stock [Member]
Share-Based Compensation [Line Items]
Common stock, shares issued						3,336
Common Stock [Member] | Common Stock [Member]
Share-Based Compensation [Line Items]
Share issued as fully vested											0	45,191
Share-Based Payment Arrangement, Nonemployee One [Member]
Share-Based Compensation [Line Items]
Share issued as fully vested													552,799
Share based payments, common stock issued													525,000
Share-Based Payment Arrangement, Nonemployee Two [Member]
Share-Based Compensation [Line Items]
Share issued as fully vested														0
Share based payments, common stock issued													405,000
Forecast [Member]
Share-Based Compensation [Line Items]
Percentage of vested				100%
IPO [Member]
Share-Based Compensation [Line Items]
Common stock, shares issued								25,335			25,335							117,925
Aggregate of stock options					50,664
Share price (in Dollars per share)														$ 1
IPO [Member] | Common Stock [Member]
Share-Based Compensation [Line Items]
Common stock, shares issued																		1,415,095
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024. Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share-Based Compensation Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Share-Based Compensation Expenses [Line Items]
Total Share-Based Compensation Expense Included in Operating Expenses	$ 668,974	$ 549,031	$ 3,547,009	$ 1,361,044	$ 119,246	$ 0
Research and Development [Member]
Schedule of Share-Based Compensation Expenses [Line Items]
Total Share-Based Compensation Expense Included in Operating Expenses	600,000		3,227,300	188,908
General and Administrative Expenses [Member]
Schedule of Share-Based Compensation Expenses [Line Items]
Total Share-Based Compensation Expense Included in Operating Expenses	$ 68,974	$ 549,031	$ 319,709	$ 1,172,136

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Fair Value of Options Granted (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted-average grant date fair value (in Dollars per share)	$ 1.76	$ 41.04	$ 3.16
Risk-free interest rate			4.33%
Expected volatility			110%
Expected term (years)			3 years 2 months 4 days
Expected dividend yield	0%	0%	0%
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free interest rate	3.62%	4.25%
Expected volatility	86%	105%
Expected term (years)	6 years 4 months 28 days	3 years 2 months 4 days
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free interest rate	4.17%	4.33%
Expected volatility	87%	110%
Expected term (years)	10 years	3 years 9 months 3 days

Commitments and Contingencies_2

Commitments and Contingencies (Details)			3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 11, 2023 USD ($) $ / shares shares	Jul. 15, 2015 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jul. 14, 2023 shares
Commitments and Contingencies [Line Items]
Operating lease costs			$ 4,938	$ 13,859	$ 24,067	$ 41,225	$ 55,084	$ 51,894
Number of non audit committee chairs			2		2
Licensed technology term.		20 years
Annual royalty payment		5%
Sales-based milestone fee		$ 75,000
Cumulative net sales		6,000,000
Operating lease							Lease Liability
Purchase share (in Shares) | shares	9,434
Common stock value						480,000	$ 520,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in Shares) | shares			2,438	0
purchase						$ 1,131,771	1,131,771
Accrued liability							75,000
Common Stock [Member]
Commitments and Contingencies [Line Items]
Shares of common stock (in Shares) | shares	10,000
Common exercise price (in Dollars per share) | $ / shares	$ 5.3
Charles Allen [Member]
Commitments and Contingencies [Line Items]
Cash compensation			$ 2,000		2,000
Paul Field [Member]
Commitments and Contingencies [Line Items]
Cash compensation			1,250		1,250
Stephen Toovey [Member]
Commitments and Contingencies [Line Items]
Cash compensation			1,250		1,250
US Government Sales [Member]
Commitments and Contingencies [Line Items]
Royalty expense		35,000,000
U.S. Army Agreement [Member]
Commitments and Contingencies [Line Items]
Royalty expense		$ 35,000,000
Board of Directors Chairman [Member]
Commitments and Contingencies [Line Items]
Annual royalty payment		3%
Board of Directors Chairman [Member] | Charles Allen [Member]
Commitments and Contingencies [Line Items]
Cash compensation							11,250
Board of Directors Chairman [Member] | Cheryl Xu [Member]
Commitments and Contingencies [Line Items]
Cash compensation							11,250
Common stock value	$ 40,000
Board of Directors Chairman [Member] | Paul Field [Member]
Commitments and Contingencies [Line Items]
Cash compensation							11,250
Common stock exercise price (in Dollars per share) | $ / shares	$ 5.3
Board of Directors Chairman [Member] | Stephen Toovey [Member]
Commitments and Contingencies [Line Items]
Cash compensation							11,250
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in Shares) | shares	5
Board of Directors Chairman [Member] | Cheryl Xu [Member]
Commitments and Contingencies [Line Items]
Cash compensation			11,250		11,250
Board of Directors Chairman [Member] | Paul Field [Member]
Commitments and Contingencies [Line Items]
Cash compensation			11,250		11,250
Board of Directors Chairman [Member] | Charles Allen [Member]
Commitments and Contingencies [Line Items]
Cash compensation			11,250		11,250
Board of Directors Chairman [Member] | Stephen Toovey [Member]
Commitments and Contingencies [Line Items]
Cash compensation			11,250		11,250
Board of Directors Chairman [Member] | Non-qualified Option [Member] | Charles Allen [Member]
Commitments and Contingencies [Line Items]
purchase	$ 40,000
Non-Audit Committee [Member] | Board of Directors Chairman [Member] | Paul Field [Member]
Commitments and Contingencies [Line Items]
Cash compensation							1,250
Non-Audit Committee [Member] | Board of Directors Chairman [Member] | Stephen Toovey [Member]
Commitments and Contingencies [Line Items]
Cash compensation							1,250
Audit Committee [Member] | Board of Directors Chairman [Member] | Charles Allen [Member]
Commitments and Contingencies [Line Items]
Cash compensation							2,000
IPO [Member]
Commitments and Contingencies [Line Items]
Payment			$ 10,000,000		$ 10,000,000		$ 10,000,000
Shares of common stock (in Shares) | shares									1,415,095

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)												1 Months Ended	9 Months Ended		11 Months Ended	12 Months Ended
		Nov. 12, 2024	Nov. 06, 2024	Oct. 31, 2024	Oct. 01, 2024	Jul. 30, 2024	Feb. 14, 2024	Feb. 01, 2024	Jan. 31, 2024	Jan. 29, 2024	Jul. 13, 2023	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Sep. 04, 2024	Feb. 27, 2024	Jan. 10, 2024	Jul. 31, 2023	May 31, 2023	Jun. 01, 2022	May 31, 2022
Subsequent Events [Line Items]
Share issued	[1]												1,861,914			484,187
Aggregate cash proceeds (in Dollars)													$ 9,990
Additional shares of common stock				229,000
Common stock exercise shares													229,000
Cash proceeds (in Dollars)														$ 1,131,771		$ 1,131,771
Reverse stock split ratio						1:12							1:12
Common stock per share (in Dollars per share)							$ 4.5
Closing bid price per share (in Dollars per share)																$ 0.385
Warrant exercise price (in Dollars per share)							$ 0.12			$ 5.082			$ 0.12					$ 1.379				$ 5.83		$ 5.83
Percentage of offering price per unit										110%	110%		110%			110%
Offering to purchase																789,136
Warrants shares							5				31,447		83,259									151,991		151,991
Pre-funded warrants									9,990				2,898,551			149,862
Pre-funded warrants per price (in Dollars per share)										$ 0.12						$ 0.375
Percentage of warrants underlying units																15%
Percentage of common shares																6%
Exercise price (in Dollars per share)										0.12													$ 5
Underwriting discounts and commissions (in Dollars)																$ 1,900,000
Pre-Funded Warrants [Member]
Subsequent Events [Line Items]
Cash proceeds (in Dollars)													$ 229
Warrant Price [Member]
Subsequent Events [Line Items]
Warrant exercise price (in Dollars per share)																$ 0.01
Warrant [Member]
Subsequent Events [Line Items]
Share issued																					15,371
Warrant exercise price (in Dollars per share)													$ 0.12
Warrants shares													78,250			938,997
Pre-funded warrants													2,898,551
Pre-funded warrants per price (in Dollars per share)													$ 4.5
WallachBeth Capital LLC [Member]
Subsequent Events [Line Items]
Percentage of pre-funded warrants																15%
Warrants exercised									375,599
Exercise price (in Dollars per share)																$ 0.4235
Subsequent Event [Member]
Subsequent Events [Line Items]
Share issued					206,551
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period					206,551
Aggregate cash proceeds (in Dollars)					$ 207
Issuance of sale (in Dollars)			$ 6,014,493
Number of common stock available for issuance			500,000
Common stock per share (in Dollars per share)							$ 0.01			$ 0.385										$ 1
Underwriting agreement							50	4,995		5,260,901
Closing bid price per share (in Dollars per share)										$ 0.375									$ 1
Warrant exercise price (in Dollars per share)										$ 0.4235
Percentage of offering price per unit										110%
Pre-funded warrants								499,538
Warrants exercised								499,538	818,177
Subsequent Event [Member] | Warrant Price [Member]
Subsequent Events [Line Items]
Warrant exercise price (in Dollars per share)										$ 0.01
Subsequent Event [Member] | Minimum [Member]
Subsequent Events [Line Items]
Reverse stock split ratio			1:3
Subsequent Event [Member] | Maximum [Member]
Subsequent Events [Line Items]
Reverse stock split ratio			1:5
Subsequent Event [Member] | WallachBeth Capital LLC [Member]
Subsequent Events [Line Items]
Common stock per share (in Dollars per share)							$ 0.375
Underwriting agreement							50			999,076
Closing bid price per share (in Dollars per share)										$ 0.01
Non-Executive Directors [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Cash payments (in Dollars)		$ 20,000
Forecast [Member]
Subsequent Events [Line Items]
Advance monash (in Dollars)															$ 65,000
Forecast [Member] | Monash [Member]
Subsequent Events [Line Items]
Advance monash (in Dollars)												$ 65,173
Over-Allotment Option [Member]
Subsequent Events [Line Items]
Percentage of warrants underlying units																15%
Exercise price (in Dollars per share)													$ 63.36			$ 5.28
[1] Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities	$ 2,306,796	$ 1,494,200
Total	2,306,796	1,494,200
Level 1 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities
Total
Level 2 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities
Total
Level 3 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities	2,306,796	1,494,200
Total	$ 2,306,796	$ 1,494,200

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements (Details)	Dec. 31, 2023	Dec. 31, 2022
Minimum [Member] | AUD [Member]
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements [Line Items]
Average Exchange Rate	0.66	0.69
Minimum [Member] | SGD [Member]
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements [Line Items]
Average Exchange Rate		1.02	[1]
Maximum [Member] | AUD [Member]
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements [Line Items]
Average Exchange Rate	0.68	0.68
Maximum [Member] | SGD [Member]
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements [Line Items]
Average Exchange Rate		1.02	[1]
[1] Through 4/30/2022 (account closure date)

Inventory - Schedule of Inven_2

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventory [Abstract]
Raw Material (API)			$ 397,487
Work in Process	$ 367,587	278,987	97,486
Finished Goods	84,449	187,182	183,943
Total Inventory		466,169	678,916
Reserve for Expiring Inventory			(160,338)
Inventory	$ 452,036	$ 466,169	$ 518,578

Property and Equipment - Sche_2

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	$ 299,241	$ 205,825	$ 148,202
Accumulated depreciation	(143,984)	(148,064)	(126,902)
Property and Equipment, Net	155,257	57,761	21,300
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	233,411	132,911	132,911
Machinery [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	55,800	55,800
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	7,000	14,084	12,261
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	$ 3,030	$ 3,030	$ 3,030

Intangible Assets - Schedule _3

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Abstract]
Patents	$ 225,485	$ 185,595	$ 145,613
Website Development Costs	104,622	79,248	27,070
Intangible Assets, at cost	330,107	264,843	172,683
Accumulated Amortization	$ (65,756)	(37,585)	(8,428)
Intangible Assets, net		$ 227,258	$ 164,255

Intangible Assets - Schedule _4

Intangible Assets - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Patents [Member]
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2024	$ 7,010	$ 6,612
2025	7,010	6,612
2026	7,010	6,612
2027	7,010	6,612
2028	51,106	6,612
Thereafter		41,817
Total	80,899	74,877
Website Development Costs [Member]
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2024	31,761	26,416
2025	12,432	23,303
2026	3,094	3,974
2027
2028
Thereafter
Total	$ 56,005	$ 53,693

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Equity-Classified Warrants (Details) - Warrants [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Warrants, Total outstanding, Ending | shares
Weighted Average Exercise Price, Total outstanding, Ending | $ / shares
Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending
Number of Warrants, Reclassified from Derivative Liabilities | shares	231,917
Weighted Average Exercise Price, Reclassified from Derivative Liabilities | $ / shares	$ 5.46
Weighted Average Remaining Contractual Life (Years), Reclassified from Derivative Liabilities	4 years 1 month 24 days
Number of Warrants, Granted | shares	3,116,384
Weighted Average Exercise Price, Granted | $ / shares	$ 6.22
Weighted Average Remaining Contractual Life (Years), Granted	5 years
Number of Warrants, Exercised | shares	(184,447)
Weighted Average Exercise Price, Exercised | $ / shares	$ 6.14
Weighted Average Remaining Contractual Life (Years), Exercised	5 years
Number of Warrants, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Number of Warrants, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Number of Warrants, Total outstanding, Ending | shares	3,163,854
Weighted Average Exercise Price, Total outstanding, Ending | $ / shares	$ 6.17
Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending	4 years 5 months 19 days
Number of Warrants,Total exercisable, December 31, 2023 | shares	3,163,854
Weighted Average Exercise Price,Total exercisable, December 31, 2023 | $ / shares	$ 6.17
Weighted Average Remaining Contractual Life (Years),Total exercisable, December 31, 2023	4 years 5 months 19 days

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Assumptions Used In Determining the Fair Value of Equity-Classified Warrants Granted (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stockholders' Equity - Schedule of Assumptions Used In Determining the Fair Value of Equity-Classified Warrants Granted (Details) [Line Items]
Stock price (in Dollars per share)	$ 3.36
Exercise price (in Dollars per share)	$ 5.08
Risk-free interest rate	3.91%
Expected volatility	95%
Expected term (years)	5 years
Expected dividend yield	0%	0%
Minimum [Member]
Stockholders' Equity - Schedule of Assumptions Used In Determining the Fair Value of Equity-Classified Warrants Granted (Details) [Line Items]
Stock price (in Dollars per share)		$ 4.68
Exercise price (in Dollars per share)		$ 4.77
Risk-free interest rate		4.07%
Expected volatility		90%
Expected term (years)		3 years 10 months 9 days
Maximum [Member]
Stockholders' Equity - Schedule of Assumptions Used In Determining the Fair Value of Equity-Classified Warrants Granted (Details) [Line Items]
Stock price (in Dollars per share)		$ 5.3
Exercise price (in Dollars per share)		$ 6.36
Risk-free interest rate		4.40%
Expected volatility		105%
Expected term (years)		5 years

Deferred Compensation (Details)

Deferred Compensation (Details) - USD ($)			1 Months Ended	12 Months Ended
	Jan. 26, 2023	May 05, 2022	Jun. 17, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 28, 2023	Jul. 14, 2023	Mar. 31, 2023	Dec. 31, 2020
Deferred Compensation [Line Items]
Received consulting services									$ 100,000
Deferred cash		$ 60,000
Deferred compensation warrants		400,000
Cash component		100,000	$ 38,900
Equity compensation		245,000
Equity compensation payment		100,000		$ 1,736,174
Deferred cash compensation			57,198
Accrued expenses			$ 12,500
Contingent deferred compensation, percentage			100%
Deferred compensation, common shares			$ 60,000
Deferred compensation, shares issued (in Shares)	65,000				65,000
Deferred compensation, per share (in Dollars per share)					$ 5
Subsequent agreement					$ 325,000
IPO [Member]
Deferred Compensation [Line Items]
Deferred compensation warrants			$ 10,000,000
Equity compensation		$ 155,000
Shares issued (in Shares)							1,415,095
Common Stock [Member]
Deferred Compensation [Line Items]
Shares issued (in Shares)		29,245
Red Chip [Member]
Deferred Compensation [Line Items]
Investment relations obligation								$ 40,000
Shares issued (in Shares)						10,554

Debt - Schedule of Promissory N

Debt - Schedule of Promissory Notes (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		$ 17,965,670
Promissory Notes (including accrued interest)
Less Current Maturities		16,855,887
Long Term Promissory Notes		1,109,783
Knight Therapeutics [Member]
Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		16,319,986
Promissory Notes (including accrued interest)
Less Current Maturities		16,319,986
Long Term Promissory Notes
Note, Including Amendment [Member]
Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		1,109,783
Promissory Notes (including accrued interest)
Less Current Maturities
Long Term Promissory Notes		1,109,783
Bridge Notes [Member]
Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		535,901
Promissory Notes (including accrued interest)
Less Current Maturities		535,901
Long Term Promissory Notes

Debt - Schedule of Bridge Not_2

Debt - Schedule of Bridge Notes and Related Party Notes (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	May 31, 2023	Dec. 31, 2022
2022 Bridge Notes [Member]
Debt - Schedule of Bridge Notes and Related Party Notes (Details) [Line Items]
Issuance date of promissory notes		May 2022
Maturity date of promissory notes		1 year
Interest rate		10%
Default interest rate		15%
Collateral	Unsecured	Unsecured
Conversion rate		3
Face amount of notes				$ 888,889
Less: unamortized debt discount				(407,555)
Add: accrued interest on promissory notes				54,567
Balance – December 31, 2023
Balance - December 31, 2022		$ 535,901
Related Party Notes [Member]
Debt - Schedule of Bridge Notes and Related Party Notes (Details) [Line Items]
Issuance date of promissory notes		May 2022
Maturity date of promissory notes		1 year
Interest rate		6%
Default interest rate		15%
Collateral	Unsecured	Unsecured
Conversion rate		3
Face amount of notes				338,889
Less: unamortized debt discount				(155,443)
Add: accrued interest on promissory notes				11,651
Balance – December 31, 2023
Balance - December 31, 2022		$ 195,097
2023 Bridge Notes [Member]
Debt - Schedule of Bridge Notes and Related Party Notes (Details) [Line Items]
Issuance date of promissory notes		May 2023
Maturity date of promissory notes		2 years
Interest rate		10%
Default interest rate		15%
Collateral	Unsecured	Unsecured
Conversion rate		3
Face amount of notes			$ 722,222
Less: unamortized debt discount
Add: accrued interest on promissory notes
Balance – December 31, 2023
Balance - December 31, 2022

Debt - Schedule of Reconcilia_2

Debt - Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note (Details) - USD ($)		1 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jan. 31, 2023	Sep. 30, 2024	Dec. 31, 2023
Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note [Abstract]
Beginning balance
Fair value at modification date - January 9, 2023				21,520,650
Fair value - mark to market adjustment				(5,379,269)
Accrued interest recognized				1,293,549
Extinguishment of Promissory Notes	$ (223,077)	$ (839,887)	$ (614,670)	(17,434,930)
Ending balance

Debt - Schedule of the Knight D

Debt - Schedule of the Knight Debenture (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of the Knight Debenture [Abstract]
Original Debenture		$ 3,000,000
Unamortized Debt Discount		(279,061)
Debenture Prior to Accumulated Interest		2,720,939
Accumulated Interest		1,555,670
Debenture		$ 4,276,609

Debt - Schedule of the Curren_2

Debt - Schedule of the Current Future Payment Obligations (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule Of The Current Future Payment Obligations Abstract
2024
2025	683
2026	3,228	683
2027	3,342	3,228
2028	142,747	3,342
Thereafter		142,747
Total	$ 150,000	$ 150,000

Derivative Liabilities - Sche_3

Derivative Liabilities - Schedule of Derivative Expense (Details) - USD ($)	May 08, 2023	May 24, 2022	Sep. 30, 2024	Dec. 31, 2023
Schedule of Derivative Expense [Abstract]
Fair value of derivative liabilities	$ 954,725	$ 1,483,888
Less: face amount of debt	(555,000)	(979,275)	$ (8,772)	$ (8,772)
Derivative expense	$ 399,725	$ 504,613

Derivative Liabilities - Sche_4

Derivative Liabilities - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning	$ 2,306,796	$ 1,494,200	$ 1,494,200
Fair value - mark to market adjustment			(2,834)	10,312
Fair value - commitment date			954,725	1,483,888
Fair value - mark to market adjustment prior to conversion or reclassification			(149,542)
Conversion of convertible promissory notes			(1,457,801)
Reclassification of warrants to equity		(838,748)	(838,748)
Recognition of contingent milestone liability			2,117,142
Fair value - mark to market adjustment			189,654
Derivative liabilities - Ending			2,306,796	1,494,200
Bridge Shares [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning		834,352	834,352
Fair value - mark to market adjustment			13,798	10,665
Fair value - commitment date			680,276	823,687
Fair value - mark to market adjustment prior to conversion or reclassification			(105,790)
Conversion of convertible promissory notes			(1,422,636)
Reclassification of warrants to equity
Recognition of contingent milestone liability
Fair value - mark to market adjustment
Derivative liabilities - Ending				834,352
Warrants [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning		578,164	578,164
Fair value - mark to market adjustment			(15,320)	13,157
Fair value - commitment date			274,449	565,007
Fair value - mark to market adjustment prior to conversion or reclassification			1,455
Conversion of convertible promissory notes
Reclassification of warrants to equity			(838,748)
Recognition of contingent milestone liability
Fair value - mark to market adjustment
Derivative liabilities - Ending				578,164
Convertible Notes Payable [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning		81,684	81,684
Fair value - mark to market adjustment			(1,312)	(13,510)
Fair value - commitment date				95,194
Fair value - mark to market adjustment prior to conversion or reclassification			(45,207)
Conversion of convertible promissory notes			(35,165)
Reclassification of warrants to equity
Recognition of contingent milestone liability
Fair value - mark to market adjustment
Derivative liabilities - Ending				81,684
Contingent Milestone Payment [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning	$ 2,306,796
Fair value - mark to market adjustment
Fair value - commitment date
Fair value - mark to market adjustment prior to conversion or reclassification
Conversion of convertible promissory notes
Reclassification of warrants to equity
Recognition of contingent milestone liability			2,117,142
Fair value - mark to market adjustment			189,654
Derivative liabilities - Ending			$ 2,306,796

Derivative Liabilities - Sche_5

Derivative Liabilities - Schedule of Fair Value of Liability-Classified Bridge Shares (Details)	May 31, 2023	Dec. 31, 2022	May 31, 2022
Measurement Input, Share Price [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability	5.3	5	5
Measurement Input, Price Volatility [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability	115.1	101.9	99.7
Measurement Input, Expected Term [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability	0.99
Measurement Input, Expected Term [Member] | Minimum [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability		0.39	1
Measurement Input, Expected Term [Member] | Maximum [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability		0.41	1.03
Measurement Input, Expected term (in years) - Warrants [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability	4.99	4.39	5
Measurement Input, Risk Free Interest Rate [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability	4.8	4.06
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability			2.76
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability			2.84
Measurement Input, Dividend yield [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability	0	0	0
Measurement Input, IPO Probability [Member]
Schedule of Conversion Features in Convertible Promissory Notes [Line Items]
Fair value of liability	95	95	95

Income Taxes - Schedule of Loss

Income Taxes - Schedule of Loss Before Provision (Benefit) for Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Loss Before Provision (Benefit) for Income Taxes [Abstract]
United States					$ (3,006,861)	$ (5,807,367)
Foreign					(806,689)	(369,917)
Total Loss before Income Taxes	$ (2,160,248)	$ 4,173,605	$ (5,905,988)	$ (1,767,394)	$ (3,813,550)	$ (6,177,284)

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal
State					250	500
Foreign
Total current provision (benefit)					250	500
Deferred:
Federal
State
Foreign
Total deferred provision (benefit)
Total Benefit	$ 250	$ 63	$ 751	$ 189	$ 250	$ 500

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation Between Income Taxes Computed at the U.S. Statutory Income Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Reconciliation Between Income Taxes Computed at the U.S. Statutory Income Tax Rate [Abstract]
Benefit for income taxes at 21% rate, Amount	$ (800,846)	$ (1,297,230)
Benefit for income taxes at 21% rate, percentage	21%	21%
State income taxes, net of federal benefit, Amount	$ (364,618)	$ (478,515)
State income taxes, net of federal benefit, percentage	9.60%	7.70%
Impact of non-U.S. earnings, amount	$ (33,994)	$ (33,897)
Impact of non-U.S. earnings, percentage	0.90%	0.50%
Permanent differences, amount	$ 280,654
Permanent differences, percentage	(7.40%)	0%
Change in fair value of promissory note, amount	$ (1,129,646)
Change in fair value of promissory note, percentage	29.60%	0%
Non-deductible interest expense, amount	$ 304,962
Non-deductible interest expense, percentage	(8.00%)	0%
Other reconciling items, net, amount	$ 2,042,657	$ 683,359
Other reconciling items, net, percentage	(53.60%)	(11.10%)
Change in valuation allowance, amount	$ (298,919)	$ 1,126,783
Change in valuation allowance, percentage	7.80%	(18.20%)
Benefit for Income Taxes, amount	$ 250	$ 500
Benefit for Income Taxes, percentage	(0.10%)	(0.10%)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carry-forward	$ 3,453,126	$ 3,338,726
Non-deductible reserves	1,058
Capitalized R&D costs	189,893
Lease liability	3,756
Share-based compensation	94,034
Gross deferred tax assets	3,741,867	3,338,726
Less valuation allowance	(3,043,135)	(3,338,726)
Total deferred tax assets, net of valuation allowance	698,732
Deferred tax liabilities:
Right of use asset	(3,719)
Prepaid expenses	(695,013)
Total deferred tax liabilities	(698,732)
Net deferred tax liabilities

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Share-Based Compensation Expenses (Details) - USD ($)		12 Months Ended
	May 05, 2022	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Share Based Compensation Expenses Abstract
Research and Development		$ 192,371
General and Administrative Expenses		1,543,803
Total Share-Based Compensation Expense Included in Operating Expenses	$ 100,000	$ 1,736,174

Share-Based Compensation - Sc_4

Share-Based Compensation - Schedule of Fair Value of Options Granted (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation - Schedule of Fair Value of Options Granted (Details) [Line Items]
Weighted-average grant date fair value (in Dollars per share)	$ 1.76	$ 41.04	$ 3.16
Risk-free interest rate			4.33%
Expected volatility			110%
Expected term (years)			3 years 2 months 4 days
Expected dividend yield	0%	0%	0%

Share-Based Compensation - Sc_5

Share-Based Compensation - Schedule of Stock Option Activities (Details) - Equity Option [Member]	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Schedule of Stock Option Activities [Line Items]
Options outstanding, December 31, 2022, Number of Options | shares
Total outstanding, December 31, 2022, Weighted Average Exercise Price | $ / shares
Options outstanding, December 31, 2022, Aggregate Intrinsic Value | $
Granted, Number of Options | shares	37,736
Granted, Weighted Average Exercise Price | $ / shares	$ 5.3
Granted, Aggregate Intrinsic Value | $
Granted, Weighted Average Remaining Contractual Life	5 years
Exercised, Number of Options | shares
Exercised, Weighted Average Exercise Price | $ / shares
Exercised, Aggregate Intrinsic Value | $
Forfeited, Number of Options | shares
Forfeited, Weighted Average Exercise Price | $ / shares
Forfeited, Aggregate Intrinsic Value | $
Expired, Number of Options | shares
Expired, Weighted Average Exercise Price | $ / shares
Expired, Aggregate Intrinsic Value | $
Options outstanding, December 31, 2023, Number of Options | shares	37,736
Total outstanding, December 31, 2023, Weighted Average Exercise Price | $ / shares	$ 5.3
Options outstanding, December 31, 2023, Aggregate Intrinsic Value | $
Options outstanding, December 31, 2023, Weighted Average Remaining Contractual Life	4 years 6 months 10 days
Options vested and exercisable, December 31, 2023, Number of Options | shares	37,736
Options vested and exercisable, December 31, 2023, Weighted Average Exercise Price | $ / shares	$ 5.3
Options vested and exercisable, December 31, 2023, Aggregate Intrinsic Value | $
Options vested and exercisable, December 31, 2023, Weighted Average Remaining Contractual Life	4 years 6 months 10 days

Share-Based Compensation - Sc_6

Share-Based Compensation - Schedule of RSU Activity (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Schedule of RSU Activity [Line Items]
Unvested balance, December 31, 2022, Number of Units | shares
Unvested balance, December 31, 2022, Weighted Average Grant Date Fair Value | $ / shares
Granted, Number of Units | shares	256,000
Granted, Weighted Average Grant Date Fair Value | $ / shares	$ 0.87
Vested, Number of Units | shares	(256,000)
Vested, Weighted Average Grant Date Fair Value | $ / shares	$ 0.87
Forfeited, Number of Units | shares
Forfeited, Weighted Average Grant Date Fair Value | $ / shares
Unvested balance, December 31, 2023, Number of Units | shares
Unvested balance, December 31, 2023, Weighted Average Grant Date Fair Value | $ / shares

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Lease Payments on a Discounted and Undiscounted Basis (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Future Minimum Lease Payments on a Discounted and Undiscounted Basis [Abstract]
Discount rate		15%
2024		$ 13,992
Thereafter
Total undiscounted minimum future payments		13,992
Imputed interest		(342)
Total operating lease payments		13,650
Current lease liabilities		13,650	$ 13,000
Non-current lease liabilities

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Other Information Related to our Operating Lease (Details)	Dec. 31, 2023
Schedule of Other Information Related to our Operating Lease [Abstract]
Weighted average remaining lease term (in years)	3 months
Weighted average discount rate	15%